Nucleic acid molecule having binding affinity to a target molecule and a method for generating the same

ABSTRACT

The present invention is related to a method for generating a nucleic acid molecule capable of binding to a target molecule comprising the following steps: a) providing a reference nucleic acid molecule, wherein the reference nucleic acid molecule is capable of binding to the target molecule and wherein the reference nucleic acid molecule comprises a sequence of nucleotides, wherein the sequence of nucleotides comprises n nucleotides; b) preparing a first level derivative of the reference nucleic acid molecule, wherein the first level derivative of the reference nucleic acid molecule differs from the reference nucleic acid molecule at one nucleotide position, wherein the first level derivative is prepared by replacing the ribonucleotide at the one nucleotide position by a 2′-deoxyribonucleotide in case the reference nucleic acid has a ribonucleotide at the nucleotide position and wherein the first level derivative is prepared by replacing the 2′-deoxyribonucleotide at the one nucleotide position by a ribonucleotide in case the reference nucleic acid has a 2′-deoxyribonucleotide at the nucleotide position and wherein the nucleotide position at which the replacement is made is the modified nucleotide position; and c) repeating step b) for each nucleotide position of the reference nucleic acid molecule, thus preparing a group of first level derivatives of the reference nucleic acid molecule, wherein the group of first level derivatives of the reference nucleic acid molecule consists of n first level derivatives, wherein each of the first level derivatives of the reference nucleic acid molecule differs from the reference nucleic acid molecule by a single nucleotide replacement and wherein each of the first level derivatives of the reference nucleic acid molecule has a single modified nucleotide position which is different from the single modified nucleotide of all of the single modified nucleotide positions of the other first level derivatives of the group of first level derivatives of the reference nucleic acid molecule.

The present invention relates to a method for generating a nucleic acidmolecule capable of binding to a target molecule, a nucleic acidmolecule obtainable by the method, the use of the nucleic acid molecule,a nucleic acid molecule capable of binding to a target molecule whereinthe nucleic acid molecule has an increased binding affinity or the samebinding affinity to the target molecule compared to a reference nucleicacid molecule. Furthermore, the present invention relates to the use ofthe nucleic acid molecule having an increased or the same bindingaffinity in a method of treatment and/or diagnosis of a disease.

Besides the use of comparatively small organic molecules the developmentof novel therapeutic concepts resorts increasingly to monoclonalantibodies, peptides and functional nucleic acid molecules, i.e. suchnucleic acid molecules that bind specifically to a target structure ortarget molecule. Representatives of these functional nucleic acidmolecules are the so called aptamers that have already been developedagainst a multitude of different biomolecules. Thereby, starting from aD-nucleic acid library, one or more D-nucleic acid molecules, the socalled aptamers, that are characterized by a particularly high affinitytowards their target structure or target molecule, are isolated inseveral steps by in vitro selection. Methods for the preparation of suchaptamers are described, for example, in European patent EP 0 533 838.

The first aptamers were discovered by use of combinatorial RNA or DNAoligonucleotide libraries. RNA aptamers as well as DNA aptamers areD-nucleic acid molecules and are quickly degraded in a biological systemsuch as the human or animal body by nucleases what makes them uselessfor therapeutic applications. Hence, the stabilization of an aptamer isthe essential step in the development process of an aptamer drugcandidate. Stabilization can be achieved by

-   -   a) protecting the 5′- and 3′-end of the aptamer by addition of        capping moieties at both the 5′- and 3′-ends of the aptamer,    -   b) incorporating modifications to the ribose or the deoxyribose        backbone, or    -   c) incorporating phosphate backbone components.

By adding capping moieties at the 5′-end of aptamers the serum and invivo stabililty of aptamers can be improved, in particular with regardto 5′->3′ nucleases and 5′->3′ exonucleases present in the body fluidsof the human and animal body. This kind of modification can beintroduced as modified phosphoamidites in the conventional solid-phasesynthesis or by post-synthesis coupling. Often a 5′-amino modifiercontaining a 5′-amino group is used, whereby the 5′-amino group canserve as a nucleophile for subsequent derivatization. The most common5′-modification is polyethylene glycol. Other modifications are selectedfrom the group of cholesterol, fatty acids, polycations and proteins. Inaddition to conferring stabilization of the 5′-end of the aptamers, suchmodification can be used for altering the pharmacokinetic profile and/orbiodistribution of the aptamer.

Adding capping moieties at the 3′-end of aptamers confers to aptamersprotection against 3′->5′ exonucleases present in serum of man andanimals. Nucleotide and non-nucleotide 3′-caps are known. The mostcommonly used 3′-cap is inverted thymidine (3′-idT).

Chemical modification at the 2′ position of the ribose or deoxyribosebackbone of aptamers are a prerequisite for the use of aptamers in vivo.These 2′-modifications are typically selected from the group of 2′-F,2′-O-methyl, 2′-amino. Techniques are available in the art to introducesaid 2′-F, 2′-O-methyl, 2′-amino modifications into the aptamer sequencewithin the SELEX process (to some extent) or in a so called post-SELEXoptimization process, wherein the individual aptamer sequence isoptimized by the stepwise substitution of the natural nucleotides by2′-F, 2′-O-methyl or 2′-amino nucleotides.

Phosphate backbone modifications introduce sulfur(s) in place ofnon-briding phosphodiester oxygens(s) thereby confering nucleaseresistance to aptamers. A preferred form of such sulfur modifiedbackbone are phosphorothioates. Phosphorothioates can be enzymaticallyincorporated into aptamers with the SELEX process or by solid-phasesynthesis. Phosphorodithioate aptamers have to be produced bysolid-phase synthesis.

Apart from aptamers the so-called spiegelmers constitute a further formof functional nucleic acids. Like aptamers, spiegelmers bindspecifically to a target molecule or target structure. Spiegelmers areidentified by a process that uses a D-nucleic acid library for in vitroselection against the enantiomeric form of the target molecule or targetstructure, and thereupon the thus identified D-nucleic acids binding tothe enantiomeric form of the target molecule or target structure areprepared as corresponding L-nucleic acids. As a result of the principleof chiral reciprocity these L-nucleic acids which are referred to asspiegelmers are able to bind to the true or actual target molecule andnot to the enantiomeric form thereof used for the selection process.Preferably such true or actual target molecule or target structure isthe target molecule or target structure as present in a biologiocalsystem such as a human or animal body. Methods for the preparation ofsuch spiegelmers are described, for example, in international patentapplication WO 98/08856.

As spiegelmers are L-nucleic acid molecules, typicallyL-oligonucleotides, assembled from L-nucleotides they cannot be degradedby natural enzymes. Apart from the target specificity, thischaracteristic qualifies them for use in the most different areas, suchas, e.g., analysis of biological samples, diagnosis and therapy.

In contrast to aptamers that have to be stabilized, prior to their use,against degradation by nucleases as outlined above, there is no need forstabilizing spiegelmers prior to their use such as in functional assays,in cell-based assays, in in vivo experiments and/or in in vivoapplications for therapy or diagnosis. The in vivo applicability ofspiegelmers was proven in man and various animal species. Forspiegelmers NOX-E36 and NOX-A12 clinical trials were initiated in 2009.

Because no chemical modification for the purpose of stabilization isneeded for spiegelmers, spiegelmers, in terms of nucleotide buildingblocks, solely consist of ribonucleotides or 2′-deoxyribonucleotides,more precisely of L-ribonucleotides or L-2′-deoxyribonucleotides. Anadvantage of spiegelmers in drug development arising thereform is theabsence of the time-consuming, costly and—to date regarded as—riskyprocess of substituting non-modified nucleotides, i.e. L-ribonucleotidesand L-2′-deoxyribonucleotides, by modified nucleotides such as2′-F-ribonucleotides, 2′-O-methylribonucleotides and2′-aminoribonucleotides. A further advantage of spiegelmers solelyconsisting of L-ribonucleotides or L-2′-deoxyribonucleotides in drugdevelopment is the absence of potential toxic effects or intolerance ofsuch chemically modified nucleotides and/or the degradation productsthereof.

Thus, the in vivo potency of spiegelmers solely consisting ofL-ribonucleotides or L-2′-deoxyribonucleotides typically only depends ontheir affinity to the target molecule and, as result thereof, on theireffects on the function of the target molecule or target structure andtheir pharmacokinetic behaviour in the human or animal body.

The problem underlying the present invention is to provide a method forgenerating a nucleic acid molecule capable of binding to a targetmolecule starting from a reference nucleic acid molecule which isbinding to a target molecule. Preferably the target molecule to whichthe nucleic acid molecule is capable of bingding is the target moleculeto which the reference nucleic acid molecule is binding.

A further problem underlying the present invention is to provide amethod for generating a nucleic acid molecule capable of binding to atarget molecule starting from a reference nucleic acid molecule which isbinding to a target molecule, whereby the nucleic acid molecule capableof binding to a target molecule has the same or an improved bindingcharacteristic compared to the reference nucleic acid molecule, wherebypreferably the binding characteristic is the binding affinity to thetarget molecule.

A still further problem underlying the present invention is to provide anucleic acid molecule and more specifically a functional nucleic acidmolecule such as an aptamer or a spiegelmer having an improved bindingaffinity to its target molecule or the same binding affinity compared toa reference nucleic acid molecule.

These and other problems underlying the present invention are solved bythe subject matter of the attached independent claims. Preferredembodiments may be taken from the dependent claims.

More specifically, the problem underlying the present invention issolved in a first aspect which is also the first embodiment of the firstaspect, by a method for generating a nucleic acid molecule capable ofbinding to a target molecule comprising the following steps:

a) providing a reference nucleic acid molecule, wherein the referencenucleic acid molecule is capable of binding to the target molecule andwherein the reference nucleic acid molecule comprises a sequence ofnucleotides, wherein the sequence of nucleotides comprises nnucleotides;b) preparing a first level derivative of the reference nucleic acidmolecule, wherein the first level derivative of the reference nucleicacid molecule differs from the reference nucleic acid molecule at onenucleotide position, wherein the first level derivative is prepared byreplacing the ribonucleotide at the one nucleotide position by a2′-deoxyribonucleotide in case the reference nucleic acid has aribonucleotide at the nucleotide position and wherein the first levelderivative is prepared by replacing the 2′-deoxyribonucleotide at theone nucleotide position by a ribonucleotide in case the referencenucleic acid has a 2′-deoxyribonucleotide at the nucleotide position andwherein the nucleotide position at which the replacement is made is themodified nucleotide position; andc) repeating step b) for each nucleotide position of the referencenucleic acid molecule, thus preparing a group of first level derivativesof the reference nucleic acid molecule, wherein the group of first levelderivatives of the reference nucleic acid molecule consists of n firstlevel derivatives, wherein each of the first level derivatives of thereference nucleic acid molecule differs from the reference nucleic acidmolecule by a single nucleotide replacement and wherein each of thefirst level derivatives of the reference nucleic acid molecule has asingle modified nucleotide position which is different from the singlemodified nucleotide of all of the single modified nucleotide positionsof the other first level derivatives of the group of first levelderivatives of the reference nucleic acid molecule.

In a second embodiment of the first aspect which is also an embodimentof the first embodiment of the first aspect, the method comprises stepd) and optionally step e):

d) determining the binding characteristic to the target molecule foreach of the n first level derivatives of the reference nucleic acid; andoptionallye) identifying the/those first level derivative(s) of the referencenucleic acid molecule the binding characteristic of which exceed apredetermined threshold value.

In a third embodiment of the first aspect which is also an embodiment ofthe second embodiment of the first aspect, the binding characteristic isthe binding affinity of the first level derivative(s) of the referencenucleic acid molecule to the target molecule.

In a fourth embodiment of the first aspect which is also an embodimentof the second and the third embodiment of the first aspect, the bindingaffinity is expressed as the K_(D) value.

In a fifth embodiment of the first aspect which is also an embodiment ofthe second, the third and the fourth embodiment of the first aspect, thepredetermined threshold value is Y with Y being the quotient of (bindingaffinity of the reference nucleic acid molecule)/(binding affinity ofthe first level derivative) and wherein Y≥1, more preferably Y≥2 andmost preferably Y≥5 or Y≥10.

In a sixth embodiment of the first aspect which is also an embodiment ofthe second, the third, the fourth and the fifth embodiment of the firstaspect, the predetermined threshold value is X with X being the quotientof (K_(D) value of the reference nucleic acid molecule)/(K_(D) value ofthe first level derivative) and wherein X>1, more preferably X≥2 andmost preferably ≥5 or X≥10.

In a seventh embodiment of the first aspect which is also an embodimentof the first, the second, the third, the fourth, the fifth and the sixthembodiment of the first aspect, if in step b) the first level derivativeis prepared by replacing the ribonucleotide at the one nucleotideposition by a 2′-deoxyribonucleotide and

(a) if the ribonucleotide is adenosine-5′-phosphate, the2′-deoxyribonucleotide is 2′-deoxyadenosine-5-phosphate;(b) if the ribonucleotide is guanosine-5′-phosphate, the2′-deoxyribonucleotide is 2′-deoxyguanosine-5′-phosphate;(c) if the ribonucleotide is cytidine-5′-phosphate, the2′-deoxyribonucleotide is 2′-deoxycytidine-5′phosphate; and(d) if the ribonucleotide is uridine-5′-phosphate, the2′-deoxyribonucleotide is 2′-deoxyuridine-5′-phosphate orthymidine-5-phosphate;andif in step b) the first level derivative is prepared by replacing the2′-deoxyribonucleotide at the one nucleotide position by aribonucleotide and(a) if the 2′-deoxyribonucleotide is 2′-deoxyadenosine-5′-phosphate, theribonucleotide is adenosine-5′-phosphate;(b) if the 2′-deoxyribonucleotide is 2′-deoxyguanosine-5′phosphate, theribonucleotide is guanosine-5′-phosphate;(c) if the 2′-deoxyribonucleotide is 2′-deoxycytidine-5′phosphate, theribonucleotide is cytidine-5′-phosphate; and(d) if the 2′-deoxyribonucleotide is thymidine-5′-phosphate, theribonucleotide is uridine-5′-phosphate or 5-methyl-uridine-5′-phosphate.

In an eighth embodiment of the first aspect which is also an embodimentof the first, the second, the third, the fourth, the fifth, the sixthand the seventh embodiment of the first aspect,

if in step b) the first level derivative is prepared by replacing theribonucleotide at the one nucleotide position by a2′-deoxyribonucleotide and(a) if the ribonucleotide is adenosine-5′-phosphate, the2′-deoxyribonucleotide is 2′-deoxyadenosine-5′-phosphate;(b) if the ribonucleotide is guanosine-5′-phosphate, the2′-deoxyribonucleotide is 2′-deoxyguanosine-5′-phosphate;(c) if the ribonucleotide is cytidine-5′-phosphate, the2′-deoxyribonucleotide is 2′-deoxycytidine-5′-phosphate; and(d) if the ribonucleotide is uridine-5′-phosphate, the2′-deoxyribonucleotide is 2′-deoxyuridine-5′-phosphate;andif in step b) the first level derivative is prepared by replacing the2′-deoxyribonucleotide at the one nucleotide position by aribonucleotide and(a) if the 2′-deoxyribonucleotide is 2′-deoxyadenosine-5′-phosphate, theribonucleotide is adenosine-5′-phosphate;(b) if the 2′-deoxyribonucleotide is 2′-deoxyguanosine-5′-phosphate, theribonucleotide is guanosine-5′-phosphate;(c) if the 2′-deoxyribonucleotide is 2′-deoxycytidine-5′-phosphate, theribonucleotide is cytidine-5′-phosphate; and(d) if the 2′-deoxyribonucleotide is thymidine-5′-phosphate, theribonucleotide is 5-methyl-uridine-5′phosphate.

In a ninth embodiment of the first aspect which is also an embodiment ofthe first, the second, the third, the fourth, the fifth and the sixthembodiment of the first aspect, the reference nucleic acid is aribonucleic acid molecule and wherein in step b) the first levelderivative is prepared by replacing the ribonucleotide at the onenucleotide position by a 2′-deoxyribonucleotide and wherein if

(a) the ribonucleotide is adenosine-5′-phosphate, the2′-deoxyribonucleotide is 2′-deoxyadenosine-5′-phosphate;(b) the ribonucleotide is guanosine5′-phosphate, the2′-deoxyribonucleotide is 2′-deoxyguanosine-5′-phosphate;(c) the ribonucleotide is cytidine-5′-phosphate, the2′-deoxyribonucleotide is 2′-deoxycytidine-5′-phosphate;(d) the ribonucleotide is uridine-5′-phosphate, the2′-deoxyribonucleotide is 2′-deoxy uridine-5′-phosphate orthymidine-5′phosphate.

In a tenth embodiment of the first aspect which is also an embodiment ofthe first, the second, the third, the fourth, the fifth, the sixth, theseventh, the eighth and the ninth embodiment of the first aspect, thereference nucleic acid is a 2′-deoxyribonucleic acid molecule andwherein in step b) the first level derivative is prepared by replacingthe 2′-deoxyribonucleotide at the one nucleotide position by aribonucleotide and wherein if

(a) if the 2′-deoxyribonucleotide is 2′-deoxyadenosine-5′-phosphate, theribonucleotide is adenosine-5′-phosphate;(b) if the 2′-deoxyribonucleotide is 2′-deoxyguanosine-5′-phosphate, theribonucleotide is guanosine-5′-phosphate;(c) if the 2′-deoxyribonucleotide is 2′-deoxycytidine-5′-phosphate, theribonucleotide is cytidine-5′-phosphate; and(d) if the 2′-deoxyribonucleotide is thymidine-5′phosphate, theribonucleotide is uridine-5′-phosphate or 5-methyl-uridine5′-phosphate.

In an eleventh embodiment of the first aspect which is also anembodiment of the tenth embodiment of the first aspect, if the2′-deoxyribonucleotide is thymidine-5′-phosphate, the ribonucleotide is5-methyl-uridine-5′-phosphate.

In a twelfth embodiment of the first aspect which is also an embodimentof the first, the second, the third, the fourth, the fifth, the sixth,the seventh, the eighth, the ninth, the tenth and the eleventhembodiment of the first aspect, the method is a method for generating anucleic acid molecule capable of binding to the target molecule, whereinthe binding affinity of the nucleic acid molecule is increased or thesame as the binding affinity of the reference nucleic acid molecule tothe target molecule.

In a thirteenth embodiment of the first aspect which is also anembodiment of the second, the third, the fourth, the fifth, the sixth,the seventh, the eighth, the ninth, the tenth, the eleventh and thetwelfth embodiment of the first aspect, the first level derivative thebinding characteristic of which exceeds the predetermined thresholdvalue, is a or the nucleic acid molecule capable of binding to a or thetarget molecule.

In a fourteenth embodiment of the first aspect which is also anembodiment of the second, the third, the fourth, the fifth, the sixth,the seventh, the eighth, the ninth, the tenth, the eleventh, the twelfthand the thirteenth embodiment of the first aspect, a second levelderivative of the reference nucleic acid molecule is prepared, whereinthe second level derivative differs from the reference nucleic acidmolecule at at least a first nucleotide position and a second nucleotideposition,

wherein the first nucleotide position is the modified nucleotideposition of a first first level derivative of the reference nucleic acidmolecule from the group of derivatives of the reference nucleic acidmolecule consisting of n derivatives and wherein the first levelderivative is one the binding characteristic of which exceeds thepredetermined threshold value, and wherein the nucleotide of the firstnucleotide position is identical to the nucleotide at the modifiedposition of the first first level derivative of the reference nucleicacid molecule, andwherein the second nucleotide position is the modified nucleotideposition of a second first level derivative of the reference nucleicacid molecule from the group of derivatives of the reference nucleicacid molecule consisting of n derivatives and wherein the second firstlevel derivative is one the binding characteristic of which exceeds thepredetermined threshold value and wherein the nucleotide of the secondnucleotide position is identical to the nucleotide at the modifiedposition of the second first level derivative of the reference nucleicacid molecule.

In a fifteenth embodiment of the first aspect which is also anembodiment of the fourteenth embodiment of the first aspect, the firstfirst level derivative and the second first level derivative is anycombination of two first level derivatives, wherein the bindingcharacteristic of each of the two first level derivatives exceeds thepredetermined threshold.

In a sixteenth embodiment of the first aspect which is also anembodiment of the fourteenth and the fifteenth embodiment of the firstaspect, the first first level derivative and the second level derivativeare the two first level derivatives which have a binding characteristicsuperior to the rest of the first level derivatives of the group offirst level derivatives of the reference nucleic acid moleculeconsisting of n nucleotides.

In a seventeenth embodiment of the first aspect which is also anembodiment of the fourteenth, the fifteenth and the sixteenth embodimentof the first aspect, the second level derivative of the referencenucleic acid molecule is capable of binding to the target molecule.

In an eighteenth embodiment of the first aspect which is also anembodiment of the fifteenth, the sixteenth and the seventeenthembodiment of the first aspect, the method comprises:

determining the binding characteristic of the second level derivative ofthe reference nucleic acid molecule to the target molecule; andoptionally

-   -   identifying the/those second level derivative(s) of the        reference nucleic acid molecule the binding characteristic of        which exceed a predetermined threshold value.

In a nineteenth embodiment of the first aspect which is also anembodiment of the eighteenth embodiment of the first aspect, the bindingcharacteristic is the binding affinity of the second level derivative(s)of the reference nucleic acid molecule to the target molecule.

In a twentieth embodiment of the first aspect which is also anembodiment of the eighteenth and the nineteenth embodiment of the firstaspect, the binding affinity is expressed as the K_(D) value.

In a twenty-first embodiment of the first aspect which is also anembodiment of the eighteenth, the nineteenth and the twentiethembodiment of the first aspect, the predetermined threshold value is Ywith Y being the quotient of (binding affinity of the reference nucleicacid molecule)/(binding affinity of the second level derivative) andwherein Y>1, more preferably Y≥2 and most preferably Y≥5 or Y≥10 orY≥20.

In a twenty-second embodiment of the first aspect which is also anembodiment of the eighteenth, the nineteenth, the twentieth and thetwenty-first embodiment of the first aspect, the predetermined thresholdvalue is X with X being the quotient of (KD value of the referencenucleic acid molecule)/(KD value of the second level derivative) andwherein X>1, more preferably X≥2 and most preferably X≥5 or X≥10 orX≥20.

In a twenty-third embodiment of the first aspect which is also anembodiment of the fourteenth, the fifteenth, the sixteenth, theseventeenth, the eighteenth, the nineteenth, the twentieth, thetwenty-first and the twenty-second embodiment of the first aspect, thesecond level derivative the binding characteristic of which exceeds thepredetermined threshold value, is a or the nucleic acid molecule capableof binding to a or the target molecule.

In a twenty-fourth embodiment of the first aspect which is also anembodiment of the second, the third, the fourth, the fifth, the sixth,the seventh, the eighth, the ninth, the tenth, the eleventh, thetwelfth, the thirteenth, the fourteenth, the fifteenth, the sixteenth,the seventeenth, the eighteenth, the nineteenth, the twentieth, thetwenty-first, the twenty-second and the twenty-third embodiment of thefirst aspect, a third level derivative of the reference nucleic acidmolecule is prepared, wherein the third level derivative differs fromthe reference nucleic acid molecule at at least a first nucleotideposition, a second nucleotide position and a third nucleotide position,

wherein the first nucleotide position is the modified nucleotideposition of a first first level derivative of the reference nucleic acidmolecule from the group of derivatives of the reference nucleic acidmolecule consisting of n derivatives and wherein the first levelderivative is one the binding characteristic of which exceeds thepredetermined threshold value, and wherein the nucleotide of the firstnucleotide position is identical to the nucleotide at the modifiedposition of the first first level derivative of the reference nucleicacid molecule,wherein the second nucleotide position is the modified nucleotideposition of a second first level derivative of the reference nucleicacid molecule from the group of derivatives of the reference nucleicacid molecule consisting of n derivatives and wherein the second firstlevel derivative is one the binding characteristic of which exceeds thepredetermined threshold value and wherein the nucleotide of the secondnucleotide position is identical to the nucleotide at the modifiedposition of the second first level derivative of the reference nucleicacid molecule,wherein the third nucleotide position is the modified nucleotideposition of a third first level derivative of the reference nucleic acidmolecule from the group of derivatives of the reference nucleic acidmolecule consisting of n derivatives and wherein the third first levelderivative is one the binding characteristic of which exceeds thepredetermined threshold value and wherein the nucleotide of the thirdnucleotide position is identical to the nucleotide at the modifiedposition of the third first level derivative of the reference nucleicacid molecule.

In a twenty-fifth embodiment of the first aspect which is also anembodiment of the twenty-fourth embodiment of the first aspect, thefirst first level derivative, the second first level derivative and thethird first level derivative is any combination of three first levelderivatives, wherein the binding characteristic of each of the threefirst level derivatives exceeds the predetermined threshold.

In a twenty-sixth embodiment of the first aspect which is also anembodiment of the twenty-fourth and the twenty-fifth embodiment of thefirst aspect, the first first level derivative, the second first levelderivative and the third first level derivative are the three firstlevel derivatives which have a binding characteristic superior to therest of the first level derivatives of the group of first levelderivatives of the reference nucleic acid molecule consisting of nnucleotides.

In a twenty-seventh embodiment of the first aspect which is also anembodiment of the twenty-fourth, the twenty-fifth and the twenty-sixthembodiment of the first aspect, the third level derivative of thereference nucleic acid molecule is capable of binding to the targetmolecule.

In a twenty-eighth embodiment of the first aspect which is also anembodiment of the twenty-fifth, the twenty-sixth and the twenty-seventhembodiment of the first aspect, the method comprises:

-   -   determining the binding characteristic of the third level        derivative of the reference nucleic acid molecule to the target        molecule; and optionally    -   identifying the/those third level derivative(s) of the reference        nucleic acid molecule the binding characteristic of which exceed        a predermined threshold value.

In a twenty-ninth embodiment of the first aspect which is also anembodiment of the twenty-eighth embodiment of the first aspect, thebinding characteristic is the binding affinity of the third levelderivative(s) of the reference nucleic acid molecule to the targetmolecule.

In a thirtieth embodiment of the first aspect which is also anembodiment of the twenty-eighth and the twenty-ninth embodiment of thefirst aspect, the binding affinity is expressed as the K_(D) value.

In a thirty-first embodiment of the first aspect which is also anembodiment of the twenty-eighth, the twenty-ninth and the thirtiethembodiment of the first aspect, the predetermined threshold value is Ywith Y being the quotient of (binding affinity of the reference nucleicacid molecule)/(binding affinity of the third level derivative) andwherein Y>1, more preferably Y≥2 and most preferably Y≥5 or Y≥10 orY≥20.

In a thirty-second embodiment of the first aspect which is also anembodiment of the twenty-eighth, the twenty-ninth, the thirtieth and thethirty-first embodiment of the first aspect, the predetermined thresholdvalue is X with X being the quotient of (KD value of the referencenucleic acid molecule)/(KD value of the third level derivative) andwherein X>1, more preferably X≥2 and most preferably X≥5 or X≥10 orX≥20.

In a thirty-third embodiment of the first aspect which is also anembodiment of the twenty-fourth, the twenty-fifth, the twenty-sixth, thetwenty-seventh, the twenty-eighth, the twenty-ninth, the thirtieth, thethirty-first and the thirty-second embodiment of the first aspect, thethird level derivative the binding characteristic of which exceeds thepredetermined threshold value, is a or the nucleic acid molecule capableof binding to a or the target molecule.

In a thirty-fourth embodiment of the first aspect which is also anembodiment of the second, the third, the fourth, the fifth, the sixth,the seventh, the eighth, the ninth, the tenth, the eleventh, thetwelfth, the thirteenth, the fourteenth, the fifteenth, the sixteenth,the seventeenth, the eighteenth, the nineteenth, the twentieth, thetwenty-first, the twenty-second, the twenty-third, the twenty-fourth,the twenty-fifth, the twenty-sixth, the twenty-seventh, thetwenty-eighth, the twenty-ninth, the thirtieth, the thirty-first, thethirty-second and the thirty-third embodiment of the first aspect, afourth level derivative of the reference nucleic acid molecule isprepared, wherein the fourth level derivative differs from the referencenucleic acid molecule at at least a first nucleotide position, a secondnucleotide position, a third nucleotide position and a fourth nucleotideposition,

wherein the first nucleotide position is the modified nucleotideposition of a first first level derivative of the reference nucleic acidmolecule from the group of derivatives of the reference nucleic acidmolecule consisting of n derivatives and wherein the first levelderivative is one the binding characteristic of which exceeds thepredetermined threshold value, and wherein the nucleotide of the firstnucleotide position is identical to the nucleotide at the modifiedposition of the first first level derivative of the reference nucleicacid molecule,wherein the second nucleotide position is the modified nucleotideposition of a second first level derivative of the reference nucleicacid molecule from the group of derivatives of the reference nucleicacid molecule consisting of n derivatives and wherein the second firstlevel derivative is one the binding characteristic of which exceeds thepredetermined threshold value and wherein the nucleotide of the secondnucleotide position is identical to the nucleotide at the modifiedposition of the second first level derivative of the reference nucleicacid molecule,wherein the third nucleotide position is the modified nucleotideposition of a third first level derivative of the reference nucleic acidmolecule from the group of derivatives of the reference nucleic acidmolecule consisting of n derivatives and wherein the third first levelderivative is one the binding characteristic of which exceeds thepredetermined threshold value and wherein the nucleotide of the thirdnucleotide position is identical to the nucleotide at the modifiedposition of the third level derivative of the reference nucleic acidmolecule, andwherein the fourth nucleotide position is the modified nucleotideposition of a fourth first level derivative of the reference nucleicacid molecule from the group of derivatives of the reference nucleicacid molecule consisting of n derivatives and wherein the fourth firstlevel derivative is one the binding characteristic of which exceeds thepredetermined threshold value and wherein the nucleotide of the fourthnucleotide position is identical to the nucleotide at the modifiedposition of the fourth first level derivative of the reference nucleicacid molecule.

In a thirty-fifth embodiment of the first aspect which is also anembodiment of the thirty-fourth embodiment of the first aspect, thefirst first level derivative, the second first level derivative, thethird first level derivative and the fourth first level derivative isany combination of four first level derivatives, wherein the bindingcharacteristic of each of the four first level derivatives exceeds thepredetermined threshold.

In a thirty-sixth embodiment of the first aspect which is also anembodiment of the thirty-fourth and thirty-fifth embodiment of the firstaspect, wherein the first first level derivative, the second first levelderivative, the third first level derivative and the fourth first levelderivative are the four first level derivatives which have a bindingcharacteristic superior to the rest of the first level derivatives ofthe group of first level derivatives of the reference nucleic acidmolecule consisting of n nucleotides.

In a thirty-seventh embodiment of the first aspect which is also anembodiment of the thirty-fourth, the thirty-fifth and the thirty-sixthembodiment of the first aspect, the fourth level derivative of thereference nucleic acid molecule is capable of binding to the targetmolecule.

In a thirty-eighth embodiment of the first aspect which is also anembodiment of the thirty-fifth, the thirty-sixth and the thirty-seventhembodiment of the first aspect, the method comprises:

-   -   determining the binding characteristic of the fourth level        derivative of the reference nucleic acid molecule to the target        molecule; and optionally    -   identifying the/those fourth level derivative(s) of the        reference nucleic acid molecule the binding characteristic of        which exceed a predetermined threshold value.

In a thirty-ninth embodiment of the first aspect which is also anembodiment of the thirty-eighth embodiment of the first aspect, thebinding characteristic is the binding affinity of the fourth levelderivative(s) of the reference nucleic acid molecule to the targetmolecule.

In a fortieth embodiment of the first aspect which is also an embodimentof the thirty-eighth and the thirty-ninth embodiment of the firstaspect, the binding affinity is expressed as the K_(D) value.

In a forty-first embodiment of the first aspect which is also anembodiment of the thirty-eighth, the thirty-ninth and the fortiethembodiment of the first aspect, the predetermined threshold value is Ywith Y being the quotient of (binding affinity of the reference nucleicacid molecule)/(binding affinity of the fourth level derivative) andwherein Y>1, more preferably Y≥2 and most preferably Y≥5 or Y≥10 orY≥20.

In a forty-second embodiment of the first aspect which is also anembodiment of the thirty-eighth, the thirty-ninth, the fortieth and theforty-first embodiment of the first aspect, the predetermined thresholdvalue is X with X being the quotient of (KD value of the referencenucleic acid molecule)/(KD value of the first level derivative) andwherein X>1, more preferably X≥2 and most preferably X≥5 or X≥10 orX≥20.

In a forty-third embodiment of the first aspect which is also anembodiment of the thirty-fourth, the thirty-fifth, the thirty-sixth, thethirty-seventh, the thirty-eighth, the thirty-ninth, the fortieth, theforty-first and the forty-second embodiment of the first aspect, thefourth level derivative the binding characteristic of which exceeds thepredetermined threshold value, is a or the nucleic acid molecule capableof binding to a or the target molecule.

In a forty-fourth embodiment of the first aspect which is also anembodiment of the second, the third, the fourth, the fifth, the sixth,the seventh, the eighth, the ninth, the tenth, the eleventh, thetwelfth, the thirteenth, the fourteenth, the fifteenth, the sixteenth,the seventeenth, the eighteenth, the nineteenth, the twentieth, thetwenty-first, the twenty-second, the twenty-third, the twenty-fourth,the twenty-fifth, the twenty-sixth, the twenty-seventh, thetwenty-eighth, the twenty-ninth, the thirtieth, the thirty-first, thethirty-second, the thirty-third, the thirty-fourth, the thirty-fifth,the thirty-sixth, the thirty-seventh, the thirty-eighth, thethirty-ninth, the fortieth, the forty-first, the forty-second and theforty-third embodiment of the first aspect, a fifth level derivative ofthe reference nucleic acid molecule is prepared, wherein the fifth levelderivative differs from the reference nucleic acid molecule at at leasta first nucleotide position, a second nucleotide position, a thirdnucleotide position, a fourth nucleotide position and a fifth nucleotideposition,

wherein the first nucleotide position is the modified nucleotideposition of a first first level derivative of the reference nucleic acidmolecule from the group of derivatives of the reference nucleic acidmolecule consisting of n derivatives and wherein the first levelderivative is one the binding characteristic of which exceeds thepredetermined threshold value, and wherein the nucleotide of the firstnucleotide position is identical to the nucleotide at the modifiedposition of the first first level derivative of the reference nucleicacid molecule,wherein the second nucleotide position is the modified nucleotideposition of a second first level derivative of the reference nucleicacid molecule from the group of derivatives of the reference nucleicacid molecule consisting of n derivatives and wherein the second firstlevel derivative is one the binding characteristic of which exceeds thepredetermined threshold value and wherein the nucleotide of the secondnucleotide position is identical to the nucleotide at the modifiedposition of the second first level derivative of the reference nucleicacid molecule,wherein the third nucleotide position is the modified nucleotideposition of a third first level derivative of the reference nucleic acidmolecule from the group of derivatives of the reference nucleic acidmolecule consisting of n derivatives and wherein the third first levelderivative is one the binding characteristic of which exceeds thepredetermined threshold value and wherein the nucleotide of the thirdnucleotide position is identical to the nucleotide at the modifiedposition of the third level derivative of the reference nucleic acidmolecule,wherein the fourth nucleotide position is the modified nucleotideposition of a fourth first level derivative of the reference nucleicacid molecule from the group of derivatives of the reference nucleicacid molecule consisting of n derivatives and wherein the fourth firstlevel derivative is one the binding characteristic of which exceeds thepredetermined threshold value and wherein the nucleotide of the fourthnucleotide position is identical to the nucleotide at the modifiedposition of the fourth first level derivative of the reference nucleicacid molecule, andwherein the fifth nucleotide position is the modified nucleotideposition of a fifth first level derivative of the reference nucleic acidmolecule from the group of derivatives of the reference nucleic acidmolecule consisting of n derivatives and wherein the fifth first levelderivative is one the binding characteristic of which exceeds thepredetermined threshold value and wherein the nucleotide of the fifthnucleotide position is identical to the nucleotide at the modifiedposition of the fifth first level derivative of the reference nucleicacid molecule.

In a forty-fifth embodiment of the first aspect which is also anembodiment of the forty-fourth embodiment of the first aspect, the firstfirst level derivative, the second first level derivative, the thirdfirst level derivative, the fourth first level derivative and the fifthfirst level derivative is any combination of five first levelderivatives, wherein the binding characteristic of each of the fivefirst level derivatives exceeds the predetermined threshold.

In a forty-sixth embodiment of the first aspect which is also anembodiment of the forty-fourth and the forty-fifth embodiment of thefirst aspect, the first first level derivative, the second first levelderivative, the third first level derivative, the fourth first levelderivative and the fifth first level derivative are the five first levelderivatives which have a binding characteristic superior to the rest ofthe first level derivatives of the group of first level derivatives ofthe reference nucleic acid molecule consisting of n nucleotides.

In a forty-seventh embodiment of the first aspect which is also anembodiment of the forty-fourth, the forty-fifth and the forty-sixthembodiment of the first aspect, the fifth level derivative of thereference nucleic acid molecule is capable of binding to the targetmolecule.

In a forty-eighth embodiment of the first aspect which is also anembodiment of the forty-fifth, the forty-sixth and the forty-seventhembodiment of the first aspect, the method comprises:

-   -   determining the binding characteristic of the fifth level        derivative of the reference nucleic acid molecule to the target        molecule; and optionally    -   identifying the/those fifth level derivative(s) of the reference        nucleic acid molecule the binding characteristic of which exceed        a predetermined threshold value.

In a forty-ninth embodiment of the first aspect which is also anembodiment of the forty-eighth embodiment of the first aspect, thebinding characteristic is the binding affinity of the fifth levelderivative(s) of the reference nucleic acid molecule to the targetmolecule.

In a fiftieth embodiment of the first aspect which is also an embodimentof the forty-eighth and the forty-ninth embodiment of the first aspect,the binding affinity is expressed as the K_(D) value.

In a fifty-first embodiment of the first aspect which is also anembodiment of the forty-eighth, the forty-ninth and the fiftiethembodiment of the first aspect, the predetermined threshold value is Ywith Y being the quotient of (binding affinity of the reference nucleicacid molecule)/(binding affinity of the fifth level derivative) andwherein Y>1, more preferably Y≥2 and most preferably Y≥5 or Y≥10 orY≥20.

In a fifty-second embodiment of the first aspect which is also anembodiment of the forty-eighth, the forty-ninth, the fiftieth and thefifty-first embodiment of the first aspect, the predetermined thresholdvalue is X with X being the quotient of (KD value of the referencenucleic acid molecule)/(KD value of the fifth level derivative) andwherein X>1, more preferably X≥2 and most preferably X≥5 or X≥10 orX≥20.

In a fifty-third embodiment of the first aspect which is also anembodiment of the forty-fourth, the forty-fifth, the forty-sixth, theforty-seventh, the forty-eighth, the forty-ninth, the fiftieth, thefifty-first and the fifty-second embodiment of the first aspect, thefifth level derivative the binding characteristic of which exceeds thepredetermined threshold value, is a or the nucleic acid molecule capableof binding to a or the target molecule.

In a fifty-fourth embodiment of the first aspect which is also anembodiment of the second, the third, the fourth, the fifth, the sixth,the seventh, the eighth, the ninth, the tenth, the eleventh, thetwelfth, the thirteenth, the fourteenth, the fifteenth, the sixteenth,the seventeenth, the eighteenth, the nineteenth, the twentieth, thetwenty-first, the twenty-second, the twenty-third, the twenty-fourth,the twenty-fifth, the twenty-sixth, the twenty-seventh, thetwenty-eighth, the twenty-ninth, the thirtieth, the thirty-first, thethirty-second, the thirty-third, the thirty-fourth, the thirty-fifth,the thirty-sixth, the thirty-seventh, the thirty-eighth, thethirty-ninth, the fortieth, the forty-first, the forty-second, theforty-third, the forty-fourth, the forty-fifth, the forty-sixth, theforty-seventh, the forty-eighth, the forty-ninth, the fiftieth, thefifty-first, the fifty-second and the fifty-third embodiment of thefirst aspect, a sixth level derivative of the reference nucleic acidmolecule is prepared, wherein the sixth level derivative differs fromthe reference nucleic acid molecule at at least a first nucleotideposition, a second nucleotide position, a third nucleotide position, afourth nucleotide position, a fifth nucleotide position and a sixthnucleotide position,

wherein the first nucleotide position is the modified nucleotideposition of a first first level derivative of the reference nucleic acidmolecule from the group of derivatives of the reference nucleic acidmolecule consisting of n derivatives and wherein the first levelderivative is one the binding characteristic of which exceeds thepredetermined threshold value, and wherein the nucleotide of the firstnucleotide position is identical to the nucleotide at the modifiedposition of the first first level derivative of the reference nucleicacid molecule,wherein the second nucleotide position is the modified nucleotideposition of a second first level derivative of the reference nucleicacid molecule from the group of derivatives of the reference nucleicacid molecule consisting of n derivatives and wherein the second firstlevel derivative is one the binding characteristic of which exceeds thepredetermined threshold value and wherein the nucleotide of the secondnucleotide position is identical to the nucleotide at the modifiedposition of the second first level derivative of the reference nucleicacid molecule,wherein the third nucleotide position is the modified nucleotideposition of a third first level derivative of the reference nucleic acidmolecule from the group of derivatives of the reference nucleic acidmolecule consisting of n derivatives and wherein the third first levelderivative is one the binding characteristic of which exceeds thepredetermined threshold value and wherein the nucleotide of the thirdnucleotide position is identical to the nucleotide at the modifiedposition of the third level derivative of the reference nucleic acidmolecule,wherein the fourth nucleotide position is the modified nucleotideposition of a fourth first level derivative of the reference nucleicacid molecule from the group of derivatives of the reference nucleicacid molecule consisting of n derivatives and wherein the fourth firstlevel derivative is one the binding characteristic of which exceeds thepredetermined threshold value and wherein the nucleotide of the fourthnucleotide position is identical to the nucleotide at the modifiedposition of the fourth first level derivative of the reference nucleicacid molecule,wherein the fifth nucleotide position is the modified nucleotideposition of a fifth first level derivative of the reference nucleic acidmolecule from the group of derivatives of the reference nucleic acidmolecule consisting of n derivatives and wherein the fifth first levelderivative is one the binding characteristic of which exceeds thepredetermined threshold value and wherein the nucleotide of the fifthnucleotide position is identical to the nucleotide at the modifiedposition of the fifth first level derivative of the reference nucleicacid molecule, andwherein the sixth nucleotide position is the modified nucleotideposition of a sixth first level derivative of the reference nucleic acidmolecule from the group of derivatives of the reference nucleic acidmolecule consisting of n derivatives and wherein the sixth first levelderivative is one the binding characteristic of which exceeds thepredetermined threshold value and wherein the nucleotide of the sixthnucleotide position is identical to the nucleotide at the modifiedposition of the sixth first level derivative of the reference nucleicacid molecule.

In a fifty-fifth embodiment of the first aspect which is also anembodiment of the fifty-fourth embodiment of the first aspect, the firstfirst level derivative, the second first level derivative, the thirdfirst level derivative, the fourth first level derivative, the fifthfirst level derivative and the sixth first level derivative is anycombination of six first level derivatives, wherein the bindingcharacteristic of each of the six first level derivatives exceeds thepredetermined threshold.

In a fifty-sixth embodiment of the first aspect which is also anembodiment of the fifty-fourth and the fifty-fifth embodiment of thefirst aspect, the first first level derivative, the second first levelderivative, the third first level derivative, the fourth first levelderivative, the fifth first level derivative and the sixth first levelderivative are the six first level derivatives which have a bindingcharacteristic superior to the rest of the first level derivatives ofthe group of first level derivatives of the reference nucleic acidmolecule consisting of n nucleotides.

In a fifty-seventh embodiment of the first aspect which is also anembodiment of the fifty-fourth, the fifty-fifth and the fifty-sixthembodiment of the first aspect, the sixth level derivative of thereference nucleic acid molecule is capable of binding to the targetmolecule.

In a fifty-eighth embodiment of the first aspect which is also anembodiment of the fifty-fifth, the fifty-sixth and the fifty-seventhembodiment of the first aspect, the method comprises:

-   -   determining the binding characteristic of the sixth level        derivative of the reference nucleic acid molecule to the target        molecule; and optionally    -   identifying the/those sixth level derivative(s) of the reference        nucleic acid molecule the binding characteristic of which exceed        a predetermined threshold value.

In a fifty-ninth embodiment of the first aspect which is also anembodiment of the fifty-eighth embodiment of the first aspect, thebinding characteristic is the binding affinity of the sixth levelderivative(s) of the reference nucleic acid molecule to the targetmolecule.

In a sixtieth embodiment of the first aspect which is also an embodimentof the fifty-eighth and the fifty-ninth embodiment of the first aspect,the binding affinity is expressed as the K_(D) value.

In a sixty-first embodiment of the first aspect which is also anembodiment of the fifty-eighth, the fifty-ninth and the sixtiethembodiment of the first aspect, the predetermined threshold value is Ywith Y being the quotient of (binding affinity of the reference nucleicacid molecule)/(binding affinity of the sixth level derivative) andwherein Y>1, more preferably Y≥2 and most preferably Y≥5 or Y≥10 orY≥20.

In a sixty-second embodiment of the first aspect which is also anembodiment of the fifty-eighth, the fifty-ninth, the sixtieth and thesixty-first embodiment of the first aspect, the predetermined thresholdvalue is X with X being the quotient of (KD value of the referencenucleic acid molecule)/(KD value of the sixth level derivative) andwherein X>1, more preferably X≥2 and most preferably X≥5 or X≥10 orX≥20.

In a sixty-third embodiment of the first aspect which is also anembodiment of the fifty-fourth, the fifty-fifth, the fifty-sixth, thefifty-seventh, the fifty-eighth, the fifty-ninth, the sixtieth, thesixty-first and the sixty-second embodiment of the first aspect, thesixth level derivative the binding characteristic of which exceeds thepredetermined threshold value, is a or the nucleic acid molecule capableof binding to a or the target molecule.

In a sixty-fourth embodiment of the first aspect which is also anembodiment of the second, the third, the fourth, the fifth, the sixth,the seventh, the eighth, the ninth, the tenth, the eleventh, thetwelfth, the thirteenth, the fourteenth, the fifteenth, the sixteenth,the seventeenth, the eighteenth, the nineteenth, the twentieth, thetwenty-first, the twenty-second, the twenty-third, the twenty-fourth,the twenty-fifth, the twenty-sixth, the twenty-seventh, thetwenty-eighth, the twenty-ninth, the thirtieth, the thirty-first, thethirty-second, the thirty-third, the thirty-fourth, the thirty-fifth,the thirty-sixth, the thirty-seventh, the thirty-eighth, thethirty-ninth, the fortieth, the forty-first, the forty-second, theforty-third, the forty-fourth, the forty-fifth, the forty-sixth, theforty-seventh, the forty-eighth, the forty-ninth, the fiftieth, thefifty-first, the fifty-second, the fifty-third, the fifty-fourth, thefifty-fifth, the fifty-sixth, the fifty-seventh, the fifty-eighth, thefifty-ninth, the sixtieth, the sixty-first, the sixty-second and thesixty-third embodiment of the first aspect, a seventh level derivativeof the reference nucleic acid molecule is prepared, wherein the seventhlevel derivative differs from the reference nucleic acid molecule at atleast a first nucleotide position, a second nucleotide position, a thirdnucleotide position, a fourth nucleotide position, a fifth nucleotideposition, a sixth nucleotide position and a seventh nucleotide position,

wherein the first nucleotide position is the modified nucleotideposition of a first first level derivative of the reference nucleic acidmolecule from the group of derivatives of the reference nucleic acidmolecule consisting of n derivatives and wherein the first levelderivative is one the binding characteristic of which exceeds thepredetermined threshold value, and wherein the nucleotide of the firstnucleotide position is identical to the nucleotide at the modifiedposition of the first first level derivative of the reference nucleicacid molecule,wherein the second nucleotide position is the modified nucleotideposition of a second first level derivative of the reference nucleicacid molecule from the group of derivatives of the reference nucleicacid molecule consisting of n derivatives and wherein the second firstlevel derivative is one the binding characteristic of which exceeds thepredetermined threshold value and wherein the nucleotide of the secondnucleotide position is identical to the nucleotide at the modifiedposition of the second first level derivative of the reference nucleicacid molecule,wherein the third nucleotide position is the modified nucleotideposition of a third first level derivative of the reference nucleic acidmolecule from the group of derivatives of the reference nucleic acidmolecule consisting of n derivatives and wherein the third first levelderivative is one the binding characteristic of which exceeds thepredetermined threshold value and wherein the nucleotide of the thirdnucleotide position is identical to the nucleotide at the modifiedposition of the third level derivative of the reference nucleic acidmolecule,wherein the fourth nucleotide position is the modified nucleotideposition of a fourth first level derivative of the reference nucleicacid molecule from the group of derivatives of the reference nucleicacid molecule consisting of n derivatives and wherein the fourth firstlevel derivative is one the binding characteristic of which exceeds thepredetermined threshold value and wherein the nucleotide of the fourthnucleotide position is identical to the nucleotide at the modifiedposition of the fourth first level derivative of the reference nucleicacid molecule,wherein the fifth nucleotide position is the modified nucleotideposition of a fifth first level derivative of the reference nucleic acidmolecule from the group of derivatives of the reference nucleic acidmolecule consisting of n derivatives and wherein the fifth first levelderivative is one the binding characteristic of which exceeds thepredetermined threshold value and wherein the nucleotide of the fifthnucleotide position is identical to the nucleotide at the modifiedposition of the fifth first level derivative of the reference nucleicacid molecule,wherein the sixth nucleotide position is the modified nucleotideposition of a sixth first level derivative of the reference nucleic acidmolecule from the group of derivatives of the reference nucleic acidmolecule consisting of n derivatives and wherein the sixth first levelderivative is one the binding characteristic of which exceeds thepredetermined threshold value and wherein the nucleotide of the sixthnucleotide position is identical to the nucleotide at the modifiedposition of the sixth first level derivative of the reference nucleicacid molecule, andwherein the seventh nucleotide position is the modified nucleotideposition of a seventh first level derivative of the reference nucleicacid molecule from the group of derivatives of the reference nucleicacid molecule consisting of n derivatives and wherein the seventh firstlevel derivative is one the binding characteristic of which exceeds thepredetermined threshold value and wherein the nucleotide of the sixthnucleotide position is identical to the nucleotide at the modifiedposition of the seventh first level derivative of the reference nucleicacid molecule.

In a sixty-fifth embodiment of the first aspect which is also anembodiment of the sixty-fourth embodiment of the first aspect, the firstfirst level derivative, the second first level derivative, the thirdfirst level derivative, the fourth first level derivative, the fifthfirst level derivative, the sixth first level derivative and the seventhfirst level derivative is any combination of seven first levelderivatives, wherein the binding characteristic of each of the seventhfirst level derivatives exceeds the predetermined threshold.

In a sixty-sixth embodiment of the first aspect which is also anembodiment of the sixty-fourth and the sixty-fifth embodiment of thefirst aspect, the first first level derivative, the second first levelderivative, the third first level derivative, the fourth first levelderivative, the fifth first level derivative, the sixth first levelderivative and the seventh first level derivative are the seven firstlevel derivatives which have a binding characteristic superior to therest of the first level derivatives of the group of first levelderivatives of the reference nucleic acid molecule consisting of nnucleotides.

In a sixty-seventh embodiment of the first aspect which is also anembodiment of the sixty-fourth, the sixty-fifth and the sixty-sixthembodiment of the first aspect, the seventh level derivative of thereference nucleic acid molecule is capable of binding to the targetmolecule.

In a sixty-eighth embodiment of the first aspect which is also anembodiment of the sixty-fifth, the sixty-sixth and the sixty-seventhembodiment of the first aspect, the method comprises:

-   -   determining the binding characteristic of the seventh level        derivative of the reference nucleic acid molecule to the target        molecule; and optionally    -   identifying the/those seventh level derivative(s) of the        reference nucleic acid molecule the binding characteristic of        which exceed a predetermined threshold value.

In a sixty-ninth embodiment of the first aspect which is also anembodiment of the sixty-eighth embodiment of the first aspect, thebinding characteristic is the binding affinity of the seventh levelderivative(s) of the reference nucleic acid molecule to the targetmolecule.

In a seventieth embodiment of the first aspect which is also anembodiment of the sixty-eighth and the sixty-ninth embodiment of thefirst aspect, the binding affinity is expressed as the K_(D) value.

In a seventy-first embodiment of the first aspect which is also anembodiment of the sixty-eighth, the sixty-ninth and the seventiethembodiment of the first aspect, the predetermined threshold value is Ywith Y being the quotient of (binding affinity of the reference nucleicacid molecule)/(binding affinity of the seventh level derivative) andwherein Y>1, more preferably Y≥2 and most preferably Y≥5 or Y≥10 orY≥20.

In a seventy-second embodiment of the first aspect which is also anembodiment of the sixty-eighth, the sixty-ninth, the seventieth and theseventy-first embodiment of the first aspect, the predeterminedthreshold value is X with X being the quotient of (KD value of thereference nucleic acid molecule)/(KD value of the seventh levelderivative) and wherein X>1, more preferably X≥2 and most preferably X≥5or X≥10 or X≥20.

In a seventy-third embodiment of the first aspect which is also anembodiment of the sixty-fourth, the sixty-fifth, the sixty-sixth, thesixty-seventh, the sixty-eighth, the sixty-ninth, the seventieth, theseventy-first and the seventy-second embodiment of the first aspect, theseventh level derivative the binding characteristic of which exceeds thepredetermined threshold value, is a or the nucleic acid molecule capableof binding to a or the target molecule.

In a seventy-fourth embodiment of the first aspect which is also anembodiment of the first, the second, the third, the fourth, the fifth,the sixth, the seventh, the eighth, the ninth, the tenth, the eleventh,the twelfth, the thirteenth, the fourteenth, the fifteenth, thesixteenth, the seventeenth, the eighteenth, the nineteenth, thetwentieth, the twenty-first, the twenty-second, the twenty-third, thetwenty-fourth, the twenty-fifth, the twenty-sixth, the twenty-seventh,the twenty-eighth, the twenty-ninth, the thirtieth, the thirty-first,the thirty-second, the thirty-third, the thirty-fourth, thethirty-fifth, the thirty-sixth, the thirty-seventh, the thirty-eighth,the thirty-ninth, the fortieth, the forty-first, the forty-second, theforty-third, the forty-fourth, the forty-fifth, the forty-sixth, theforty-seventh, the forty-eighth, the forty-ninth, the fiftieth, thefifty-first, the fifty-second, the fifty-third, the fifty-fourth, thefifty-fifth, the fifty-sixth, the fifty-seventh, the fifty-eighth, thefifty-ninth, the sixtieth, the sixty-first, the sixty-second, thesixty-third, the sixty-fourth, the sixty-fifth, the sixty-sixth, thesixty-seventh, the sixty-eighth, the sixty-ninth, the seventieth, theseventy-first, the seventy-second and the seventy-third embodiment ofthe first aspect, the nucleic acid capable of binding to a targetmolecule is an L-nucleic acid, the reference nucleic acid molecule is anL-nucleic acid and each and any of the derivatives of the referencenucleic acid molecule is an L-nucleic acid.

The problem underlying the present invention is solved in a secondaspect which is also the first embodiment of the second aspect, by anucleic acid molecule capable of binding to a target molecule obtainableby a method according to any one of the first, the second, the third,the fourth, the fifth, the sixth, the seventh, the eighth, the ninth,the tenth, the eleventh, the twelfth, the thirteenth, the fourteenth,the fifteenth, the sixteenth, the seventeenth, the eighteenth, thenineteenth, the twentieth, the twenty first, the twenty second, thetwenty third, the twenty fourth, the twenty fifth, the twenty-sixth, thetwenty seventh, the twenty-eighth, the twenty-ninth, the thirtieth, thethirty-first, the thirty-second, the thirty-third, the thirty-fourth,the thirty-fifth, the thirty-sixth, the thirty-seventh, thethirty-eighth, the thirty-ninth, the fortieth, the forty-first, theforty-second, the forty-third, the forty-fourth, the forty-fifth, theforty-sixth, the forty-seventh, the forty-eighth, the forty-ninth, thefiftieth, the fifty-first, the fifty-second, the fifty-third, thefifty-fourth, the fifty-fifth, the fifty-sixth, the fifty-seventh, thefifty-eighth, the fifty-ninth, the sixtieth, the sixty-first, thesixty-second, the sixty-third, the sixty-fourth, the sixty-fifth, thesixty-sixth, the sixty-seventh, the sixty-eighth, the sixty-ninth, theseventieth, the seventy-first, the seventy-second, the seventy-third andthe seventy-fourth embodiment of the first aspect.

In a second embodiment of the second aspect which is also an embodimentof the first embodiment of the second aspect, the nucleic acid moleculecomprises at least one modification.

In a third embodiment of the second aspect which is also an embodimentof the first and the second embodiment of the second aspect, the nucleicacid molecule is for use in a method for the treatment and/or preventionof a disease.

In a fourth embodiment of the second aspect which is also an embodimentof the first and the second embodiment of the second aspect, the nucleicacid molecule is for use in a method for the diagnosis of a disease.

In a fifth embodiment of the second aspect which is also an embodimentof the third and the fourth embodiment of the second aspect, the diseaseis a disease which involves the target molecule.

The problem underlying the present invention is solved in a third aspectwhich is also the first embodiment of the third aspect, by use of anucleic acid molecule according to any one of the first and the secondembodiment of the second aspect for the manufacture of a medicament forthe treatment of a disease.

The problem underlying the present invention is solved in a fourthaspect which is also the first embodiment of the fourth aspect, by useof a nucleic acid molecule according to any one of the first and thesecond embodiment of the second aspect for the manufacture of adiagnostic agent for the treatment of a disease.

In a second embodiment of the third aspect which is also the secondembodiment of the fourth aspect and an embodiment of the firstembodiment of the third aspect and an embodiment of the first embodimentof the fourth aspect, the disease is a disease which involves the targetmolecule.

The problem underlying the present invention is solved in a fifth aspectwhich is also the first embodiment of the fifth aspect, by apharmaceutical composition comprising a nucleic acid molecule accordingto any one of the first and the second embodiment of the second aspectand a pharmaceutically acceptable carrier.

The problem underlying the present invention is solved in a sixth aspectwhich is also the first embodiment of the sixth aspect, by a nucleicacid molecule capable of binding to a target molecule,

wherein the nucleic acid molecule has a binding affinity to the targetmolecule,wherein the binding affinity of the nucleic acid molecule to the targetmolecule is increased or the same compared to the binding affinity of areference nucleic acid molecule to the target molecule,wherein

-   -   a) the nucleic acid molecule comprises a sequence of nucleotides        and the reference nucleic acid molecule comprises a sequence of        nucleotides, or    -   b) the nucleic acid molecule comprises a sequence of nucleotides        and at least one modification group and the reference nucleic        acid molecule comprises a sequence of nucleotides and the at        least one modification group,        wherein the sequence of nucleotides of the nucleic acid molecule        and the sequence of nucleotides of the reference nucleic acid        molecule are at least partially identical with respect to the        nucleobase moiety of the nucleotides but differ with respect to        the sugar moiety of the nucleotides,        wherein the sequence of nucleotides of the nucleic acid molecule        consists of both ribonucleotides and 2′-deoxyribonucleotides and        wherein the sequence of nucleotides of the reference nucleic        acid molecule consists of either ribonucleotides or        2′-deoxyribonucleotides.

In a second embodiment of the sixth aspect which is also an embodimentof the first embodiment of the sixth aspect,

a) the nucleic acid molecule consists of a sequence of nucleotides andthe reference nucleic acid molecule consists of a sequence ofnucleotides, orb) the nucleic acid molecule consists of a sequence of nucleotides andat least one modification group and the reference nucleic acid moleculeconsists of a sequence of nucleotides and the at least one modificationgroup,wherein the sequence of nucleotides of the nucleic acid molecule and thesequence of nucleotides of the reference nucleic acid molecule areidentical with respect to the nucleobase moiety of the nucleotides butdiffer with respect to the sugar moiety of the nucleotides.

In a third embodiment of the sixth aspect which is also an embodiment ofthe second embodiment of the sixth aspect, the binding affinity of thenucleic acid molecule to the target molecule is increased compared tothe binding affinity of a reference nucleic acid molecule to the targetmolecule.

In a fourth embodiment of the sixth aspect which is also the sixthembodiment of the second aspect and an embodiment of the first, thesecond, the third, the forth and the fifth embodiment of the secondaspect, and an embodiment of first, the second and the third embodimentof the sixth aspect, the ribonucleotides are L-ribonucleotides andwherein the 2′-deoxyribonucleotides are L-2′-deoxyribonucleotides.

In a fifth embodiment of the sixth aspect which is also the seventhembodiment of the second aspect and an embodiment of the first, thesecond, the third, the forth, the fifth and the sixth embodiment of thesecond aspect, and an embodiment of first, the second, the third and thefourth embodiment of the sixth aspect, the nucleic acid molecule is anL-nucleic acid molecule,

wherein the L-nucleic acid molecule consists of L-nucleotides, and thereference nucleic acid molecule is an L-reference nucleic acid molecule,wherein the L-reference nucleic acid molecule consists of L-nucleotides.

In a sixth embodiment of the sixth aspect which is also the eighthembodiment of the second aspect and an embodiment of the first, thesecond, the third, the forth, the fifth, the sixth and the seventhembodiment of the second aspect, and an embodiment of first, the second,the third, the fourth and the fifth embodiment of the sixth aspect, thenucleic acid molecule and/or the reference nucleic acid molecule areantagonists of an activity mediated by the target molecule.

In a seventh embodiment of the sixth aspect which is also the ninthembodiment of the second aspect and an embodiment of the first, thesecond, the third, the forth, the fifth, the sixth, the seventh and theeighth embodiment of the second aspect, and an embodiment of first, thesecond, the third, the fourth, the fifth and the sixth embodiment of thesixth aspect, excretion rate of the nucleic acid molecule comprising asequence of nucleotides and at least one modification group from anorganism is decreased compared to a nucleic acid molecule consisting ofthe sequence of nucleotides.

In an eighth embodiment of the sixth aspect which is also the tenthembodiment of the second aspect and an embodiment of the first, thesecond, the third, the forth, the fifth, the sixth, the seventh and theeighth embodiment of the second aspect, and an embodiment of first, thesecond, the third, the fourth, the fifth and the sixth embodiment of thesixth aspect, the nucleic acid molecule comprising a sequence ofnucleotides and at least one modification has an increased retentiontime in an organism compared to a nucleic acid molecule consisting ofthe sequence of nucleotides.

In a ninth embodiment of the sixth aspect which is also the eleventhembodiment of the second aspect and an embodiment of the ninth and thetenth embodiment of the second aspect, and an embodiment of the seventhand the eighth embodiment of the sixth aspect, the modification group isselected from the group comprising biodegradable and non-biodegradablemodifications, preferably the modification group is selected from thegroup comprising polyethylene glycol, linear polyethylene glycol,branched polyethylene glycol, hydroxyethyl starch, a peptide, a protein,a polysaccharide, a sterol, polyoxypropylene, polyoxyamidate and poly(2-hydroxyethyl)-L-glutamine.

In a tenth embodiment of the sixth aspect which is also the twelfthembodiment of the second aspect and an embodiment of the eleventhembodiment of the second aspect, and an embodiment of the ninthembodiment of the sixth aspect, the modification group is a polyethyleneglycol, preferably consisting of a linear polyethylene glycol orbranched polyethylene glycol, wherein the molecular weight of thepolyethylene glycol is preferably from about 20,000 to about 120,000 Da,more preferably from about 30,000 to about 80,000 Da and most preferablyabout 40,000 Da.

In an eleventh embodiment of the sixth aspect which is also thethirteenth embodiment of the second aspect and an embodiment of theeleventh embodiment of the second aspect, and an embodiment of the ninthembodiment of the sixth aspect, the modification group is hydroxyethylstarch, wherein preferably the molecular weight of the hydroxyethylstarch is from about 50 to about 1000 kDa, more preferably from about100 to about 700 kDa and most preferably from 200 to 500 kDa.

In a twelfth embodiment of the sixth aspect which is also the fourteenthembodiment of the second aspect and an embodiment of the ninth, thetenth, the eleventh, the twelfth and the thirteenth embodiment of thesecond aspect, and an embodiment of the seventh, the eighth, the ninth,the tenth, the eleventh and the twelfth embodiment of the sixth aspect,the organism is an animal or a human body, preferably a human body.

In a thirteenth embodiment of the sixth aspect which is also thefifteenth embodiment of the second aspect and an embodiment of thefirst, the second, the third, the fourth, the fifth, the sixth, theseventh, the eighth, the ninth, the tenth, the eleventh and the twelfthembodiment of the sixth aspect, and an embodiment of the sixth, theseventh, the eighth, the ninth, the tenth, the eleventh, the twelfth,the thirteenth and the fourteenth embodiment of the sixth aspect, thenucleic acid molecule is for use in a method for the treatment and/orprevention of a disease.

In a fourteenth embodiment of the sixth aspect which is also thesixteenth embodiment of the second aspect and an embodiment of thefirst, the second, the third, the fourth, the fifth, the sixth, theseventh, the eighth, the ninth, the tenth, the eleventh, the twelfth,the thirteenth, the fourteenth and the fifteenth embodiment of thesecond aspect, and an embodiment of the first, the second, the third,the fourth, the fifth, the sixth, the seventh, the eighth, the ninth,the tenth, the eleventh, the twelfth and the thirteenth embodiment ofthe sixth aspect, the nucleic acid molecule and the reference nucleicacid molecule are resistant to nuclease activity.

It will be understood by a person skilled in the art that the followingembodiments and features may also be realized in connection with thefeatures and embodiments described herein, in particular in connectionwith the aspects and embodiments as subject to the claims attachedhereto.

The present inventors have also found that by following a rationalapproach starting from a reference nucleic acid molecule which iscapable of binding to a target molecule a—further—nucleic acid moleculecan be generated which binds to a target molecule, whereby it ispreferred that the nucleic acid molecule which is capable of binding toa target molecule binds to the target molecule of the reference nucleicacid molecule. Such rational approach comprises a method comprising thefollowing steps:

a) providing a reference nucleic acid molecule, wherein the referencenucleic acid molecule is capable of binding to the target molecule andwherein the reference nucleic acid molecule comprises a sequence ofnucleotides, wherein the sequence of nucleotides comprises nnucleotides;b) preparing a first level derivative of the reference nucleic acidmolecule, wherein the first level derivative of the reference nucleicacid molecule differs from the reference nucleic acid molecule at onenucleotide position, wherein the first level derivative is prepared byreplacing the ribonucleotide at the one nucleotide position by adeoxyribonucleotide in case the reference nucleic acid has aribonucleotide at the nucleotide position and wherein the first levelderivative is prepared by replacing the deoxyribonucleotide at the onenucleotide position by a ribonucleotide in case the reference nucleicacid has a deoxyribonucleotide at the nucleotide position and whereinthe nucleotide position at which the replacement is made is the modifiednucleotide position; andc) repeating step b) for each nucleotide position of the referencenucleic acid molecule, thus preparing a group of first level derivativesof the reference nucleic acid molecule, wherein the group of first levelderivatives of the reference nucleic acid molecule consists of n firstlevel derivatives, wherein each of the first level derivatives of thereference nucleic acid molecule differs from the reference nucleic acidmolecule by a single nucleotide replacement and wherein each of thefirst level derivatives of the reference nucleic acid molecule has asingle modified nucleotide position which is different from the singlemodified nucleotide of all of the single modified nucleotide positionsof the other first level derivatives of the group of first levelderivatives of the reference nucleic acid molecule.

In an embodiment the first level derivatives comprise a sequence ofnucleotides, wherein the sequence of nucleotides comprises nnucleotides.

It is within the present invention that the terms first level derivativeand first level derivative of the reference nucleic acid molecule areused in a synonymous manner if not indicated to the contrary.

It is also within the present invention that the terms group of firstlevel derivatives and group of first level derivatives of the referencenucleic acid molecule are used in a synonymous manner if not indicatedto the contrary.

It will be understood by a person skilled in the art that each firstlevel derivative has only one nucleotide exchange relative to thereference nucleic acid molecule. It will also be understood that in anembodiment step b) is repated (n−1)-times so that each and any of the nnucleotide positions of the reference nucleic acid molecule is subjectto a nucleotide replacement. In such group of first level derivatives ofthe reference nucleic acid molecule, the group of first levelderivatives, in its entirety, represents all derivatives which can beprepared starting from the reference nucleic acid molecule wherein eachof the derivatives differs from the reference nucleic acid molecule at asingle nucleotide position.

It is, however, also within the present invention that step b) isrepeated less than (n−1)-times. It is also within the present inventionthat step b) is not repeated at all so that at only one nucleotideposition a ribonucleotide is replaced by a deoxyribonucleotide and,respectively, a deoxyribonucletoide is replaced by a ribonucleotide.This latter embodiment will preferably be performed in case the singlenucleotide replacement will result in a derivative, which is a firstlevel derivative, if the derivative has an improved bindingcharacteristic as defined herein compared to the reference nucleic acidmolecule.

The embodiment of the method of the present invention will comprise lessthan (n−1) repetitions of step b), but preferably one or more than onerepetition if upon repeating step b) one, two, three etc. but less than(n−1) first level derivatives are obtained which have an improvedbinding characteristic as defined herein compared to the referencenucleic acid molecule.

In a further embodiment of the method of the present invention themethod comprises a step of determining the binding characteristic foreach of the n first level derivatives of the reference nucleic acid.Preferably, the binding characteristic in terms of the binding of thefirst level derivatives to the target molecule is determined. In afurther embodiment of the method of the present invention the bindingcharacteristic is determined for less than the n first levelderivatives, preferably the binding characteristic is determined for atleast one of the n first level derivatives but not for all n first levelderivatives. Also in these embodiments, the binding characteristic interms of the binding of the first level derivatives to the targetmolecule is determined.

In a further embodiment of the method of the present invention themethod comprises a step of identifying the/those first levelderivative(s) of the reference nucleic acid molecule the bindingcharacteristic of which exceed or reach a predetermined threshold value.In an embodiment thereof, either all of the first level derivativeswhich exceed or reach the predetermined threshold value are identifiedor only some of the first level derivatives which exceed or reach thepredetermined threshold value are identified.

It is also within the present invention that the threshold value is thebinding affinity of the reference nucleic acid molecule. In thisembodiment the derivative of the reference nucleic acid of any level hasthe same or a similar binding affinity to the target molecule as thereference nucleic acid molecule. This embodiment is an embodiment of anylevel derivative as disclosed herein.

In accordance with the method of the present invention the nucleic acidto be generated is a first level derivative of the reference nucleicacid molecule or any level derivative of the reference nucleic acidwhich is capable of binding to the target molecule to which thereference nucleic acid molecule is capable of binding and which reachesa threshold value.

It is within the present invention that the reference nucleic acidmolecule is an RNA molecule. In this embodiment the reference nucleicacid molecule consists of ribonucleotides.

It is within the present invention that the reference nucleic acidmolecule is a DNA molecule. In this embodiment the reference nucleicacid molecule consists of deoxyribonucleotides.

It is also within the present invention that the reference nucleic acidmolecule consists of both ribonucleotides and deoxyribonucleotides,whereby at each position of the sequence of nucleotides forming thereference nucleic acid sequence the nucleotide is either adeoxyribonucleotide or a ribonucleotide.

A further aspect of the present invention is a second level derivativeof the reference nucleic acid molecule. Such second level derivative ofthe reference nucleic acid molecule can be obtained or is obtainable bythe method of the present invention as disclosed herein and is describedherein in connection with the method of the present invention. Morespecifically, the second level derivative differs from the referencenucleic acid molecule at at least a first nucleotide position and asecond nucleotide position,

wherein the first nucleotide position is the modified nucleotideposition of a first first level derivative of the reference nucleic acidmolecule from the group of derivatives of the reference nucleic acidmolecule consisting of n derivatives and wherein the first levelderivative is one the binding characteristic of which exceeds thepredetermined threshold value, and wherein the nucleotide of the firstnucleotide position is identical to the nucleotide at the modifiedposition of the first first level derivative of the reference nucleicacid molecule, andwherein the second nucleotide position is the modified nucleotideposition of a second first level derivative of the reference nucleicacid molecule from the group of derivatives of the reference nucleicacid molecule consisting of n derivatives and wherein the second firstlevel derivative is one the binding characteristic of which exceeds thepredetermined threshold value and wherein the nucleotide of the secondnucleotide position is identical to the nucleotide at the modifiedposition of the second first level derivative of the reference nucleicacid molecule.

Further aspects of the present invention are related to a third levelderivative of the reference nucleic acid molecule, a fourth levelderivative of the reference nucleic acid molecule, a fifth levelderivative of the reference nucleic acid molecule, a sixth levelderivative of the reference nucleic acid molecule and a seventh levelderivative of the reference nucleic acid molecule. Such third, fourth,fifth, sixth and seventh level derivative of the reference nucleic acidmolecule can be obtained or is obtainable by the method of the presentinvention as disclosed herein and are described herein in connectionwith the method of the present invention.

It is to be acknowledged that in connection with the second, third,fourth, fifth, sixth and seventh level derivative of the referencenucleic acid molecule, all of which are a nucleic acid moleculeaccording to the present invention, the number of replacements is notlimited to two nucleotides in connection with the second levelderivative of the reference nucleic acid molecule, is not limited tothree nucleotides in connection with the third level derivative of thereference nucleic acid molecule, is not limited to four nucleotides inconnection with the fourth level derivative of the reference nucleicacid molecule, is not limited to five nucleotides in connection with thefifth level derivative of the reference nucleic acid molecule, is notlimited to six nucleotides in connection with the sixth level derivativeof the reference nucleic acid molecule, and is not limited to sevennucleotides in connection with the seventh level derivative of thereference nucleic acid molecule; rather such derivatives may comprisefurther replacements at other positions.

Finally, higher order level derivatives of the reference nucleic acidmolecule are encompassed, disclosed and thus encompassed by the presentinvention and are, accordingly, a nucleic acid molecule according to thepresent invention. Such higher order level derivatives are, for example,the eighth level derivatives, ninth order derivatives etc. The maximumorder level derivative is the n^(th) level derivative of the referencenucleic acid molecule in view of the fact that the reference nucleicacid molecule comprises n nucleotides. As the reference nucleic acidmolecule comprises n nucleotides a maximum of n nucleotides of thereference nucleic acid molecule are replaced in accordance with therules and guidance provided herein. In such nth level derivative of thereference nucleic acid molecule each and any nucleotide is thus replacedin accordance with the present invention. It is, however, also withinthe present invention that the higher order level derivatives are(n-x)^(th) order level derivatives with x being any integer from 1 ton+2. In such (n-x)^(th) order level derivatives with x being any integerfrom 1 to n+2, (n-x) nucleotides of such derivative are replacedrelative to the reference nucleic acid molecule in accordance with thetechnical teaching provided herein, with x being any integer from 1 ton+2.

It is also an embodiment of the method of the present invention thatwhen combining the nucleotide replacements of various first levelderivatives of the reference nucleic acid molecule into higher orderlevel derivatives that the various individual first level derivativesreach or exceed a or the predetermined threshold value. It is, however,also an embodiment of the method of the present invention that whencombining the nucleotide replacements of various first level derivativesof the reference nucleic acid molecule into higher order levelderivatives none of the various individual first level derivativesreaches or exceeds a or the predetermined threshold value. Finally it isan embodiment of the method of the present invention that when combiningthe nucleotide replacements of various first level derivatives of thereference nucleic acid molecule into higher order level derivatives someof the first level derivatives of the reference nucleic acid moleculereach or exceed a or the predetermined threshold value, whereas othersof the first level derivatives of the reference nucleic acid molecule donot reach or nor not exceed a or the predetermined threshold.

The present invention is also based on the surprising finding that it ispossible to increase the binding affinity of a nucleic acid molecule toa target compared to the binding affinity of a reference nucleic acidmolecule, wherein the nucleic acid molecule comprise a sequence ofnucleotides and the reference molecule comprise a sequence ofnucleotides, wherein the sequence of nucleotides of the nucleic acidmolecule and the sequence of nucleotides of the reference nucleic acidmolecule are at least partially identical with respect to the nucleobasemoiety of the nucleotides but differ with respect to the sugar moiety ofthe nucleotides, wherein the sequence of nucleotides of the nucleic acidmolecule consists of both ribonucleotides and deoxyribonucleotides andwherein the sequence of nucleotides of the reference nucleic acidmolecule consists of either ribonucleotides or deoxyribonucleotides.

As preferably used herein a reference nucleic acid molecule is a nucleicacid molecule which is used as a reference or benchmark for a certaincharacteristic which is to be assessed or determined for both a nucleicacid molecule and a nucleic acid molecule of the invention in particularon the one hand, and, on the other hand, for the nucleic acid moleculeacting as or being used as (the) reference nucleic acid molecule. In anembodiment the characterisitic is the binding affinity of the nucleicacid molecule, preferably the nucleic acid molecule of the presentinvention, and the binding affinity of the reference nucleic acidmolecule for the target molecule of the nucleic acid molecule of thepresent invention and for the target molecule of the reference thenucleic acid molecule. In a preferred embodiment, the target molecule ofthe nucleic acid molecule of the present invention is the targetmolecule of the reference nucleic acid molecule, more preferably thetarget molecule of the nucleic acid molecule of the present invention isthe same target molecule as the reference nucleic acid molecule.

As preferably used herein, a sequence of nucleotides of a nucleic acidmolecule of the present invention is partially identical with or to asequence of nucleotides of the reference nucleic acid molecule if atleast one nucleobase of a nucleotide contained in the sequence ofnucleotides of the nucleic acid molecule of the present invention isidentical to at least one nucleobase of a nucleotide contained in thesequence of nucleotides of the reference nucleic acid molecule. In anembodiment, at least 75% preferably 85%, more preferably 90% and mostpreferably more than 95%, 96%, 97%, 98%, 99% or 100% of the nucleobasesof the nucleotides of the nucleic acid molecule of the present inventionare identical to the nucleobases of the nucleotides of the referencenucleic acid molecule. In an alternative embodiment, at least 75%preferably 85%, more preferably 90% and most preferably more than 95%,96%, 97%, 98%, 99% or 100% of the nucleobases of the nucleotides of thereference nucleic acid molecule of the present invention are identicalto the nucleobases of the nucleotides of the nucleic acid molecule ofthe present invention. In a further embodiment of the nucleic acidmolecule of the present invention all of the nucleobases are identicalto the nucleobases of the reference nucleic acid molecule with theexception that in case a 2′-deoxyribonucleotide is replaced by aribonucleotide and the deoxyribonucleotide is2′-deoxyadenosine-5-phosphate; 2′-deoxyguanosine-5′-phosphate;2′-deoxycytidine-5′phosphate; thymidine-5′-phosphate, the ribonucleotideis adenosine-5′-phosphate, guanosine-5′-phosphatecytidine-5′-5-methyl-uridine-5′-phosphate phosphate oruridine-5′-phosphate and that in case a ribonucleotide is replaced by adeoxyribonucleotide and the ribonucleotide is adenosine-5′-phosphate,guanosine-5′-phosphate cytidine-5′phosphate, uridine-5′-phosphate, thedeoxyribonucleotide is 2′-deoxyadenosine-5-phosphate;2′-deoxyguanosine-5′-phosphate; 2′-deoxycytidine-5′phosphate;2′-deoxyuridine-5′-phosphate or thymidine-5-phosphate.

In accordance with the present invention, the identity or partialidentity of the sequence of nucleotides of the nucleic acid molecule ofthe present invention with or to the sequence of nucleotides of thereference nucleic acid molecule is determined based on or with respectto the nucleobase moiety of the nucleotides. In connection therewith andas preferably used herein a nucleobase or nucleobase moiety is thenitrogenous base of a nucleoside and a nucleotide, respectively. Morepreferably, a nucleobase is selected from the group comprising adenine,guanine, thymine, cytosine and uracil. Thus, the identity or particalidentity of the sequence of nucleotides of the nucleic acid molecule ofthe present invention with or to the sequence of nucleotides of thereference nucleic acid molecule is determined by the chemistry of thenucleobase of the nucleotides. Accordingly, in connection with thepresent invention a 2′-deoxyadenosine-5′-(tri)phosphate is regarded asbeing identical to an adenosine-5′-(tri)phosphate, a2′-deoxyguanosine-5′-(tri)phosphate is regarded as being identical to aguanosine-5′-(tri)phosphate, a thymidine-5′-(tri)phosphate is regardedas being identical to a 5-Methyluridine 5′-(tri)phosphate, a2′-deoxycytidine 5′-(tri)phosphate is regarded as being identical to acytidine 5′-(tri)phosphate and a deoxyuridin 5′-(tri)phosphate isregarded as being identical to an uridine 5′-(tri)phosphate.

Throughout this patent application commonly known acronyms are used todescribe the composition of nucleic acids, whereby the letters A, G, C,U and T signify a ribonucleotide or a 2′-deoxyribonucleotide containingthe nucleobase adenine, guanine, cytosine, uracil or thyminerespectively. When positioned at the 5′-end of a syntheticoligonucleotide the nucleotide is a nucleoside, i.e. it carries no5′-phosphate group. It is to be determined by the reader from thefigure, the figure legend or the text of a given example whether thesequences shown are primarily ribonucleotide sequences (RNA) or2′-deoxyribonculeotide sequences (also referred to asdeoxyribonucleotide sequences or DNA). Generally there is one or severalpositions that are then exchanged from a ribonucleotide to a2′-deoxyribonucleotide or vice versa. The incorporation of one orseveral 2′deoxyribonucleotides into a primarily ribonucleotide sequenceis signified by a lowercase “d” before the capital letter that indicatesthe identity of the nucleobase (see above). Conversely, one or several2′deoxyribonucleotide incorporations into a ribonucleotide sequence aresignified by a lowercase “d” before the capital letter that indicatesthe identity of the nucleobase. A nucleotide is known to someone skilledin the art as being a ribose-5′-phosphate or a2′-deoxyribose-5′-phosphate, with a nucleobase attached at the1′-position. The linkage with the nucleobase occurs with the 9-positionof the purine nucleobases (A, G) and with the 1-position of thepyrimidine nucleobases (C, T, U).

It is within the present invention that the nucleic acid according tothe present invention is a nucleic acid molecule. Insofar the termsnucleic acid and nucleic acid molecule are used herein in a synonymousmanner if not indicated to the contrary. Moreover, such nucleic acidsare preferably also referred to herein as the nucleic acid moleculesaccording to the present invention, the nucleic acids according to thepresent invention, the inventive nucleic acids or the inventive nucleicacid molecules.

The features of the nucleic acid according to the present invention asdescribed herein can be realised in any aspect of the present inventionwhere the nucleic acid is used, either alone or in any combination.

As preferably used herein the term glucagon refers to any glucagonincluding, but not limited to, mammalian glucagon. Preferably, themammalian glucagon is selected from the group comprising human, rat,mouse, monkey, pig, rabbit, hamster, dog, sheep, chicken and bovineglucagon.

As preferably used herein the term S1P refers to any S1P including, butnot limited to, mammalian S1P. Preferably, the mammalian S1P is selectedfrom the group comprising human, rat, mouse, monkey, pig, rabbit,hamster, dog, sheep, chicken and bovine S1P.

As preferably used herein the term CGRP refers to any CGRP including,but not limited to, mammalian CGRP. Preferably, the mammalian CGRP isselected from the group comprising human, rat, mouse, monkey, pig,rabbit, hamster, dog, sheep, chicken and bovine CGRP.

As preferably used herein the term C5a refers to any C5a including, butnot limited to, mammalian C5a. Preferably, the mammalian C5a is selectedfrom the group comprising human, rat, mouse, monkey, pig, rabbit,hamster, dog, sheep, chicken and bovine C5a.

An antagonist to glucagon as preferably used herein is a molecule thatbinds to glucagon—such as the nucleic acid molecule disclosed herein—andinhibits the function of glucagon, preferably in an in vitro assay or inan in vivo model as described, for example, in the Examples.

An antagonist to S1P as preferably used herein is a molecule that bindsto S1P—such as the nucleic acid molecule disclosed herein—and inhibitsthe function of S1P, preferably in an in vitro assay or in an in vivomodel as described, for example, in the Examples.

An antagonist to C5a as preferably used herein is a molecule that bindsto C5a—such as the nucleic acid molecule disclosed herein—and inhibitsthe function of C5a, preferably in an in vitro assay or in an in vivomodel as described, for example, in the Examples.

An antagonist to CGRP as preferably used herein is a molecule that bindsto CGRP—such as the nucleic acid molecule disclosed herein—and inhibitsthe function of CGRP, preferably in an in vitro assay or in an in vivomodel as described, for example, in the Examples.

The nucleic acid molecule according to the present invention as well asthe reference nucleic acid preferably comprises three differentstretches of nucleotides: a first terminal stretch of nucleotides, acentral stretch of nucleotides and a second terminal stretch ofnucleotides. As in the field of nucleic acid molecules any sequence ofnucleotides is indicated in a 5′→3′-direction, the first terminalstretch of nucleotides is arranged at the 5′ end of the central stretch,and the second terminal stretch of nucleotides is arranged at the 3′ endof the central stretch of nucleotides. Because of this, the firstterminal stretch of nucleotides is also referred to herein as the5′-terminal stretch of nucleotides, and the second terminal stretch ofnucleotides is also referred to herein as the 3′-terminal stretch ofnucleotides, and vice versa. However, it is also within the presentinvention that the first terminal stretch of nucleotides is referred toherein as the 3′-terminal stretch of nucleotides, and the secondterminal stretch of nucleotides is referred to herein as the 5′-terminalstretch of nucleotides, and vice versa. This applies in particular inthose embodiments where the first stretch of nucleotides and the secondstretch of nucleotides are base complementary to each other.

In an embodiment of the nucleic acid molecule of the present invention,the first stretch of nucleotides and the second stretch of nucleotidesare base complementary to each other. As preferably used herein twostretches of nucleotides are base complementary to each other if saidtwo stretches, at least on paper or in silico, hybridize to each other,whereby upon hybridization a double-stranded structure is formed. Thehybridization occurs or is made in accordance with known rules for basepairing such as and preferably Watson-Crick base pairing rules. However,and as will be acknowledged by the one skilled in the art other basepairing rules such as Hoogsten base pairing may occur or may be applied.It will also be acknowledged by a person skilled in the art that, alsoin connection with the nucleic acid molecule of the present invention,such hybridization results in a double-stranded structure. Suchdouble-stranded structure may be part of a single nucleic acid moleculewhere two spatially separated stretches of a single strand of a nucleicacid molecule are hybridized. Alternatively, such double-strandedstructure may be formed by two or more separate strands of two or moreseparate nucleic acid molecules. It will also be acknowledged by aperson skilled in the art that any hybridization is not necessarilyoccurring or made over the entire length of the two stretches.

In a further embodiment two stretches of nucleotides are basecomplementary to each other if said two stretches may, in principle,hybridize under in vitro and/or in vitro conditions. The sameconsiderations disclosed herein as to the first stretch of nucleotidesand the second stretch of nucleotides being base complementary to eachother and as to hybridization of the first stretch of nucleotides andthe second stretch of nucleotides on paper or in silico equally apply tothis embodiment. However, it has to be acknowledged that under such invitro and/or in vivo conditions hybridization may or may not occur.

It is also to be acknowledged that in connection with the instantinvention the feature that two stretches hybridize to each otherpreferably indicates that such hybridization is assumed to happen due tobase complementarity of the two stretches but does not necessarily haveto happen under any in vitro and/or in vivo conditions.

The three stretches of nucleotides of nucleic acid molecules—the firstterminal stretch of nucleotides, the central stretch of nucleotides andsecond terminal stretch of nucleotides—are arranged to each other in5′→3′-direction: the first terminal stretch of nucleotides—the centralstretch of nucleotides—the second terminal stretch of nucleotides.However, alternatively, the second terminal stretch of nucleotides, thecentral stretch of nucleotides and the terminal first stretch ofnucleotides are arranged to each other in 5′ 4 3′-direction.

The differences in the sequences of the defined stretches between thedifferent nucleic acid molecules such as the nucleic acid molecule ofthe present invention on the one hand and the reference nucleic acidmolecule on the other hand, influence the binding affinity to the targetmolecule the nucleic acid molecule of the present invention is capableof binding to. In a preferred embodiment, based on binding analysis ofthe nucleic acid molecule of the present invention the central stretchof nucleotides of the nucleic acids according to the present inventionand the nucleotides forming the same are individually and morepreferably in their entirety essential for binding of the nucleic acidmolecule of the present invention to the target molecule.

The terms ‘stretch’ and ‘stretch of nucleotide’ are used herein in asynonymous manner if not indicated to the contrary.

In a preferred embodiment the nucleic acid according to the presentinvention is a single nucleic acid molecule. In a further embodiment,the single nucleic acid molecule is present as a multitude of the singlenucleic acid molecule or as a multitude of the single nucleic acidmolecule species.

It will be acknowledged by the ones skilled in the art that the nucleicacid molecule of the present invention preferably consists ofnucleotides which are covalently linked to each other, preferablythrough phosphodiester links or linkages.

In a preferred embodiment the term arrangement as used herein, means theorder or sequence of structural or functional features or elementsdescribed herein in connection with the nucleic acids disclosed herein.

A nucleic acid molecule of the present invention shall also comprise anucleic acid molecule which is essentially homologous to the nucleicacid molecule of the present invention and in particular to theparticular sequence(s) disclosed herein. The term substantiallyhomologous shall be understood such as the homology is at least 75%,preferably 85%, more preferably 90% and most preferably more that 95%,96%, 97%, 98% or 99%.

The actual percentage of homologous nucleotides present in the nucleicacid molecule of the present invention will depend on the total numberof nucleotides present in the nucleic acid molecule. The percentmodification can be based upon the total number of nucleotides presentin the nucleic acid molecule.

The homology between two nucleic acid molecules can be determined asknown to the person skilled in the art. More specifically, a sequencecomparison algorithm may be used for calculating the percent sequencehomology for the test sequence(s) relative to the reference sequence,based on the designated program parameters. The test sequence ispreferably the sequence or nucleic acid molecule which is said to behomologous or to be tested whether it is homologous, and if so, to whatextent, to a different nucleic acid molecule, whereby such differentnucleic acid molecule is also referred to as the homology referencesequence. Optimal alignment of sequences for comparison can beconducted, e.g., by the local homology algorithm of Smith & Waterman(Smith & Waterman, 1981) by the homology alignment algorithm ofNeedleman & Wunsch (Needleman & Wunsch, 1970) by the search forsimilarity method of Pearson & Lipman (Pearson & Lipman, 1988), bycomputerized implementations of these algorithms (GAP, BESTFIT, FASTA,and TFASTA in the Wisconsin Genetics Software Package, Genetics ComputerGroup, 575 Science Dr., Madison, Wis.), or by visual inspection.

One example of an algorithm that is suitable for determining percentsequence identity is the algorithm used in the basic local alignmentsearch tool (hereinafter “BLAST”), see, e.g. Altschul et al (Altschul etal. 1990 and Altschul et al, 1997). Software for performing BLASTanalyses is publicly available through the National Center forBiotechnology Information (hereinafter “NCBI”). The default parametersused in determining sequence identity using the software available fromNCBI, e.g., BLASTN (for nucleotide sequences) and BLASTP (for amino acidsequences) are described in McGinnis et al (McGinnis et al, 2004).

A nucleic acid molecule of the present invention shall also comprisenucleic acid molecule which has a certain degree of identity relative tothe nucleic acid molecule of the present invention and in particular tothe particular nucleic acid molecules of the present invention disclosedherein and defined by their nucleotide sequence. More preferably, theinstant invention also comprises those nucleic acid molecules which havean identity of at least 75%, preferably 85%, more preferably 90% andmost preferably more than 95%, 96%, 97%, 98% or 99% relative to thenucleic acid molecule of the present invention and in particular to theparticular nucleic acid molecule of the present invention disclosedherein and defined by their nucleotide sequence or a part thereof.

The term inventive nucleic acid or nucleic acid according to or of thepresent invention shall also comprise those nucleic acid moleculescomprising the nucleic acids sequences disclosed herein or part thereof,such as, e.g., a metabolite or derivative of the nucleic acid accordingto the present invention, preferably to the extent that the nucleicacids or said parts are involved in the or capable of binding toglucagon. Such a nucleic acid may be derived from the ones disclosedherein, e.g., by truncation. Truncation may be related to either or bothof the ends of the nucleic acids as disclosed herein. Also, truncationmay be related to the inner sequence of nucleotides, i.e. it may berelated to the nucleotide(s) between the 5′ and the 3′ terminalnucleotide, respectively. Moreover, truncation shall comprise thedeletion of as little as a single nucleotide from the sequence of thenucleic acids disclosed herein. Truncation may also be related to morethan one stretch of the inventive nucleic acid(s), whereby the stretchcan be as little as one nucleotide long. The binding of a nucleic acidaccording to the present invention can be determined by the ones skilledin the art using routine experiments or by using or adopting a method asdescribed herein, preferably as described herein in the example part.

It is also within the present invention that the nucleic acid moleculeof the present invention is part of a longer nucleic acid moleculewhereby this longer nucleic acid molecule comprises several partswhereby at least one such part is a nucleic acid molecule, or a partthereof, of the present invention. The other part(s) of such longernucleic acid molecule can be either one or several D-nucleic acid(s) orL-nucleic acid(s). Any combination may be used in connection with thepresent invention. These other part(s) of the longer nucleic acid canexhibit a function which is different from binding. One possiblefunction is to allow interaction with other molecules, whereby suchother molecules such as, e.g., for immobilization, cross-linking,detection or amplification. In a further embodiment of the presentinvention the nucleic acids according to the invention comprise, asindividual or combined moieties, several of the nucleic acids of thepresent invention. Such nucleic acid comprising several of the nucleicacids of the present invention is also encompassed by the term longernucleic acid.

L-nucleic acid molecules as used herein are nucleic acid moleculesconsisting of L-nucleotides, preferably consisting completely ofL-nucleotides, more preferably the L-nucleotides are L-ribonucleotidesor L-2′-deoxyribonucleotides. In a preferred embodiment the L-nucleicacid molecules consisting completely of L-ribonucleotides orL-2′-deoxyribonucleotides. In another preferred embodiment the theL-nucleic acid molecules consisting L-ribonucleotides andL-2′-deoxyribonucleotides.

D-nucleic acid molecules as used herein are nucleic acid moleculesconsisting of D-nucleotides, preferably consisting completely ofD-nucleotides, more preferably the D-nucleotides are D-ribonucleotidesor D-2′-deoxyribonucleotides. In a preferred embodiment the D-nucleicacid molecules consisting completely of D-ribonucleotides orD-2′-deoxyribonucleotides. In another preferred embodiment the theD-nucleic acid molecules consisting D-ribonucleotides andD-2′-deoxyribonucleotides.

The terms nucleic acid and nucleic acid molecule are used herein in aninterchangeable manner if not explicitly indicated to the contrary.

Also, if not indicated to the contrary, any nucleotide sequence is setforth herein in 5′→3′ direction.

As preferably used herein any position of a nucleotide is determined orreferred to relative to the 5′ end of a sequence, a stretch or asubstretch. Accordingly, a second nucleotide is the second nucleotidecounted from the 5′ end of the sequence, stretch and substretch,respectively. Also, in accordance therewith, a penultimate nucleotide isthe second nucleotide counted from the 3′ end of a sequence, stretch andsubstretch, respectively.

Designing the nucleic acid molecule of the present invention as anL-nucleic acid molecule is advantageous for several reasons. L-nucleicacids are enantiomers of naturally occurring D-nucleic acids. D-nucleicacids, however, are not very stable in aqueous solutions andparticularly in biological systems or biological samples due to thewidespread presence of nucleases. Naturally occurring nucleases,particularly nucleases from animal cells, are not capable of degradingL-nucleic acids. Because of this the biological half-life of anL-nucleic acid is significantly increased in such a system, includingthe animal and human body. Due to the lacking degradability of L-nucleicacids no nuclease degradation products are generated and thus no sideeffects arising therefrom observed. This aspect delimits the L-nucleicacids from factually all other compounds which are used in the therapyof diseases and/or disorders involving the presence of a targetmolecule. L-nucleic acids which specifically bind to a target moleculethrough a mechanism different from Watson Crick base pairing, oraptamers which consists partially or completely of L-nucleotides,particularly with those parts of the aptamer being involved in thebinding of the aptamer to the target molecule, are also calledspiegelmers. Aptamers and spiegelmers as such are known to a personskilled in the art and are, among others, described in ‘The AptamerHandbook’ (eds. Klussmann, 2006).

It is also within the present invention that the nucleic acid moleculeof the present invention, regardless whether it is present as aD-nucleic acid molecule, an L-nucleic acid molecule or a D,L-nucleicacid molecule, may be present as a single stranded or a double strandednucleic acid molecule. Preferably, the nucleic acid molecule of thepresent invention is a single stranded nucleic acid molecule whichexhibits defined secondary structures due to the primary sequence andmay thus also form tertiary structures. The nucleic acid molecule of thepresent invention, however, may also be double stranded in the meaningthat two strands which are complementary or partially complementary toeach other are hybridised to each other.

The nucleic acid molecule of the present invention may be modified ormay comprise at least one modification group. Such modifications may berelated to the single nucleotide of the nucleic acid and are well knownin the art. Examples for such modification are described by, amongothers, Venkatesan et al. (Venkatesan, Kim et al. 2003) and Kusser(Kusser 2000). Such modification can be a H atom, a F atom or O—CH₃group or NH₂-group at the 2′ position of the individual nucleotide ofwhich the nucleic acid consists. Also, the nucleic acid of the presentinvention can comprise at least one LNA nucleotide. In an embodiment thenucleic acid according to the present invention consists of LNAnucleotides.

In an embodiment, the nucleic acid molecule of the present invention maybe a multipartite nucleic acid. A multipartite nucleic acid as usedherein is a nucleic acid which consists of at least two separate nucleicacid strands. These at least two nucleic acid strands form a functionalunit whereby the functional unit is a ligand to a target molecule,preferable the target molecule, or is capable of binding to a targetmolecule, preferable the target molecule. The at least two nucleic acidstrands may be derived from any nucleic acid molecule of the presentinvention by either cleaving the nucleic acid molecule to generate twostrands or by synthesising one nucleic acid corresponding to a firstpart of the inventive, i.e. overall nucleic acid and another nucleicacid corresponding to the second part of the overall nucleic acid. It isto be acknowledged that both the cleavage and the synthesis may beapplied to generate a multipartite nucleic acid where there are morethan two strands as exemplified above. In other words, the at least twoseparate nucleic acid strands are typically different from two strandsbeing complementary and hybridising to each other although a certainextent of complementarity between said at least two separate nucleicacid strands may exist and whereby such complementarity may result inthe hybridisation of said separate strands.

Finally, it is also within the present invention that a fully closed,i.e. circular structure for the nucleic acids of the present inventionis realized, i.e. that the nucleic acid molecule according to thepresent invention is closed in an embodiment, preferably through acovalent linkage, whereby more preferably such covalent linkage is madebetween the 5′ end and the 3′ end of the nucleic acid sequence(s) of thenucleic acid molecule of the present invention.

A possibility to determine the binding constants of the nucleic acidmolecule of the present invention is the use of the methods as describedin the examples which confirms the above finding that the nucleic acidmolecule of the present invention exhibits a favourable K_(D) valuerange. An appropriate measure in order to express the intensity of thebinding between the individual nucleic acid molecule and the targetmolecule is the so-called K_(D) value which as such as well the methodfor its determination are known to the one skilled in the art.

Preferably, the K_(D) value shown by the nucleic acid molecule of thepresent invention is below 1 μM. A K_(D) value of about 1 μM is said tobe characteristic for a non-specific binding of a nucleic acid moleculeto a target molecule. As will be acknowledged by the ones skilled in theart, the K_(D) value of a group of compounds such as the nucleic acidmolecule of the present invention is within a certain range. Theabove-mentioned K_(D) of about 1 μM is a preferred upper limit for theK_(D) value. The lower limit for the K_(D) of a target binding nucleicacid molecule can be as little as about 10 picomolar or can be higher.It is within the present invention that the K_(D) values of individualnucleic acid molecule binding to the target molecule are preferablywithin this range. Preferred ranges can be defined by choosing any firstnumber within this range and any second number within this range.Preferred upper K_(D) values are 250 nM and 100 nM, preferred lowerK_(D) values are 50 nM, 10 nM, 1 nM, 100 pM and 10 pM. The morepreferred upper K_(D) value is 10 nM, the more preferred lower K_(D)value is 100 pM.

In addition to the binding properties of the nucleic acid molecule ofthe present invention, the nucleic acid molecule of the presentinvention inhibits the function of the respective target molecule. Theinhibition of the function of the target molecule—for instance thestimulation of a respective receptor of the target molecule as describedpreviously—is achieved by binding of nucleic acid molecule of thepresent invention to the target molecule and forming a complex of anucleic acid molecule of the present invention and the target molecule.Such complex of a nucleic acid molecule and the target molecule cannotstimulate the receptor(s) that normally are stimulated by the targetmolecule. Accordingly, the inhibition of receptor function by a nucleicacid molecule of the present invention is independent from therespective receptor that can be stimulated by the target molecule, butresults from preventing the stimulation of the receptor by the targetmolecule by the nucleic acid molecule according to the presentinvention.

A possibility to determine the inhibitory constant of the nucleic acidmolecule of the present invention is the use of the methods as describedin the examples which confirms the above finding that the nucleic acidmolecule of the present invention exhibits a favourable inhibitoryconstant which allows the use of such nucleic acid molecule in atherapeutic treatment scheme. An appropriate measure in order to expressthe intensity of the inhibitory effect of the individual nucleic acidmolecule on the interaction with the target molecule, the targetmolecule and the respective receptor, is the so-called half maximalinhibitory concentration (abbr. IC₅₀) which as such as well the methodfor its determination are known to the one skilled in the art.

Preferably, the IC₅₀ value shown by the nucleic acid molecule of thepresent invention is below 1 μM. An IC₅₀ value of about 1 μM is said tobe characteristic for a non-specific inhibition of target functions by anucleic acid molecule. As will be acknowledged by the ones skilled inthe art, the IC₅₀ value of a group of compounds such as the nucleic acidmolecule of the present invention is within a certain range. Theabove-mentioned IC₅₀ of about 1 μM is a preferred upper limit for theIC₅₀ value. The lower limit for the IC₅₀ of target binding nucleic acidmolecules such as the nucleic acid molecule of the present invention canbe as little as about 10 picomolar or can be higher. It is within thepresent invention that the IC₅₀ values of a nucleic acid molecule of thepresent invention is preferably within this range. Preferred ranges canbe defined by choosing any first number within this range and any secondnumber within this range. Preferred upper IC₅₀ values are 250 nM and 100nM, preferred lower IC₅₀ values are 50 nM, 10 nM, 1 nM, 100 pM and 10pM. The more preferred upper IC₅₀ value is 5 nM, the more preferredlower IC₅₀ value is 1 nM.

The nucleic acid molecule of the present invention may have any lengthprovided that they are still able to bind to or inihibit a function ofthe target molecule. It will be acknowledged in the art that there arepreferred lengths of the nucleic acid molecule of the presentinventions. Typically, the length is between 15 and 120 nucleotides. Itwill be acknowledged by the ones skilled in the art that any integerbetween 15 and 120 is a possible length for the nucleic acid molecule ofthe present invention. More preferred ranges for the length of thenucleic acids according to the present invention are lengths of about 20to 100 nucleotides, about 20 to 80 nucleotides, about 20 to 60nucleotides, about 20 to 54 nucleotides and about 39 to 44 nucleotides.

It is within the present invention that the nucleic acids disclosedherein comprise a modification group which preferably is a highmolecular weight moiety and/or which preferably allows to modify thecharacteristics of the nucleic acid in terms of, among others, residencetime in the animal body, preferably the human body. A particularlypreferred embodiment of such modification is PEGylation and HESylationof the nucleic acids according to the present invention. As used hereinPEG stands for poly(ethylene glycole) and HES for hydroxyethly starch.PEGylation as preferably used herein is the modification of a nucleicacid according to the present invention whereby such modificationconsists of a PEG moiety which is attached to a nucleic acid accordingto the present invention. HESylation as preferably used herein is themodification of a nucleic acid according to the present inventionwhereby such modification consists of a HES moiety which is attached toa nucleic acid according to the present invention. These modificationsas well as the process of modifying a nucleic acid using suchmodifications, is described in European patent application EP 1 306 382,the disclosure of which is herewith incorporated in its entirety byreference.

In the case of PEG being such high molecular weight moiety the molecularweight is preferably about 20,000 to about 120,000 Da, more preferablyfrom about 30,000 to about 80,000 Da and most preferably about 40,000Da. In the case of HES being such high molecular weight moiety themolecular weight is is preferably from about 50 to about 1000 kDa, morepreferably from about 100 to about 700 kDa and most preferably from 200to 500 kDa. HES exhibits a molar substitution of 0.1 to 1.5, morepreferably of 1 to 1.5 and exhibits a substitution sample expressed asthe C2/C6 ratio of approximately 0.1 to 15, preferably of approximately3 to 10. The process of HES modification is, e.g., described in Germanpatent application DE 1 2004 006 249.8 the disclosure of which isherewith incorporated in its entirety by reference.

The modification can, in principle, be made to the nucleic acidmolecules of the present invention at any position thereof. Preferablysuch modification is made either to the 5′-terminal nucleotide, the3′-terminal nucleotide and/or any nucleotide between the 5′ nucleotideand the 3′ nucleotide of the nucleic acid molecule.

The modification and preferably the PEG and/or HES moiety can beattached to the nucleic acid molecule of the present invention eitherdirectly or indirectly, preferably through a linker. It is also withinthe present invention that the nucleic acid molecule according to thepresent invention comprises one or more modifications, preferably one ormore PEG and/or HES moiety. In an embodiment the individual linkermolecule attaches more than one PEG moiety or HES moiety to a nucleicacid molecule according to the present invention. The linker used inconnection with the present invention can itself be either linear orbranched. This kind of linkers are known to the ones skilled in the artand are further described in patent applications WO2005/074993 andWO2003/035665.

In a preferred embodiment the linker is a biodegradable linker. Thebiodegradable linker allows to modify the characteristics of the nucleicacid according to the present invention in terms of, among other,residence time in an animal body, preferably in a human body, due torelease of the modification from the nucleic acid according to thepresent invention. Usage of a biodegradable linker may allow a bettercontrol of the residence time of the nucleic acid according to thepresent invention. A preferred embodiment of such biodegradable linkeris a biodegradable linker as described in, but not limited to,international patent applications WO2006/052790, WO2008/034122,WO2004/092191 and WO2005/099768.

It is within the present invention that the modification or modificationgroup is a biodegradable modification, whereby the biodegradablemodification can be attached to the nucleic acid molecule of the presentinvention either directly or indirectly, preferably through a linker.The biodegradable modification allows to modify the characteristics ofthe nucleic acid according to the present invention in terms of, amongother, residence time in an animal body, preferably in a human body, dueto release or degradation of the modification from the nucleic acidaccording to the present invention. Usage of biodegradable modificationmay allow a better control of the residence time of the nucleic acidaccording to the present invention. A preferred embodiment of suchbiodegradable modification is biodegradable as described in, but notrestricted to, international patent applications WO2002/065963,WO2003/070823, WO2004/113394 and WO2000/41647, preferably inWO2000/41647, page 18, line 4 to 24.

Beside the modifications as described above, other modifications can beused to modify the characteristics of the nucleic acids according to thepresent invention, whereby such other modifications may be selected fromthe group of proteins, lipids such as cholesterol and sugar chains suchas amylase, dextran etc.

Without wishing to be bound by any theory, it seems that by modifyingthe nucleic acids according to the present invention with high molecularweight moiety such as a polymer and more particularly one or several ofthe polymers disclosed herein, which are preferably physiologicallyacceptable, the excretion kinetic is changed. More particularly, itseems that due to the increased molecular weight of such modifiedinventive nucleic acids and due to the nucleic acids of the inventionnot being subject to metabolism particularly when in the L form,excretion from an animal body, preferably from a mammalian body and morepreferably from a human body is decreased. As excretion typically occursvia the kidneys, the present inventors assume that the glomerularfiltration rate of the thus modified nucleic acids is significantlyreduced compared to the nucleic acids not having this kind of highmolecular weight modification which results in an increase in theresidence time in the animal body. In connection therewith it isparticularly noteworthy that, despite such high molecular weightmodification the specificity of the nucleic acids according to thepresent invention is not affected in a detrimental manner. Insofar, thenucleic acids according to the present invention have among others, thesurprising characteristic—which normally cannot be expected frompharmaceutically active compounds—such that a pharmaceutical formulationproviding for a sustained release is not necessarily required to providefor a sustained release of the nucleic acids according to the presentinvention. Rather the nucleic acids according to the present inventionin their modified form comprising a high molecular weight moiety, can assuch already be used as a sustained release-formulation as they act, dueto their modification, already as if they were released from asustained-release formulation. Insofar, the modification(s) of thenucleic acid molecules according to the present invention as disclosedherein and the thus modified nucleic acid molecules according to thepresent invention and any composition comprising the same may providefor a distinct, preferably controlled pharmacokinetics andbiodistribution thereof. This also includes residence time incirculation and distribution to tissues. Such modifications are furtherdescribed in the patent application WO2003/035665.

However, it is also within the present invention that the nucleic acidsaccording to the present invention do not comprise any modification andparticularly no high molecular weight modification such as PEGylation orHESylation. Such embodiment is particularly preferred when the nucleicacid according to the present invention shows preferential distributionto any target organ or tissue in the body or when a fast clearance ofthe nucleic acid according to the present invention from the body afteradministration is desired. Nucleic acids according to the presentinvention as disclosed herein with a preferential distribution profileto any target organ or tissue in the body would allow establishment ofeffective local concentrations in the target tissue while keepingsystemic concentration of the nucleic acids low. This would allow theuse of low doses which is not only beneficial from an economic point ofview, but also reduces unnecessary exposure of other tissues to thenucleic acid agent, thus reducing the potential risk of side effects.Fast clearance of the nucleic acids according to the present inventionfrom the body after administration might be desired, among others, incase of in vivo imaging or specific therapeutic dosing requirementsusing the nucleic acids according to the present invention ormedicaments comprising the same.

A further aspect of the present invention is related to the use of anucleic acid molecule of the present invention and/or an antagonists ofthe present invention for the generation or manufacture of a medicamentor a diagnostic agent. A still further aspect of the present inventionis related to the use of a nucleic acid molecule of the presentinvention, and/or an antagonists of the present invention in a method oftreating or preventing a disease.

A further aspect of the present invention is related to a pharmaceuticalcomposition of the present invention contains at least a nucleic acidmolecule of the present invention optionally together with furtherpharmaceutically active compounds, whereby the nucleic acid molecule ofthe present invention preferably acts as pharmaceutically activecompound itself. Such pharmaceutical composition comprises in apreferred embodiment at least a pharmaceutically acceptable carrier.Such carrier may be, e.g., water, buffer, PBS, glucose solution,preferably a 5% glucose, salt balanced solution, citrate, starch, sugar,gelatine or any other acceptable carrier substance. Such carriers aregenerally known to the one skilled in the art. It will be acknowledgedby the person skilled in the art that any embodiments, use and aspectsof or related to the pharmaceutical composition of the present inventionis also applicable to the medicament of the present invention, and viceversa.

It will be acknowledged by a person skilled in the art that the nucleicacid molecule of the present invention, the medicament and/orpharmaceutical composition containing the same can be used in particularfor the treatment and/or prevention and/or diagnosis of any disease inwhich the target molecule to which the nucleic acid molecule of theinvention is capable of binding is involved. More specifically, suchdisease is any disease where the binding of the nucleic acid molecule ofthe present invention to the target molecule, or where antagonizing theeffect of the target molecule, preferably by means of the nucleic acidmolecule of the present invention, is, in principle, suitable to treatthe disease, to prevent the disease or to alleviate the symptoms of thedisease.

In one embodiment of the medicament of the present invention, suchmedicament is for use in combination with other treatments for any ofthe diseases disclosed herein, particularly those for which themedicament of the present invention is to be used.

In one embodiment of the pharmaceutical composition of the presentinvention, such pharmaceutical composition is for use in combinationwith other treatments for any of the diseases disclosed herein,particularly those for which the medicament of the present invention isto be used.

“Combination therapy” (or “co-therapy”) includes the administration of amedicament of the invention and at least a second or further agent aspart of a specific treatment regimen intended to provide the beneficialeffect from the co-action of these therapeutic agents, i. e. themedicament of the present invention and said second or further agent.The beneficial effect of the combination includes, but is not limitedto, pharmacokinetic or pharmacodynamic co-action resulting from thecombination of therapeutic agents. Administration of these therapeuticagents in combination typically is carried out over a defined timeperiod (usually minutes, hours, days or weeks depending upon thecombination selected).

“Combination therapy” may be, but generally is not, intended toencompass the administration of two or more of these therapeutic agentsas part of separate monotherapy regimens. “Combination therapy” isintended to embrace administration of these therapeutic agents in asequential manner, that is, wherein each therapeutic agent isadministered at a different time, as well as administration of thesetherapeutic agents, or at least two of the therapeutic agents, in asubstantially simultaneous manner. Substantially simultaneousadministration can be accomplished, for example, by administering to asubject a single capsule having a fixed ratio of each therapeutic agentor in multiple, single capsules for each of the therapeutic agents.

Sequential or substantially simultaneous administration of eachtherapeutic agent can be effected by any appropriate route including,but not limited to, topical routes, oral routes, intravenous routes,intramuscular routes, and direct absorption through mucous membranetissues. The therapeutic agents can be administered by the same route orby different routes. For example, a first therapeutic agent of thecombination selected may be administered by injection while the othertherapeutic agents of the combination may be administered topically.

Alternatively, for example, all therapeutic agents may be administeredtopically or all therapeutic agents may be administered by injection.The sequence in which the therapeutic agents are administered is notnarrowly critical unless noted otherwise. “Combination therapy” also canembrace the administration of the therapeutic agents as described abovein further combination with other biologically active ingredients. Wherethe combination therapy further comprises a non-drug treatment, thenon-drug treatment may be conducted at any suitable time so long as abeneficial effect from the co-action of the combination of thetherapeutic agents and non-drug treatment is achieved. For example, inappropriate cases, the beneficial effect is still achieved when thenon-drug treatment is temporally removed from the administration of thetherapeutic agents, perhaps by days or even weeks.

As outlined in general terms above, the medicament according to thepresent invention can be administered, in principle, in any form knownto the ones skilled in the art. A preferred route of administration issystemic administration, more preferably by parenteral administration,preferably by injuction. Alternatively, the medicament may beadministered locally. Other routes of administration compriseintramuscular, intraperitoneal, and subcutaneous, per orum, intranasal,intratracheal or pulmonary with preference given to the route ofadministration that is the least invasive, while ensuring efficiancy.

Parenteral administration is generally used for subcutaneous,intramuscular or intravenous injections and infusions. Additionally, oneapproach for parenteral administration employs the implantation of aslow-release or sustained-released systems, which assures that aconstant level of dosage is maintained, that are well known to theordinary skill in the art.

Furthermore, preferred medicaments of the present invention can beadministered in intranasal form via topical use of suitable intranasalvehicles, inhalants, or via transdermal routes, using those forms oftransdermal skin patches well known to those of ordinary skill in thatart. To be administered in the form of a transdermal delivery system,the dosage administration will, of course, be continuous rather thanintermittent throughout the dosage regimen. Other preferred topicalpreparations include creams, ointments, lotions, aerosol sprays andgels.

Subjects that will respond favorably to the method of the inventioninclude medical and veterinary subjects generally, including humanbeings and human patients. Among other subjects for whom the methods andmeans of the invention are useful are cats, dogs, large animals, avianssuch as chickens, and the like.

The medicament of the present invention will generally comprise aneffective amount of the active component(s) of the therapy, including,but not limited to, a nucleic acid molecule of the present invention,dissolved or dispersed in a pharmaceutically acceptable medium.Pharmaceutically acceptable media or carriers include any and allsolvents, dispersion media, coatings, antibacterial and antifungalagents, isotonic and absorption delaying agents and the like. The use ofsuch media and agents for pharmaceutical active substances is well knownin the art. Supplementary active ingredients can also be incorporatedinto the medicament of the present invention.

In a further aspect the present invention is related to a pharmaceuticalcomposition. Such pharmaceutical composition comprises at least one ofthe nucleic acids according to the present invention and preferably apharmaceutically acceptable binder. Such binder can be any binder usedand/or known in the art. More particularly such binder is any binder asdiscussed in connection with the manufacture of the medicament disclosedherein. In a further embodiment, the pharmaceutical compositioncomprises a further pharmaceutically active agent.

The preparation of a medicament and a pharmaceutical composition will beknown to those of skill in the art in light of the present disclosure.Typically, such compositions may be prepared as injectables, either asliquid solutions or suspensions; solid forms suitable for solution in,or suspension in, liquid prior to injection; as tablets or other solidsfor oral administration; as time release capsules; or in any other formcurrently used, including eye drops, creams, lotions, salves, inhalantsand the like. The use of sterile formulations, such as saline-basedwashes, by surgeons, physicians or health care workers to treat aparticular area in the operating field may also be particularly useful.Compositions may also be delivered via microdevice, microparticle orsponge.

Upon formulation, a medicament will be administered in a mannercompatible with the dosage formulation, and in such amount as ispharmacologically effective. The formulations are easily administered ina variety of dosage forms, such as the type of injectable solutionsdescribed above, but drug release capsules and the like can also beemployed.

The medicament of the invention can also be administered in oral dosageforms as timed release and sustained release tablets or capsules, pills,powders, granules, elixirs, tinctures, suspensions, syrups andemulsions. Suppositories are advantageously prepared from fattyemulsions or suspensions.

The pharmaceutical composition or medicament may be sterilized and/orcontain adjuvants, such as preserving, stabilizing, wetting oremulsifying agents, solution promoters, salts for regulating the osmoticpressure and/or buffers. In addition, they may also contain othertherapeutically valuable substances. The compositions are preparedaccording to conventional mixing, granulating, or coating methods, andtypically contain about 0.1% to 75%, preferably about 1% to 50%, of theactive ingredient.

Liquid, particularly injectable compositions can, for example, beprepared by dissolving, dispersing, etc. The active compound isdissolved in or mixed with a pharmaceutically pure solvent such as, forexample, water, saline, aqueous dextrose, glycerol, ethanol, and thelike, to thereby form the injectable solution or suspension.Additionally, solid forms suitable for dissolving in liquid prior toinjection can be formulated.

The medicaments and nucleic acid molecules, respectively, of the presentinvention can also be administered in the form of liposome deliverysystems, such as small unilamellar vesicles, large unilamellar vesiclesand multilamellar vesicles. Liposomes can be formed from a variety ofphospholipids, containing cholesterol, stearylamine orphosphatidylcholines. In some embodiments, a film of lipid components ishydrated with an aqueous solution of drug to a form lipid layerencapsulating the drug, what is well known to the ordinary skill in theart. For example, the nucleic acid molecules described herein can beprovided as a complex with a lipophilic compound or non-immunogenic,high molecular weight compound constructed using methods known in theart. Additionally, liposomes may bear such nucleic acid molecules ontheir surface for targeting and carrying cytotoxic agents internally tomediate cell killing. An example of nucleic-acid associated complexes isprovided in U.S. Pat. No. 6,011,020.

The medicaments and nucleic acid molecules, respectively, of the presentinvention may also be coupled with soluble polymers as targetable drugcarriers. Such polymers can include polyvinylpyrrolidone, pyrancopolymer, polyhydroxypropyl-methacrylamide-phenol,polyhydroxyethylaspanamidephenol, or polyethyleneoxidepolylysinesubstituted with palmitoyl residues. Furthermore, the medicaments andnucleic acid molecules, respectively, of the present invention may becoupled to a class of biodegradable polymers useful in achievingcontrolled release of a drag, for example, polylactic acid, polyepsiloncapro lactone, polyhydroxy butyric acid, polyorthoesters, polyacetals,polydihydropyrans, polycyanoacrylates and cross-linked or amphipathicblock copolymers of hydrogels.

If desired, the pharmaceutical composition and medicament, respectively,to be administered may also contain minor amounts of non-toxic auxiliarysubstances such as wetting or emulsifying agents, pH buffering agents,and other substances such as for example, sodium acetate, andtriethanolamine oleate.

The dosage regimen utilizing the nucleic acid molecules and medicaments,respectively, of the present invention is selected in accordance with avariety of factors including type, species, age, weight, sex and medicalcondition of the patient; the severity of the condition to be treated;the route of administration; the renal and hepatic function of thepatient; and the particular aptamer or salt thereof employed. Anordinarily skilled physician or veterinarian can readily determine andprescribe the effective amount of the drug required to prevent, counteror arrest the progress of the condition.

Effective plasma levels of the nucleic acid according to the presentinvention preferably range from 500 fM to 200 μM, preferably from 1 nMto 20 μM, more preferably from 5 nM to 20 μM, most preferably 50 nM to20 μM in the treatment of any of the diseases disclosed herein.

The nucleic acid molecules and medicaments, respectively, of the presentinvention may preferably be administered in a single daily dose, everysecond or third day, weekly, every second week, in a single monthly doseor every third month.

It is within the present invention that the medicament as describedherein constitutes the pharmaceutical composition disclosed herein.

In a further aspect the present invention is related to a method for thetreatment of a subject who is in need of such treatment, whereby themethod comprises the administration of a pharmaceutically active amountof at least one of the nucleic acids according to the present invention.In an embodiment, the subject suffers from a disease or is at risk todevelop such disease, whereby the disease is any of those disclosedherein, particularly any of those diseases disclosed in connection withthe use of any of the nucleic acids according to the present inventionfor the manufacture of a medicament.

It is to be understood that the nucleic acid as well as the antagonistsaccording to the present invention can be used not only as a medicamentor for the manufacture of a medicament, but also for cosmetic purposes.

As preferably used herein a diagnostic or diagostic agent or diagnosticmeans is suitable to detect, either directly or indirectly thetarget—which is in the present case glucagon or S1P. The diagnostic issuitable for the detection and/or follow-up of any of the disorders anddiseases related to the target—which is in the present case glucagon orS1P, respectively, described herein. Such detection is possible throughthe binding of the nucleic acids according to the present invention totarget. Such binding can be either directly or indirectly be detected.The respective methods and means are known to the ones skilled in theart. Among others, the nucleic acids according to the present inventionmay comprise a label which allows the detection of the nucleic acidsaccording to the present invention, preferably the nucleic acid bound totarget. Such a label is preferably selected from the group comprisingradioactive, enzymatic and fluorescent labels. In principle, all knownassays developed for antibodies can be adopted for the nucleic acidsaccording to the present invention whereas the target-binding antibodyis substituted to a target-binding nucleic acid. In antibody-assaysusing unlabeled target-binding antibodies the detection is preferablydone by a secondary antibody which is modified with radioactive,enzymatic and fluorescent labels and bind to the target-binding antibodyat its Fc-fragment. In the case of a nucleic acid, preferably a nucleicacid according to the present invention, the nucleic acid is modifiedwith such a label, whereby preferably such a label is selected from thegroup comprising biotin, Cy-3 and Cy-5, and such label is detected by anantibody directed against such label, e.g. an anti-biotin antibody, ananti-Cy3 antibody or an anti-Cy5 antibody, or—in the case that the labelis biotin—the label is detected by streptavidin or avidin whichnaturally bind to biotin. Such antibody, streptavidin or avidin in turnis preferably modified with a respective label, e.g. a radioactive,enzymatic or fluorescent label (like a secondary antibody).

In a further embodiment the nucleic acid molecules according to theinvention are detected or analysed by a second detection means, whereinthe said detection means is a molecular beacon. The methodology ofmolecular beacon is known to persons skilled in the art and reviewed byMairal et al. (Mairal et al., 2008).

In connection with the detection of target a preferred method comprisesthe following steps:

-   -   (a) providing a sample which is to be tested for the presence of        target,    -   (b) providing a nucleic acid according to the present invention,    -   (c) reacting the sample with the nucleic acid, preferably in a        reaction vessel    -   whereby step (a) can be performed prior to step (b), or step (b)        can be preformed prior to step (a).

In a preferred embodiment a further step d) is provided, which consistsin the detection of the reaction of the sample with the nucleic acid.Preferably, the nucleic acid of step b) is immobilised to a surface. Thesurface may be the surface of a reaction vessel such as a reaction tube,a well of a plate, or the surface of a device contained in such reactionvessel such as, for example, a bead. The immobilisation of the nucleicacid to the surface can be made by any means known to the ones skilledin the art including, but not limited to, non-covalent or covalentlinkages. Preferably, the linkage is established via a covalent chemicalbond between the surface and the nucleic acid. However, it is alsowithin the present invention that the nucleic acid is indirectlyimmobilised to a surface, whereby such indirect immobilisation involvesthe use of a further component or a pair of interaction partners. Suchfurther component is preferably a compound which specifically interactswith the nucleic acid to be immobilised which is also referred to asinteraction partner, and thus mediates the attachment of the nucleicacid to the surface. The interaction partner is preferably selected fromthe group comprising nucleic acids, polypeptides, proteins andantibodies. Preferably, the interaction partner is an antibody, morepreferably a monoclonal antibody. Alternatively, the interaction partneris a nucleic acid, preferably a functional nucleic acid. More preferablysuch functional nucleic acid is selected from the group comprisingaptamers, spiegelmers, and nucleic acids which are at least partiallycomplementary to the nucleic acid. In a further alternative embodiment,the binding of the nucleic acid to the surface is mediated by amulti-partite interaction partner. Such multi-partite interactionpartner is preferably a pair of interaction partners or an interactionpartner consisting of a first member and a second member, whereby thefirst member is comprised by or attached to the nucleic acid and thesecond member is attached to or comprised by the surface. Themulti-partite interaction partner is preferably selected from the groupof pairs of interaction partners comprising biotin and avidin, biotinand streptavidin, and biotin and neutravidin. Preferably, the firstmember of the pair of interaction partners is biotin.

A preferred result of such method is the formation of an immobilisedcomplex of target and the nucleic acid, whereby more preferably saidcomplex is detected. It is within an embodiment that from the complexthe target is detected.

A respective detection means which is in compliance with thisrequirement is, for example, any detection means which is specific forthat/those part(s) of the target. A particularly preferred detectionmeans is a detection means which is selected from the group comprisingnucleic acids, polypeptides, proteins and antibodies, the generation ofwhich is known to the ones skilled in the art.

The method for the detection of target also comprises that the sample isremoved from the reaction vessel which has preferably been used toperform step c).

The method comprises in a further embodiment also the step ofimmobilising an interaction partner of target on a surface, preferably asurface as defined above, whereby the interaction partner is defined asherein and preferably as above in connection with the respective methodand more preferably comprises nucleic acids, polypeptides, proteins andantibodies in their various embodiments. In this embodiment, aparticularly preferred detection means is a nucleic acid according tothe present invention, whereby such nucleic acid may preferably belabelled or non-labelled. In case such nucleic acid is labelled it candirectly or indirectly be detected. Such detection may also involve theuse of a second detection means which is, preferably, also selected fromthe group comprising nucleic acids, polypeptides, proteins andembodiments in the various embodiments described herein. Such detectionmeans are preferably specific for the nucleic acid according to thepresent invention. In a more preferred embodiment, the second detectionmeans is a molecular beacon. Either the nucleic acid or the seconddetection means or both may comprise in a preferred embodiment adetection label. The detection label is preferably selected from thegroup comprising biotin, a bromo-desoxyuridine label, a digoxigeninlabel, a fluorescence label, a UV-label, a radio-label, and a chelatormolecule. Alternatively, the second detection means interacts with thedetection label which is preferably contained by, comprised by orattached to the nucleic acid. Particularly preferred combinations are asfollows:

-   -   the detection label is biotin and the second detection means is        an antibody directed against biotin, or wherein    -   the detection label is biotin and the second detection means is        an avidin or an avidin carrrying molecule, or wherein    -   the detection label is biotin and the second detection means is        a streptavidin or a stretavidin carrying molecule, or wherein    -   the detection label is biotin and the second detection means is        a neutravidin or a neutravidin carrying molecule, or    -   wherein the detection label is a bromo-desoxyuridine and the        second detection means is an antibody directed against        bromo-desoxyuridine, or wherein    -   the detection label is a digoxigenin and the second detection        means is an antibody directed against digoxigenin, or wherein    -   the detection label is a chelator and the second detection means        is a radio-nuclide, whereby it is preferred that said detection        label is attached to the nucleic acid. It is to be acknowledged        that this kind of combination is also applicable to the        embodiment where the nucleic acid is attached to the surface. In        such embodiment it is preferred that the detection label is        attached to the interaction partner.

Finally, it is also within the present invention that the seconddetection means is detected using a third detection means, preferablythe third detection means is an enzyme, more preferably showing anenzymatic reaction upon detection of the second detection means, or thethird detection means is a means for detecting radiation, morepreferably radiation emitted by a radio-nuclide. Preferably, the thirddetection means is specifically detecting and/or interacting with thesecond detection means.

Also in the embodiment with an interaction partner of target beingimmobilised on a surface and the nucleic acid according to the presentinvention is preferably added to the complex formed between theinteraction partner and the target, the sample can be removed from thereaction, more preferably from the reaction vessel where step c) and/ord) are preformed.

In an embodiment the nucleic acid according to the present inventioncomprises a fluorescence moiety and whereby the fluorescence of thefluorescence moiety is different upon complex formation between thenucleic acid and target and free target.

In a further embodiment the nucleic acid is a derivative of the nucleicacid according to the present invention, whereby the derivative of thenucleic acid comprises at least one fluorescent derivative of adenosinereplacing adenosine. In a preferred embodiment the fluorescentderivative of adenosine is ethenoadenosine.

In a further embodiment the complex consisting of the derivative of thenucleic acid according to the present invention and the target isdetected using fluorescence.

In an embodiment of the method a signal is created in step (c) or step(d) and preferably the signal is correlated with the concentration oftarget in the sample.

In a preferred aspect, the assays may be performed in 96-well plates,where components are immobilized in the reaction vessels as describedabove and the wells acting as reaction vessels.

It has to be acknowledged that the nucleic acid molecules which arecapable of binding to glucagon as described herein and more specificallyin the example part are an embodiment of the nucleic acid molecule ofthe present invention.

It has to be acknowledged that the nucleic acid molecules which arecapable of binding to S1P as described herein and more specifically inthe example part are an embodiment of the nucleic acid molecule of thepresent invention.

It has to be acknowledged that the nucleic acid molecules which arecapable of binding to CGRP as described herein and more specifically inthe example part are an embodiment of the nucleic acid molecule of thepresent invention.

It has to be acknowledged that the nucleic acid molecules which arecapable of binding to C5a as described herein and more specifically inthe example part are an embodiment of the nucleic acid molecule of thepresent invention.

The various SEQ.ID. Nos., the chemical nature of the nucleic acidmolecules according to the present invention and the target molecules asused herein, the actual sequence thereof and the internal referencenumber is summarized in the following table.

TABLE 1 SEQ ID RNA/ NO Peptide Internal Reference Sequence 5′→3′ 1 L-CGRP ACDTATCVTHRLAGLLSRSGGVVKN Peptide NFVPTNVGSKAF-NH₂ 2 L- Human C5aTLQKKIEEIAAKYKHSVVKKCCYDGACVN Peptide NDETCEQRAARISLGPRCIKAFTECCVVASQLRANISHKDMQLGR 3 L- Biotin-GlucagonHSQGTFTSDYSKYLDSRRAQDFVQWLMNT-Biotin Peptide 4 L- GlucagonHSQGTFTSDYSKYLDSRRAQDFVQWLMNT Peptide 5 L-RNA L-S1P-215-F9-002GCGUGAAUAGCCGUUGAAACGCCUUUAGAGAAGCACUAGCACGC 6 L-DNA/L-S1P-215-F9-002-D01 dG CGUGAAUAGCCGUUGAAACGCCUUUAGAGAAGCACUAGCACGCL-RNA 7 L-DNA/ L-S1P-215-F9-002-D02 G dCGUGAAUAGCCGUUGAAACGCCUUUAGAGAAGCACUAGCACGC L-RNA 8 L-DNA/L-S1P-215-F9-002-D03 GC dG UGAAUAGCCGUUGAAACGCCUUUAGAGAAGCACUAGCACGCL-RNA 9 L-DNA/ L-S1P-215-F9-002-D04 GCG dTGAAUAGCCGUUGAAACGCCUUUAGAGAAGCACUAGCACGC L-RNA 10 L-DNA/L-S1P-215-F9-002-D05 GCGU dG AAUAGCCGUUGAAACGCCUUUAGAGAAGCACUAGCACGCL-RNA 11 L-DNA/ L-S1P-215-F9-002-D06 GCGUG dAAUAGCCGUUGAAACGCCUUUAGAGAAGCACUAGCACGC L-RNA 12 L-DNA/L-S1P-215-F9-002-D07 GCGUGA dA UAGCCGUUGAAACGCCUUUAGAGAAGCACUAGCACGCL-RNA 13 L-DNA/ L-S1P-215-F9-002-D08 GCGUGAA dTAGCCGUUGAAACGCCUUUAGAGAAGCACUAGCACGC L-RNA 14 L-DNA/L-S1P-215-F9-002-D09 GCGUGAAU dA GCCGUUGAAACGCCUUUAGAGAAGCACUAGCACGCL-RNA 15 L-DNA/ L-S1P-215-F9-002-D10 GCGUGAAUA dGCCGUUGAAACGCCUUUAGAGAAGCACUAGCACGC L-RNA 16 L-DNA/ L-S1P-215-F9-002-D11GCGUGAAUAG dC CGUUGAAACGCCUUUAGAGAAGCACUAGCACGC L-RNA 17 L-DNA/L-S1P-215-F9-002-D12 GCGUGAAUAGC dC GUUGAAACGCCUUUAGAGAAGCACUAGCACGCL-RNA 18 L-DNA/ L-S1P-215-F9-002-D13 GCGUGAAUAGCC dGUUGAAACGCCUUUAGAGAAGCACUAGCACGC L-RNA 19 L-DNA/ L-S1P-215-F9-002-D14GCGUGAAUAGCCG dT UGAAACGCCUUUAGAGAAGCACUAGCACGC L-RNA 20 L-DNA/L-S1P-215-F9-002-D15 GCGUGAAUAGCCGU dT GAAACGCCUUUAGAGAAGCACUAGCACGCL-RNA 21 L-DNA/ L-S1P-215-F9-002-D16 GCGUGAAUAGCCGUU dGAAACGCCUUUAGAGAAGCACUAGCACGC L-RNA 22 L-DNA/ L-S1P-215-F9-002-D17GCGUGAAUAGCCGUUG dA AACGCCLTUUAGAGAAGCACUAGCACGC L-RNA 23 L-DNA/L-S1P-215-F9-002-D18 GCGUGAAUAGCCGUUGA dA ACGCCUUUAGAGAAGCACUAGCACGCL-RNA 24 L-DNA/ L-S1P-215-F9-002-D19 GCGUGAAUAGCCGUUGAA dACGCCUUUAGAGAAGCACUAGCACGC L-RNA 25 L-DNA/ L-S1P-215-F9-002-D20GCGUGAAUAGCCGUUGAAA dC GCCUUUAGAGAAGCACUAGCACGC L-RNA 26 L-DNA/L-S1P-215-F9-002-D21 GCGUGAAUAGCCGUUGAAAC dG CCUUUAGAGAAGCACUAGCACGCL-RNA 27 L-DNA/ L-S1P-215-F9-002-D22 GCGUGAAUAGCCGUUGAAACG dCCUUUAGAGAAGCACUAGCACGC L-RNA 28 L-DNA/ L-S1P-215-F9-002-D23GCGUGAAUAGCCGUUGAAACGC dC UUUAGAGAAGCACUAGCACGC L-RNA 29 L-DNA/L-S1P-215-F9-002-D24 GCGUGAAUAGCCGUUGAAACGCC dT UUAGAGAAGCACUAGCACGCL-RNA 30 L-DNA/ L-S1P-215-F9-002-D25 GCGUGAAUAGCCGUUGAAACGCCU dTUAGAGAAGCACUAGCACGC L-RNA 31 L-DNA/ L-S1P-215-F9-002-D26GCGUGAAUAGCCGUUGAAACGCCUU dT AGAGAAGCACUAGCACGC L-RNA 32 L-DNA/L-S1P-215-F9-002-D27 GCGUGAAUAGCCGUUGAAACGCCUUU dA GAGAAGCACUAGCACGCL-RNA 33 L-DNA/ L-S1P-215-F9-002-D28 GCGUGAAUAGCCGUUGAAACGCCUUUA dGAGAAGCACUAGCACGC L-RNA 34 L-DNA/ L-S1P-215-F9-002-D29GCGUGAAUAGCCGUUGAAACGCCUUUAG dA GAAGCACUAGCACGC L-RNA 35 L-DNA/L-S1P-215-F9-002-D30 GCGUGAAUAGCCGUUGAAACGCCUUUAGA dG AAGCACUAGCACGCL-RNA 36 L-DNA/ L-S1P-215-F9-002-D31 GCGUGAAUAGCCGUUGAAACGCCUUUAGAG dAAGCACUAGCACGC L-RNA 37 L-DNA/ L-S1P-215-F9-002-D32GCGUGAAUAGCCGUUGAAACGCCUUUAGAGA dA GCACUAGCACGC L-RNA 38 L-DNA/L-S1P-215-F9-002-D33 GCGUGAAUAGCCGUUGAAACGCCUUUAGAGAA dG CACUAGCACGCL-RNA 39 L-DNA/ L-S1P-215-F9-002-D34 GCGUGAAUAGCCGUUGAAACGCCUUUAGAGAAGdC ACUAGCACGC L-RNA 40 L-DNA/ L-S1P-215-F9-002-D35GCGUGAAUAGCCGUUGAAACGCCUUUAGAGAAGC dA CUAGCACGC L-RNA 41 L-DNA/L-S1P-215-F9-002-D36 GCGUGAAUAGCCGUUGAAACGCCUUUAGAGAAGCA dC UAGCACGCL-RNA 42 L-DNA/ L-S1P-215-F9-002-D37GCGUGAAUAGCCGUUGAAACGCCUUUAGAGAAGCAC dTA GCACGC L-RNA 43 L-DNA/L-S1P-215-F9-002-D38 GCGUGAAUAGCCGUUGAAACGCCUUUAGAGAAGCACU dA GCACGCL-RNA 44 L-DNA/ L-S1P-215-F9-002-D39GCGUGAAUAGCCGUUGAAACGCCUUUAGAGAAGCACUA dG CACGC L-RNA 45 L-DNA/L-S1P-215-F9-002-D40 GCGUGAAUAGCCGUUGAAACGCCUUUAGAGAAGCACUAG dC ACGCL-RNA 46 L-DNA/ L-S1P-215-F9-002-D41GCGUGAAUAGCCGUUGAAACGCCUUUAGAGAAGCACUAGC dA CGC L-RNA 47 L-DNA/L-S1P-215-F9-002-D42 GCGUGAAUAGCCGUUGAAACGCCUUUAGAGAAGCACUAGCA dC GCL-RNA 48 L-DNA/ L-S1P-215-F9-002-D43GCGUGAAUAGCCGUUGAAACGCCUUUAGAGAAGCACUAGCAC dG C L-RNA 49 L-DNA/L-S1P-215-F9-002-D44 GCGUGAAUAGCCGUUGAAACGCCUUUAGAGAAGCACUAGCACG dCL-RNA 50 L-DNA/ L-S1P-215-F9-002-D21- GCGUGAAUAGCCGUUGAAAC dGdCCUUUAGAGAAGCACUAGCACGC L-RNA 22 51 L-DNA/ L-S1P-215-F9-002-D21-GCGUGAAUAGCCGUUGAA dA C dG CCUUUAGAGAAGCACUAGCACGC L-RNA 19 52 L-DNA/L-S1P-215-F9-002-D21- GCGUGAAUAGCCGUUGAA dA C dGdCCUUUAGAGAAGCACUAGCACGC L-RNA 19-22 53 L-DNA/ L-SIP-215-F9-002-D01- dGCGUGAAUAGCCGUUGAA dA C dG CCUUUAGAGA dA GCACUAGCACGC L-RNA 19-21-32 54L-DNA/ L-S1P-215-F9-002-D01- dG CGUGAAUAG dC CGUUGAA dA C dG CCUUUAGAGAdA GCACUAGCACGC L-RNA 11-19-21-32 55 L-DNA/ 226-F2-001CCGUGCUGUCGGAGACUACUCGUCGAGUAGAAAUAGGUCCCCUCCCACGG L-RNA 56 L-DNA/226-F2-001-D01 dC CGUGCUGUCGGAGACUACUCGUCGAGUAGAAAUAGGUCCCCUCCCACGGL-RNA 57 L-DNA/ 226-F2-001-D02 C dCGUGCUGUCGGAGACUACUCGUCGAGUAGAAAUAGGUCCCCUCCCACGG L-RNA 58 L-DNA/226-F2-001-D03 CC dG UGCUGUCGGAGACUACUCGUCGAGUAGAAAUAGGUCCCCUCCCACGGL-RNA 59 L-DNA/ 226-F2-001-D04 CCG dTGCUGUCGGAGACUACUCGUCGAGUAGAAAUAGGUCCCCUCCCACGG L-RNA 60 L-DNA/226-F2-001-D05 CCGU dG CUGUCGGAGACUACUCGUCGAGUAGAAAUAGGUCCCCUCCCACGGL-RNA 61 L-DNA/ 226-F2-001-D06 CCGUG dCUGUCGGAGACUACUCGUCGAGUAGAAAUAGGUCCCCUCCCACGG L-RNA 62 L-DNA/226-F2-001-D07 CCGUGC dT GUCGGAGACUACUCGUCGAGUAGAAAUAGGUCCCCUCCCACGGL-RNA 63 L-DNA/ 226-F2-001-D08 CCGUGCU dGUCGGAGACUACUCGUCGAGUAGAAAUAGGUCCCCUCCCACGG L-RNA 64 L-DNA/226-F2-001-D09 CCGUGCUG dT CGGAGACUACUCGUCGAGUAGAAAUAGGUCCCCUCCCACGGL-RNA 65 L-DNA/ 226-F2-001-D10 CCGUGCUGU dCGGAGACUACUCGUCGAGUAGAAAUAGGUCCCCUCCCACGG L-RNA 66 L-DNA/ 226-F2-001-D11CCGUGCUGUC dG GAGACUACUCGUCGAGUAGAAAUAGGUCCCCUCCCACGG L-RNA 67 L-DNA/226-F2-001-D12 CCGUGCUGUCG dG AGACUACUCGUCGAGUAGAAAUAGGUCCCCUCCCACGGL-RNA 68 L-DNA/ 226-F2-001-D13 CCGUGCUGUCGG dAGACUACUCGUCGAGUAGAAAUAGGUCCCCUCCCACGG L-RNA 69 L-DNA/ 226-F2-001-D14CCGUGCUGUCGGA dG ACUACUCGUCGAGUAGAAAUAGGUCCCCUCCCACGG L-RNA 70 L-DNA/226-F2-001-D15 CCGUGCUGUCGGAG dA CUACUCGUCGAGUAGAAAUAGGUCCCCUCCCACGGL-RNA 71 L-DNA/ 226-F2-001-D16 CCGUGCUGUCGGAGA dCUACUCGUCGAGUAGAAAUAGGUCCCCUCCCACGG L-RNA 72 L-DNA/ 226-F2-001-D17CCGUGCUGUCGGAGAC dT ACUCGUCGAGUAGAAAUAGGUCCCCUCCCACGG L-RNA 73 L-DNA/226-F2-001-D18 CCGUGCUGUCGGAGACU dA CUCGUCGAGUAGAAAUAGGUCCCCUCCCACGGL-RNA 74 L-DNA/ 226-F2-001-D19 CCGUGCUGUCGGAGACUA dCUCGUCGAGUAGAAAUAGGUCCCCUCCCACGG L-RNA 75 L-DNA/ 226-F2-001-D20CCGUGCUGUCGGAGACUAC dT CGUCGAGUAGAAAUAGGUCCCCUCCCACGG L-RNA 76 L-DNA/226-F2-001-D21 CCGUGCUGUCGGAGACUACU dC GUCGAGUAGAAAUAGGUCCCCUCCCACGGL-RNA 77 L-DNA/ 226-F2-001-D22 CCGUGCUGUCGGAGACUACUC dGUCGAGUAGAAAUAGGUCCCCUCCCACGG L-RNA 78 L-DNA/ 226-F2-001-D23CCGUGCUGUCGGAGACUACUCG dT CGAGUAGAAAUAGGUCCCCUCCCACGG L-RNA 79 L-DNA/226-F2-001-D24 CCGUGCUGUCGGAGACUACUCGU dC GAGUAGAAAUAGGUCCCCUCCCACGGL-RNA 80 L-DNA/ 226-F2-001-D25 CCGUGCUGUCGGAGACUACUCGUC dGAGUAGAAAUAGGUCCCCUCCCACGG L-RNA 81 L-DNA/ 226-F2-001-D26CCGUGCUGUCGGAGACUACUCGUCG dA GUAGAAAUAGGUCCCCUCCCACGG L-RNA 82 L-DNA/226-F2-001-D27 CCGUGCUGUCGGAGACUACUCGUCGA dG UAGAAAUAGGUCCCCUCCCACGGL-RNA 83 L-DNA/ 226-F2-001-D28 CCGUGCUGUCGGAGACUACUCGUCGAG dTAGAAAUAGGUCCCCUCCCACGG L-RNA 84 L-DNA/ 226-F2-001-D29CCGUGCUGUCGGAGACUACUCGUCGAGU dA GAAAUAGGUCCCCUCCCACGG L-RNA 85 L-DNA/226-F2-001-D30 CCGUGCUGUCGGAGACUACUCGUCGAGUA dG AAAUAGGUCCCCUCCCACGGL-RNA 86 L-DNA/ 226-F2-001-D31 CCGUGCUGUCGGAGACUACUCGUCGAGUAG dAAAUAGGUCCCCUCCCACGG L-RNA 87 L-DNA/ 226-F2-001-D32CCGUGCUGUCGGAGACUACUCGUCGAGUAGA dA AUAGGUCCCCUCCCACGG L-RNA 88 L-DNA/226-F2-001-D33 CCGUGCUGUCGGAGACUACUCGUCGAGUAGAA dA UAGGUCCCCUCCCACGGL-RNA 89 L-DNA/ 226-F2-001-D34 CCGUGCUGUCGGAGACUACUCGUCGAGUAGAAA dTAGGUCCCCUCCCACGG L-RNA 90 L-DNA/ 226-F2-001-D35CCGUGCUGUCGGAGACUACUCGUCGAGUAGAAAU dA GGUCCCCUCCCACGG L-RNA 91 L-DNA/226-F2-001-D36 CCGUGCUGUCGGAGACUACUCGUCGAGUAGAAAUA dG GUCCCCUCCCACGGL-RNA 92 L-DNA/ 226-F2-001-D37 CCGUGCUGUCGGAGACUACUCGUCGAGUAGAAAUAG dGUCCCCUCCCACGG L-RNA 93 L-DNA/ 226-F2-001-D38CCGUGCUGUCGGAGACUACUCGUCGAGUAGAAAUAGG dT CCCCUCCCACGG L-RNA 94 L-DNA/226-F2-001-D39 CCGUGCUGUCGGAGACUACUCGUCGAGUAGAAAUAGGU dC CCCUCCCACGGL-RNA 95 L-DNA/ 226-F2-001-D40 CCGUGCUGUCGGAGACUACUCGUCGAGUAGAAAUAGGUCdC CCUCCCACGG L-RNA 96 L-DNA/ 226-F2-001-D41CCGUGCUGUCGGAGACUACUCGUCGAGUAGAAAUAGGUCC dC CUCCCACGG L-RNA 97 L-DNA/226-F2-001-D42 CCGUGCUGUCGGAGACUACUCGUCGAGUAGAAAUAGGUCCC dC UCCCACGGL-RNA 98 L-DNA/ 226-F2-001-D43CCGUGCUGUCGGAGACUACUCGUCGAGUAGAAAUAGGUCCCC dT CCCACGG L-RNA 99 L-DNA/226-F2-001-D44 CCGUGCUGUCGGAGACUACUCGUCGAGUAGAAAUAGGUCCCCU dC CCACGGL-RNA 100 L-DNA/ 226-F2-001-D45CCGUGCUGUCGGAGACUACUCGUCGAGUAGAAAUAGGUCCCCUC dC CACGG L-RNA 101 L-DNA/226-F2-001-D46 CCGUGCUGUCGGAGACUACUCGUCGAGUAGAAAUAGGUCCCCUCC dC ACGGL-RNA 102 L-DNA/ 226-F2-001-D47CCGUGCUGUCGGAGACUACUCGUCGAGUAGAAAUAGGUCCCCUCCC dA CGG L-RNA 103 L-DNA/226-F2-001-D48 CCGUGCUGUCGGAGACUACUCGUCGAGUAGAAAUAGGUCCCCUCCCA dC GGL-RNA 104 L-DNA/ 226-F2-001-D49CCGUGCUGUCGGAGACUACUCGUCGAGUAGAAAUAGGUCCCCUCCCAC dG G L-RNA 105 L-DNA/226-F2-001-D50 CCGUGCUGUCGGAGACUACUCGUCGAGUAGAAAUAGGUCCCCUCCCACG dGL-RNA 106 L-DNA/ 226-F2-001-D41/D44CCGUGCUGUCGGAGACUACUCGUCGAGUAGAAAUAGGUCC dC CU dC CCACGG L-RNA 107 L-RNANOX-D19001 GCCUGAUGUGGUGGUGAAGGGUUGUUGGGUGUCGACGCACAGGC 108 L-DNA/NOX-D19001-D01 dG CCUGAUGUGGUGGUGAAGGGUUGUUGGGUGUCGACGCACAGGC L-RNA 109L-DNA/ NOX-D19001-D02 Gd CCUGAUGUGGUGGUGAAGGGUUGUUGGGUGUCGACGCACAGGCL-RNA 110 L-DNA/ NOX-D19001-D03 GC dCUGAUGUGGUGGUGAAGGGUUGUUGGGUGUCGACGCACAGGC L-RNA 111 L-DNA/NOX-D19001-D04 GCC dU GAUGUGGUGGUGAAGGGUUGUUGGGUGUCGACGCACAGGC L-RNA 112L-DNA/ NOX-D19001-D05 GCCU dG AUGUGGUGGUGAAGGGUUGUUGGGUGUCGACGCACAGGCL-RNA 113 L-DNA/ NOX-D19001-D06 GCCUGdAUGUGGUGGUGAAGGGUUGUUGGGUGUCGACGCACAGGC L-RNA 114 L-DNA/ NOX-D19001-D07GCCUGAdUGUGGUGGUGAAGGGUUGUUGGGUGUCGACGCACAGGC L-RNA 115 L-DNA/NOX-D19001-D08 GCCUGAUdGUGGUGGUGAAGGGUUGUUGGGUGUCGACGCACAGGC L-RNA 116L-DNA/ NOX-D19001-D09 GCCUGAUGdUGGUGGUGAAGGGUUGUUGGGUGUCGACGCACAGGCL-RNA 117 L-DNA/ NOX-D19001-D10GCCUGAUGUdGGUGGUGAAGGGUUGUUGGGUGUCGACGCACAGGC L-RNA 118 L-DNA/NOX-D19001-D11 GCCUGAUGUGdGUGGUGAAGGGUUGUUGGGUGUCGACGCACAGGC L-RNA 119L-DNA/ NOX-D19001-D12 GCCUGAUGUGGdUGGUGAAGGGUUGUUGGGUGUCGACGCACAGGCL-RNA 120 L-DNA/ NOX-D19001-D13GCCUGAUGUGGUdGGUGAAGGGUUGUUGGGUGUCGACGCACAGGC L-RNA 121 L-DNA/NOX-D19001-D14 GCCUGAUGUGGUGdGUGAAGGGUUGUUGGGUGUCGACGCACAGGC L-RNA 122L-DNA/ NOX-D19001-D15 GCCUGAUGUGGUGGdUGAAGGGUUGUUGGGUGUCGACGCACAGGCL-RNA 123 L-DNA/ NOX-D19001-D16GCCUGAUGUGGUGGUdGAAGGGUUGUUGGGUGUCGACGCACAGGC L-RNA 124 L-DNA/NOX-D19001-D17 GCCUGAUGUGGUGGUGdAAGGGUUGUUGGGUGUCGACGCACAGGC L-RNA 125L-DNA/ NOX-D19001-D18 GCCUGAUGUGGUGGUGAdAGGGUUGUUGGGUGUCGACGCACAGGCL-RNA 126 L-DNA/ NOX-D19001-D19GCCUGAUGUGGUGGUGAAdGGGUUGUUGGGUGUCGACGCACAGGC L-RNA 127 L-DNA/NOX-D19001-D20 GCCUGAUGUGGUGGUGAAGdGGUUGUUGGGUGUCGACGCACAGGC L-RNA 128L-DNA/ NOX-D19001-D21 GCCUGAUGUGGUGGUGAAGGdGUUGUUGGGUGUCGACGCACAGGCL-RNA 129 L-DNA/ NOX-D19001-D22GCCUGAUGUGGUGGUGAAGGGdUUGUUGGGUGUCGACGCACAGGC L-RNA 130 L-DNA/NOX-D19001-D23 GCCUGAUGUGGUGGUGAAGGGUdUGUUGGGUGUCGACGCACAGGC L-RNA 131L-DNA/ NOX-D19001-D24 GCCUGAUGUGGUGGUGAAGGGUUdGUUGGGUGUCGACGCACAGGCL-RNA 132 L-DNA/ NOX-D19001-D25GCCUGAUGUGGUGGUGAAGGGUUGdUUGGGUGUCGACGCACAGGC L-RNA 133 L-DNA/NOX-D19001-D26 GCCUGAUGUGGUGGUGAAGGGUUGUdUGGGUGUCGACGCACAGGC L-RNA 134L-DNA/ NOX-D19001-D27 GCCUGAUGUGGUGGUGAAGGGUUGUUdGGGUGUCGACGCACAGGCL-RNA 135 L-DNA/ NOX-D19001-D28GCCUGAUGUGGUGGUGAAGGGUUGUUGdGGUGUCGACGCACAGGC L-RNA 136 L-DNA/NOX-D19001-D29 GCCUGAUGUGGUGGUGAAGGGUUGUUGGdGUGUCGACGCACAGGC L-RNA 137L-DNA/ NOX-D19001-D30 GCCUGAUGUGGUGGUGAAGGGUUGUUGGGdUGUCGACGCACAGGCL-RNA 138 L-DNA/ NOX-D19001-D31GCCUGAUGUGGUGGUGAAGGGUUGUUGGGUdGUCGACGCACAGGC L-RNA 139 L-DNA/NOX-D19001-D32 GCCUGAUGUGGUGGUGAAGGGUUGUUGGGUGdUCGACGCACAGGC L-RNA 140L-DNA/ NOX-D19001-D33 GCCUGAUGUGGUGGUGAAGGGUUGUUGGGUGUdCGACGCACAGGCL-RNA 141 L-DNA/ NOX-D19001-D34GCCUGAUGUGGUGGUGAAGGGUUGUUGGGUGUCdGACGCACAGGC L-RNA 142 L-DNA/NOX-D19001-D35 GCCUGAUGUGGUGGUGAAGGGUUGUUGGGUGUCGdACGCACAGGC L-RNA 143L-DNA/ NOX-D19001-D36 GCCUGAUGUGGUGGUGAAGGGUUGUUGGGUGUCGAdCGCACAGGCL-RNA 144 L-DNA/ NOX-D19001-D37GCCUGAUGUGGUGGUGAAGGGUUGUUGGGUGUCGACdGCACAGGC L-RNA 145 L-DNA/NOX-D19001-D38 GCCUGAUGUGGUGGUGAAGGGUUGUUGGGUGUCGACGdCACAGGC L-RNA 146L-DNA/ NOX-D19001-D39 GCCUGAUGUGGUGGUGAAGGGUUGUUGGGUGUCGACGCdA CAGGCL-RNA 147 L-DNA/ NOX-D19001-D40GCCUGAUGUGGUGGUGAAGGGUUGUUGGGUGUCGACGCAdC AGGC L-RNA 148 L-DNA/NOX-D19001-D41 GCCUGAUGUGGUGGUGAAGGGUUGUUGGGUGUCGACGCAC dA GGC L-RNA 149L-DNA/ NOX-D19001-D42 GCCUGAUGUGGUGGUGAAGGGUUGUUGGGUGUCGACGCACA dG GCL-RNA 150 L-DNA/ NOX-D19001-D43GCCUGAUGUGGUGGUGAAGGGUUGUUGGGUGUCGACGCACAG dG C L-RNA 151 L-DNA/NOX-D19001-D44 GCCUGAUGUGGUGGUGAAGGGUUGUUGGGUGUCGACGCACAGG dC L-RNA 152L-DNA/ NOX-D19001-D09-30 GCCUGAUGdUGGUGGUGAAGGGUUGUUGGGdUGUCGACGCACAGGCL-RNA 153 L-DNA/ NOX-D19001-D09-32GCCUGAUGdUGGUGGUGAAGGGUUGUUGGGUGdUCGACGCACAGGC L-RNA 154 L-DNA/NOX-D19001-D09-40 GCCUGAUGdUGGUGGUGAAGGGUUGUUGGGUGUCGACGCAdCAGGC L-RNA155 L-DNA/ NOX-D19001-D30-32GCCUGAUGUGGUGGUGAAGGGUUGUUGGGdUGdUCGACGCACAGGC L-RNA 156 L-DNA/NOX-D19001-D30-40 GCCUGAUGUGGUGGUGAAGGGUUGUUGGGdUGUCGACGCAdC AGGC L-RNA157 L-DNA/ NOX-D19001-D32-40 GCCUGAUGUGGUGGUGAAGGGUUGUUGGGUGdUCGACGCAdCAGGC L-RNA 158 L-DNA/ NOX-D19001-D09-30-32GCCUGAUGdUGGUGGUGAAGGGUUGUUGGGdUGdUCGACGCACAGGC L-RNA 159 L-DNA/NOX-D19001-D09-30-40 GCCUGAUGdUGGUGGUGAAGGGUUGUUGGGdUGUCGACGCA dC AGGCL-RNA 160 L-DNA/ NOX-D19001-D09-32-40GCCUGAUGdUGGUGGUGAAGGGUUGUUGGGUGdUCGACGCA dC AGGC L-RNA 161 L-DNA/NOX-D19001-D30-32-40 GCCUGAUGUGGUGGUGAAGGGUUGUUGGGdUGdUCGACGCA dC AGGCL-RNA 162 L-DNA/ NOX-D19001-D09-30-32-GCCUGAUGdUGGUGGUGAAGGGUUGUUGGGdUGdUCGACGCA dC AGGC L-RNA 40 163 L-DNA/NOX-D19001-D09-16-30- GCCUGAUGdUGGUGGUdGAAGGGUUGUUGGGdUGdUCGACGCA dCAGGC L-RNA 32-40 164 L-DNA/ NOX-D19001-D09-17-30-GCCUGAUGdUGGUGGUGdAAGGGUUGUUGGGdUGdUCGACGCA dC AGGC L-RNA 32-40 165L-DNA/ NOX-D19001-D09-16-17-GCCUGAUGdUGGUGGUdGdAAGGGUUGUUGGGdUGdUCGACGCA dC AGGC L-RNA 30-32-40 (=NOX-D19001-6xDNA) 166 L-DNA/ NOX-D19001-D07-30GCCUGAdUGUGGUGGUGAAGGGUUGUUGGGdUGUCGACGCACAGGC L-RNA 167 L-DNA/NOX-D19001-D07-30-40 GCCUGAdUGUGGUGGUGAAGGGUUGUUGGGdUGUCGACGCAdC AGGCL-RNA 168 L-DNA/ NOX-D19001-D07-30-32-GCCUGAdUGUGGUGGUGAAGGGUUGUUGGGdUGdUCGACGCAdC AGGC L-RNA 40 169 L-DNA/NOX-D19001-D07-16-30- GCCUGAdUGUGGUGGUdGAAGGGUUGUUGGGdUGdUCGACGCA dCAGGC L-RNA 32-40 170 L-DNA/ NOX-D19001-D07-17-30-GCCUGAdUGUGGUGGUGdAAGGGUUGUUGGGdUGdUCGACGCA dC AGGC L-RNA 32-40 171L-DNA/ NOX-D19001-D07-16-17-GCCUGAdUGUGGUGGUdGdAAGGGUUGUUGGGdUGdUCGACGCA dC AGGC L-RNA 30-32-40 172L-RNA NOX-G11stabi2CAGACGUGUGUGGGUAGAUGCACCUGCGAUUCGCUAAAAAGUGCCACACGUCUG 173 LDNA/NOX-G11-D01 dC AGACGUGUGUGGGUAGAUGCACCUGCGAUUCGCUAAAAAGUGCCACACGUCUGL-RNA 174 L-DNA/ NOX-G11-D02 C dAGACGUGUGUGGGUAGAUGCACCUGCGAUUCGCUAAAAAGUGCCACACGUCUG L-RNA 175 LDNA/NOX-G11-D03 CA dG ACGUGUGUGGGUAGAUGCACCUGCGAUUCGCUAAAAAGUGCCACACGUCUGL-RNA 176 L-DNA/ NOX-G11-D04 CAG dACGUGUGUGGGUAGAUGCACCUGCGAUUCGCUAAAAAGUGCCACACGUCUG L-RNA 177 L-DNA/NOX-G11-D05 CAGA dC GUGUGUGGGUAGAUGCACCUGCGAUUCGCUAAAAAGUGCCACACGUCUGL-RNA 178 L-DNA/ NOX-G11-D06 CAGAC dGUGUGUGGGUAGAUGCACCUGCGAUUCGCUAAAAAGUGCCACACGUCUG L-RNA 179 L-DNA/NOX-G11-D07 CAGACG dT GUGUGGGUAGAUGCACCUGCGAUUCGCUAAAAAGUGCCACACGUCUGL-RNA 180 L-DNA/ NOX-G11-D08 CAGACGU dGUGUGGGUAGAUGCACCUGCGAUUCGCUAAAAAGUGCCACACGUCUG L-RNA 181 L-DNA/NOX-G11-D09 CAGACGUG dT GUGGGUAGAUGCACCUGCGAUUCGCUAAAAAGUGCCACACGUCUGL-RNA 182 L-DNA/ NOX-G11-D10 CAGACGUGU dGUGGGUAGAUGCACCUGCGAUUCGCUAAAAAGUGCCACACGUCUG L-RNA 183 L-DNA/NOX-G11-D11 CAGACGUGUG dT GGGUAGAUGCACCUGCGAUUCGCUAAAAAGUGCCACACGUCUGL-RNA 184 L-DNA/ NOX-G11-D12 CAGACGUGUGU dGGGUAGAUGCACCUGCGAUUCGCUAAAAAGUGCCACACGUCUG L-RNA 185 L-DNA/ NOX-G11-D13CAGACGUGUGUG dG GUAGAUGCACCUGCGAUUCGCUAAAAAGUGCCACACGUCUG L-RNA 186L-DNA/ NOX-G11-D14 CAGACGUGUGUGG dGUAGAUGCACCUGCGAUUCGCUAAAAAGUGCCACACGUCUG L-RNA 187 L-DNA/ NOX-G11-D15CAGACGUGUGUGGG dT AGAUGCACCUGCGAUUCGCUAAAAAGUGCCACACGUCUG L-RNA 188L-DNA/ NOX-G11-D16 CAGACGUGUGUGGGU dAGAUGCACCUGCGAUUCGCUAAAAAGUGCCACACGUCUG L-RNA 189 L-DNA/ NOX-G11-D17CAGACGUGUGUGGGUA dG AUGCACCUGCGAUUCGCUAAAAAGUGCCACACGUCUG L-RNA 190L-DNA/ NOX-G11-D18 CAGACGUGUGUGGGUAG dAUGCACCUGCGAUUCGCUAAAAAGUGCCACACGUCUG L-RNA 191 L-DNA/ NOX-G11-D19CAGACGUGUGUGGGUAGA dT GCACCUGCGAUUCGCUAAAAAGUGCCACACGUCUG L-RNA 192L-DNA/ NOX-G11-D20 CAGACGUGUGUGGGUAGAU dGCACCUGCGAUUCGCUAAAAAGUGCCACACGUCUG L-RNA 193 L-DNA/ NOX-G11-D21CAGACGUGUGUGGGUAGAUG dC ACCUGCGAUUCGCUAAAAAGUGCCACACGUCUG L-RNA 194L-DNA/ NOX-G11-D22 CAGACGUGUGUGGGUAGAUGC dACCUGCGAUUCGCUAAAAAGUGCCACACGUCUG L-RNA 195 L-DNA/ NOX-G11-D23CAGACGUGUGUGGGUAGAUGCA dC CUGCGAUUCGCUAAAAAGUGCCACACGUCUG L-RNA 196L-DNA/ NOX-G11-D24 CAGACGUGUGUGGGUAGAUGCAC dCUGCGAUUCGCUAAAAAGUGCCACACGUCUG L-RNA 197 L-DNA/ NOX-G11-D25CAGACGUGUGUGGGUAGAUGCACC dT GCGAUUCGCUAAAAAGUGCCACACGUCUG L-RNA 198L-DNA/ NOX-G11-D26 CAGACGUGUGUGGGUAGAUGCACCU dGCGAUUCGCUAAAAAGUGCCACACGUCUG L-RNA 199 L-DNA/ NOX-G11-D27CAGACGUGUGUGGGUAGAUGCACCUG dC GAUUCGCUAAAAAGUGCCACACGUCUG L-RNA 200L-DNA/ NOX-G11-D28 CAGACGUGUGUGGGUAGAUGCACCUGC dGAUUCGCUAAAAAGUGCCACACGUCUG L-RNA 201 L-DNA/ NOX-G11-D29CAGACGUGUGUGGGUAGAUGCACCUGCG dA UUCGCUAAAAAGUGCCACACGUCUG L-RNA 202L-DNA/ NOX-G11-D30 CAGACGUGUGUGGGUAGAUGCACCUGCGA dTUCGCUAAAAAGUGCCACACGUCUG L-RNA 203 L-DNA/ NOX-G11-D31CAGACGUGUGUGGGUAGAUGCACCUGCGAU dT CGCUAAAAAGUGCCACACGUCUG L-RNA 204L-DNA/ NOX-G11-D32 CAGACGUGUGUGGGUAGAUGCACCUGCGAUU dCGCUAAAAAGUGCCACACGUCUG L-RNA 205 L-DNA/ NOX-G11-D33CAGACGUGUGUGGGUAGAUGCACCUGCGAUUC dG CUAAAAAGUGCCACACGUCUG L-RNA 206L-DNA/ NOX-G11-D34 CAGACGUGUGUGGGUAGAUGCACCUGCGAUUCG dCUAAAAAGUGCCACACGUCUG L-RNA 207 L-DNA/ NOX-G11-D35CAGACGUGUGUGGGUAGAUGCACCUGCGAUUCGC dT AAAAAGUGCCACACGUCUG L-RNA 208L-DNA/ NOX-G11-D36 CAGACGUGUGUGGGUAGAUGCACCUGCGAUUCGCU dAAAAAGUGCCACACGUCUG L-RNA 209 L-DNA/ NOX-G11-D37CAGACGUGUGUGGGUAGAUGCACCUGCGAUUCGCUA dA AAAGUGCCACACGUCUG L-RNA 210L-DNA/ NOX-G11-D38 CAGACGUGUGUGGGUAGAUGCACCUGCGAUUCGCUAA dAAAGUGCCACACGUCUG L-RNA 211 L-DNA/ NOX-G11-D39CAGACGUGUGUGGGUAGAUGCACCUGCGAUUCGCUAAA dA AGUGCCACACGUCUG L-RNA 212L-DNA/ NOX-G11-D40 CAGACGUGUGUGGGUAGAUGCACCUGCGAUUCGCUAAAA dAGUGCCACACGUCUG L-RNA 213 L-DNA/ NOX-G11-D41CAGACGUGUGUGGGUAGAUGCACCUGCGAUUCGCUAAAAA dG UGCCACACGUCUG L-RNA 214L-DNA/ NOX-G11-D42 CAGACGUGUGUGGGUAGAUGCACCUGCGAUUCGCUAAAAAG dTGCCACACGUCUG L-RNA 215 L-DNA/ NOX-G11-D43CAGACGUGUGUGGGUAGAUGCACCUGCGAUUCGCUAAAAAGU dGC CACACGUCUG L-RNA 216L-DNA/ NOX-G11-D44 CAGACGUGUGUGGGUAGAUGCACCUGCGAUUCGCUAAAAAGUG dCCACACGUCUG L-RNA 217 L-DNA/ NOX-G11-D45CAGACGUGUGUGGGUAGAUGCACCUGCGAUUCGCUAAAAAGUGC dC ACACGUCUG L-RNA 218L-DNA/ NOX-G11-D46 CAGACGUGUGUGGGUAGAUGCACCUGCGAUUCGCUAAAAAGUGCC dACACGUCUG L-RNA 219 L-DNA/ NOX-G11-D47CAGACGUGUGUGGGUAGAUGCACCUGCGAUUCGCUAAAAAGUGCCA dC ACGUCUG L-RNA 220L-DNA/ NOX-G11-D48 CAGACGUGUGUGGGUAGAUGCACCUGCGAUUCGCUAAAAAGUGCCAC dACGUCUG L-RNA 221 L-DNA/ NOX-G11-D49CAGACGUGUGUGGGUAGAUGCACCUGCGAUUCGCUAAAAAGUGCCACA dC GUCUG L-RNA 222L-DNA/ NOX-G11-D50 CAGACGUGUGUGGGUAGAUGCACCUGCGAUUCGCUAAAAAGUGCCACAC dGUCUG L-RNA 223 L-DNA/ NOX-G11-D51CAGACGUGUGUGGGUAGAUGCACCUGCGAUUCGCUAAAAAGUGCCACACG dT CUG L-RNA 224L-DNA/ NOX-G11-D52 CAGACGUGUGUGGGUAGAUGCACCUGCGAUUCGCUAAAAAGUGCCACACGUdC UG L-RNA 225 L-DNA/ NOX-G11-D53CAGACGUGUGUGGGUAGAUGCACCUGCGAUUCGCUAAAAAGUGCCACACGUC dT G L-RNA 226L-DNA/ NOX-G11-D54 CAGACGUGUGUGGGUAGAUGCACCUGCGAUUCGCUAAAAAGUGCCACACGUCUdG L-RNA 227 L-DNA 257-E1-001GCAGTGGGGAAATGGGAGGGCTAGGTGGAAGGAATCTGAGCTACTGC 228 L-DNA/ 257-E1-R1-001rG CAGTGGGGAAATGGGAGGGCTAGGTGGAAGGAATCTGAGCTACTGC L-RNA 229 L-DNA/257-E1-R2-001 G rC AGTGGGGAAATGGGAGGGCTAGGTGGAAGGAATCTGAGCTACTGC L-RNA230 L-DNA/ 257-E1-R3-001 GC rAGTGGGGAAATGGGAGGGCTAGGTGGAAGGAATCTGAGCTACTGC L-RNA 231 L-DNA/257-E1-R4-001 GCA rG TGGGGAAATGGGAGGGCTAGGTGGAAGGAATCTGAGCTACTGC L-RNA232 L-DNA/ 257-E1-R5-001 GCAG rUGGGGAAATGGGAGGGCTAGGTGGAAGGAATCTGAGCTACTGC L-RNA 233 L-DNA/257-E1-R6-001 GCAGT rG GGGAAATGGGAGGGCTAGGTGGAAGGAATCTG13GCTACTGC L-RNA234 L-DNA/ 257-E1-R7-001 GCAGTG rGGGAAATGGGAGGGCTAGGTGGAAGGAATCTGAGCTACTGC L-RNA 235 L-DNA/ 257-E1-R8-001GCAGTGG rG GAAATGGGAGGGCTAGGTGGAAGGAATCTGAGCTACTGC L-RNA 236 L-DNA/257-E1-R9-001 GCAGTGGG rG AAATGGGAGGGCTAGGTGGAAGGAATCTGAGCTACTGC L-RNA237 L-DNA/ 257-E1-R10-001 GCAGTGGGG rAAATGGGAGGGCTAGGTGGAAGGAATCTGAGCTACTGC L-RNA 238 L-DNA/ 257-E1-R11-001GCAGTGGGGA rA ATGGGAGGGCTAGGTGGAAGGAATCTGAGCTACTGC L-RNA 239 L-DNA/257-E1-R12-001 GCAGTGGGGAA rA TGGGAGGGCTAGGTGGAAGGAATCTGAGCTACTGC L-RNA240 L-DNA/ 257-E1-R13-001 GCAGTGGGGAAA rUGGGAGGGCTAGGTGGAAGGAATCTGAGCTACTGC L-RNA 241 L-DNA/ 257-E1-R14-001GCAGTGGGGAAAT rG GGAGGGCTAGGTGGAAGGAATCTGAGCTACTGC L-RNA 242 L-DNA/257-E1-R15-001 GCAGTGGGGAAATG rG GAGGGCTAGGTGGAAGGAATCTGAGCTACTGC L-RNA243 L-DNA/ 257-E1-R16-001 GCAGTGGGGAAATGG rGAGGGCTAGGTGGAAGGAATCTGAGCTACTGC L-RNA 244 L-DNA/ 257-E1-R17-001GCAGTGGGGAAATGGG rA GGGCTAGGTGGAAGGAATCTGAGCTACTGC L-RNA 245 L-DNA/257-E1-R18-001 GCAGTGGGGAAATGGGA rG GGCTAGGTGGAAGGAATCTGAGCTACTGC L-RNA246 L-DNA/ 257-E1-R19-001 GCAGTGGGGAAATGGGAG rGGCTAGGTGGAAGGAATCTGAGCTACTGC L-RNA 247 L-DNA/ 257-E1-R20-001GCAGTGGGGAAATGGGAGG rG CTAGGTGGAAGGAATCTGAGCTACTGC L-RNA 248 L-DNA/257-E1-R21-001 GCAGTGGGGAAATGGGAGGG rC TAGGTGGAAGGAATCTGAGCTACTGC L-RNA249 L-DNA/ 257-E1-R22-001 GCAGTGGGGAAATGGGAGGGC rUAGGTGGAAGGAATCTGAGCTACTGC L-RNA 250 L-DNA/ 257-E1-R23-001GCAGTGGGGAAATGGGAGGGCT rA GGTGGAAGGAATCTGAGCTACTGC L-RNA 251 L-DNA/257-E1-R24-001 GCAGTGGGGAAATGGGAGGGCTA rG GTGGAAGGAATCTGAGCTACTGC L-RNA252 L-DNA/ 257-E1-R25-001 GCAGTGGGGAAATGGGAGGGCTAG rGTGGAAGGAATCTGAGCTACTGC L-RNA 253 L-DNA/ 257-E1-R26-001GCAGTGGGGAAATGGGAGGGCTAGG rU GGAAGGAATCTGAGCTACTGC L-RNA 254 L-DNA/257-E1-R27-001 GCAGTGGGGAAATGGGAGGGCTAGGT rG GAAGGAATCTGAGCTACTGC L-RNA255 L-DNA/ 257-E1-R28-001 GCAGTGGGGAAATGGGAGGGCTAGGTG rGAAGGAATCTGAGCTACTGC L-RNA 256 L-DNA/ 257-E1-R29-001GCAGTGGGGAAATGGGAGGGCTAGGTGG rA AGGAATCTGAGCTACTGC L-RNA 257 L-DNA/257-E1-R30-001 GCAGTGGGGAAATGGGAGGGCTAGGTGGA rA GGAATCTGAGCTACTGC L-RNA258 L-DNA/ 257-E1-R31-001 GCAGTGGGGAAATGGGAGGGCTAGGTGGAA rGGAATCTGAGCTACTGC L-RNA 259 L-DNA/ 257-E1-R32-001GCAGTGGGGAAATGGGAGGGCTAGGTGGAAG rG AATCTGAGCTACTGC L-RNA 260 L-DNA/257-E1-R33-001 GCAGTGGGGAAATGGGAGGGCTAGGTGGAAGG rA ATCTGAGCTACTGC L-RNA261 L-DNA/ 257-E1-R34-001 GCAGTGGGGAAATGGGAGGGCTAGGTGGAAGGA rATCTGAGCTACTGC L-RNA 262 L-DNA/ 257-E1-R35-001GCAGTGGGGAAATGGGAGGGCTAGGTGGAAGGAA rU CTGAGCTACTGC L-RNA 263 L-DNA/257-E1-R36-001 GCAGTGGGGAAATGGGAGGGCTAGGTGGAAGGAAT rC TGAGCTACTGC L-RNA264 L-DNA/ 257-E1-R37-001 GCAGTGGGGAAATGGGAGGGCTAGGTGGAAGGAATC rUGAGCTACTGC L-RNA 265 L-DNA/ 257-E1-R38-001GCAGTGGGGAAATGGGAGGGCTAGGTGGAAGGAATCT rG AGCTACTGC L-RNA 266 L-DNA/257-E1-R39-001 GCAGTGGGGAAATGGGAGGGCTAGGTGGAAGGAATCTG rA GCTACTGC L-RNA267 L-DNA/ 257-E1-R40-001 GCAGTGGGGAAATGGGAGGGCTAGGTGGAAGGAATCTGA rGCTACTGC L-RNA 268 L-DNA/ 257-E1-R41-001GCAGTGGGGAAATGGGAGGGCTAGGTGGAAGGAATCTGAG rC TACTGC L-RNA 269 L-DNA/257-E1-R42-001 GCAGTGGGGAAATGGGAGGGCTAGGTGGAAGGAATCTGAGC rU ACTGC L-RNA270 L-DNA/ 257-E1-R43-001 GCAGTGGGGAAATGGGAGGGCTAGGTGGAAGGAATCTGAGCT rACTGC L-RNA 271 L-DNA/ 257-E1-R44-001GCAGTGGGGAAATGGGAGGGCTAGGTGGAAGGAATCTGAGCTA rC TGC L-RNA 272 L-DNA/257-E1-R45-001 GCAGTGGGGAAATGGGAGGGCTAGGTGGAAGGAATCTGAGCTAC rU GC L-RNA273 L-DNA/ 257-E1-R46-001 GCAGTGGGGAAATGGGAGGGCTAGGTGGAAGGAATCTGAGCTACTrG C L-RNA 274 L-DNA/ 257-E1-R47-001GCAGTGGGGAAATGGGAGGGCTAGGTGGAAGGAATCTGAGCTACTG rC L-RNA 275 L-DNA/257-E1-R15/29-001 GCAGTGGGGAAATG rG GAGGGCTAGGTGG rA AGGAATCTGAGCTACTGCL-RNA 276 L-DNA/ 257-E1-R29/30-001 GCAGTGGGGAAATGGGAGGGCTAGGTGG rArAGGAATCTGAGCTACTGC L-RNA 277 L-DNA/ 257-E1-R15/29/30-001 GCAGTGGGGAAATGrG GAGGGCTAGGTGG rArA GGAATCTGAGCTACTGC L-RNA 278 L-DNA/257-E1-R18/29/30-001 GCAGTGGGGAAATGGGA rG GGCTAGGTGG rArAGGAATCTGAGCTACTGC L-RNA 279 L-DNA/ 257-E1-R15/18/29/30-001GCAGTGGGGAAATGrGGA rG GGCTAGGTGG rArA GGAATCTGAGCTACTGC L-RNA 280 L-DNA/257-E1-6xR-001 GCAGTGGG rG AAATG rG GA rGrG GCTAGGTGG rArAGGAATCTGAGCTACTGC L-RNA (= 257-E1-R9/15/18/19/ 29/30-001) 281 L-RNANOX-D19 5′-40kDa-PEG- GCCUGAUGUGGUGGUGAAGGGUUGUUGGGUGUCGACGCACAGGC 282L-DNA/ 257-E1-7xR-021 GCGCGGG rG AAA rT G rG GA rGrG GCTAGGTGG rArAGGAATCTGAGCCGCGC L-RNA 283 L-DNA/ 257-E1-7xR-022 GCGCGGG rG AAATG rG GArGrG GC rT AGGTGG rArA GGAATCTGAGCCGCGC L-RNA 284 L-DNA/ 257-E1-7xR-023GCGCGGG rG AAATG rG GA rGrG GCTAGG rT GG rArA GGAATCTGAGCCGCGC L-RNA 285L-DNA/ 257-E1-7xR-024 GCGCGGG rG AAATG rG GA rGrG GCTAGGTGG rArA GGAA rTCTGAGCCGCGC L-RNA 286 L-DNA/ 257-E1-7xR-025 GCGCGGG rG AAATG rG GA rGrGGCTAGGTGG rArA GGAATC rT GAGCCGCGC L-RNA 287 L-DNA 259-H6-002ACTCGAGAGGAAAGGTTGGTAAAGGTTCGGTTGGATTCACTCGAGT L-RNA 288 L-DNA/259-H6-002-R01 rA CTCGAGAGGAAAGGTTGGTAAAGGTTCGGTTGGATTCACTCGAGT L-RNA289 L-DNA/ 259-H6-002-R02 A rCTCGAGAGGAAAGGTTGGTAAAGGTTCGGTTGGATTCACTCGAGT L-RNA 290 L-DNA/259-H6-002-R03 AC rU CGAGAGGAAAGGTTGGTAAAGGTTCGGTTGGATTCACTCGAGT L-RNA291 L-DNA/ 259-H6-002-R04 ACT rCGAGAGGAAAGGTTGGTAAAGGTTCGGTTGGATTCACTCGAGT L-RNA 292 L-DNA/259-H6-002-R05 ACTC rG AGAGGAAAGGTTGGTAAAGGTTCGGTTGGATTCACTCGAGT L-RNA293 L-DNA/ 259-H6-002-R06 ACTCG rAGAGGAAAGGTTGGTAAAGGTTCGGTTGGATTCACTCGAGT L-RNA 294 L-DNA/ 259-H6-002-R07ACTCGA rG AGGAAAGGTTGGTAAAGGTTCGGTTGGATTCACTCGAGT L-RNA 295 L-DNA/259-H6-002-R08 ACTCGAG rA GGAAAGGTTGGTAAAGGTTCGGTTGGATTCACTCGAGT L-RNA296 L-DNA/ 259-H6-002-R09 ACTCGAGA rGGAAAGGTTGGTAAAGGTTCGGTTGGATTCACTCGAGT L-RNA 297 L-DNA/ 259-H6-002-R10ACTCGAGAG rG AAAGGTTGGTAAAGGTTCGGTTGGATTCACTCGAGT L-RNA 298 L-DNA/259-H6-002-R11 ACTCGAGAGG rA AAGGTTGGTAAAGGTTCGGTTGGATTCACTCGAGT L-RNA299 L-DNA/ 259-H6-002-R12 ACTCGAGAGGA rAAGGTTGGTAAAGGTTCGGTTGGATTCACTCGAGT L-RNA 300 L-DNA/ 259-H6-002-R13ACTCGAGAGGAA rA GGTTGGTAAAGGTTCGGTTGGATTCACTCGAGT L-RNA 301 L-DNA/259-H6-002-R14 ACTCGAGAGGAAA rG GTTGGTAAAGGTTCGGTTGGATTCACTCGAGT L-RNA302 L-DNA/ 259-H6-002-R15 ACTCGAGAGGAAAG rGTTGGTAAAGGTTCGGTTGGATTCACTCGAGT L-RNA 303 L-DNA/ 259-H6-002-R16ACTCGAGAGGAAAGG rU TGGTAAAGGTTCGGTTGGATTCACTCGAGT L-RNA 304 L-DNA/259-H6-002-R17 ACTCGAGAGGAAAGGT rU GGTAAAGGTTCGGTTGGATTCACTCGAGT L-RNA305 L-DNA/ 259-H6-002-R18 ACTCGAGAGGAAAGGTT rGGTAAAGGTTCGGTTGGATTCACTCGAGT L-RNA 306 L-DNA/ 259-H6-002-R19ACTCGAGAGGAAAGGTTG rG TAAAGGTTCGGTTGGATTCACTCGAGT L-RNA 307 L-DNA/259-H6-002-R20 ACTCGAGAGGAAAGGTTGG rU AAAGGTTCGGTTGGATTCACTCGAGT L-RNA308 L-DNA/ 259-H6-002-R21 ACTCGAGAGGAAAGGTTGGT rAAAGGTTCGGTTGGATTCACTCGAGT L-RNA 309 L-DNA/ 259-H6-002-R22ACTCGAGAGGAAAGGTTGGTA rA AGGTTCGGTTGGATTCACTCGAGT L-RNA 310 L-DNA/259-H6-002-R23 ACTCGAGAGGAAAGGTTGGTAA rA GGTTCGGTTGGATTCACTCGAGT L-RNA311 L-DNA/ 259-H6-002-R24 ACTCGAGAGGAAAGGTTGGTAAA rGGTTCGGTTGGATTCACTCGAGT L-RNA 312 L-DNA/ 259-H6-002-R25ACTCGAGAGGAAAGGTTGGTAAAG rG TTCGGTTGGATTCACTCGAGT L-RNA 313 L-DNA/259-H6-002-R26 ACTCGAGAGGAAAGGTTGGTAAAGG rU TCGGTTGGATTCACTCGAGT L-RNA314 L-DNA/ 259-H6-002-R27 ACTCGAGAGGAAAGGTTGGTAAAGGT rUCGGTTGGATTCACTCGAGT L-RNA 315 L-DNA/ 259-H6-002-R28ACTCGAGAGGAAAGGTTGGTAAAGGTT rC GGTTGGATTCACTCGAGT L-DNA/ 316 L-DNA/259-H6-002-R29 ACTCGAGAGGAAAGGTTGGTAAAGGTTC rG GTTGGATTCACTCGAGT L-RNA317 L-DNA/ 259-H6-002-R30 ACTCGAGAGGAAAGGTTGGTAAAGGTTCG rGTTGGATTCACTCGAGT L-RNA 318 L-DNA/ 259-H6-002-R31ACTCGAGAGGAAAGGTTGGTAAAGGTTCGG rU TGGATTCACTCGAGT L-RNA 319 L-DNA/259-H6-002-R32 ACTCGAGAGGAAAGGTTGGTAAAGGTTCGGT rU GGATTCACTCGAGT L-RNA320 L-DNA/ 259-H6-002-R33 ACTCGAGAGGAAAGGTTGGTAAAGGTTCGGTT rGGATTCACTCGAGT L-RNA 321 L-DNA/ 259-H6-002-R34ACTCGAGAGGAAAGGTTGGTAAAGGTTCGGTTG rG ATTCACTCGAGT L-RNA 322 L-DNA/259-H6-002-R35 ACTCGAGAGGAAAGGTTGGTAAAGGTTCGGTTGG rA TTCACTCGAGT L-RNA323 L-DNA/ 259-H6-002-R36 ACTCGAGAGGAAAGGTTGGTAAAGGTTCGGTTGGA rUTCACTCGAGT L-RNA 324 L-DNA/ 259-H6-002-R37ACTCGAGAGGAAAGGTTGGTAAAGGTTCGGTTGGAT rU CACTCGAGT L-RNA 325 L-DNA/259-H6-002-R38 ACTCGAGAGGAAAGGTTGGTAAAGGTTCGGTTGGATT rC ACTCGAGT L-RNA326 L-DNA/ 259-H6-002-R39 ACTCGAGAGGAAAGGTTGGTAAAGGTTCGGTTGGATTC rACTCGAGT L-RNA 327 L-DNA/ 259-H6-002-R40ACTCGAGAGGAAAGGTTGGTAAAGGTTCGGTTGGATTCA rC TCGAGT L-RNA 328 L-DNA/259-H6-002-R41 ACTCGAGAGGAAAGGTTGGTAAAGGTTCGGTTGGATTCAC rU CGAGT L-RNA329 L-DNA/ 259-H6-002-R42 ACTCGAGAGGAAAGGTTGGTAAAGGTTCGGTTGGATTCACT rCGAGT L-RNA 330 L-DNA/ 259-H6-002-R43ACTCGAGAGGAAAGGTTGGTAAAGGTTCGGTTGGATTCACTC rG AGT L-RNA 331 L-DNA/259-H6-002-R44 ACTCGAGAGGAAAGGTTGGTAAAGGTTCGGTTGGATTCACTCG rA GT L-RNA332 L-DNA/ 259-H6-002-R45 ACTCGAGAGGAAAGGTTGGTAAAGGTTCGGTTGGATTCACTCGArG T L-RNA 333 L-DNA/ 259-H6-002-R46ACTCGAGAGGAAAGGTTGGTAAAGGTTCGGTTGGATTCACTCGAG rU L-RNA 334 L-DNA/259-H6-002-R13_R24 ACTCGAGAGGAA rA GGTTGGTAAA rG GTTCGGTTGGATTCACTCGAGTL-RNA 335 L-DNA/ 259-H6-002-R13_R36 ACTCGAGAGGAA rAGGTTGGTAAAGGTTCGGTTGGA rU TCACTCGAGT L-RNA 336 L-DNA/259-H6-002-R13_R24_ ACTCGAGAGGAA rA GGTTGGTAAA rG GTTCGGTTGGA rUTCACTCGAGT L-RNA R36 337 L-DNA/ 259-H6-002-R13_R24_ ACTCGAGAGGAA rAGGTTGGTAAA rG GTTCG rG TTGGA rU TCACTCGAGT L-RNA R30_R36 338 L-RNA226-F2-001-51-40kDa- 5′-40kDa-PEG- PEGCCGUGCUGUCGGAGACUACUCGUCGAGUAGAAAUAGGUCCCCUCCCACGG 339 L-DNA/226-F2-001-D41-5′- 5′-40kDa-PEG- L-RNA 40kDa-PEG, NOX-L41CCGUGCUGUCGGAGACUACUCGUCGAGUAGAAAUAGGUCC dC CUCCCACGG 340 L-RNA5′-40kDa-PEG- 5′-40kDa-PEG- L-S1P-215-F9-002GCGUGAAUAGCCGUUGAAACGCCUUUAGAGAAGCACUAGCACGC 341 L-DNA/ 5′-40kDa-PEG-5′-40kDa- L-RNA L-S1P-215-F9-002-D01- dG CGUGAAUAGCCGUUGAA dA C dGCCUUUAGAGA dA GCACUAGCACGC 19-21-32 342 D- L-S1P-215-F9-002-GG-GCGUGAAUAGCCGUUGAAACGCCUUUAGAGAAGCACUAGCACGC RNA/L- 5′diD-G5′-GG is D-RNA RNA

The present invention is further illustrated by the figures, examplesand the sequence listing from which further features, embodiments andadvantages may be taken, wherein

The present invention is further illustrated by the figures, examplesand the sequence listing from which further features, embodiments andadvantages may be taken, wherein

FIGS. 1A-C show nucleic acid molecule L-S1P-215-F9-002 consisting ofribonucleotides and derivatives nucleic acid molecule L-S1P-215-F9-002,whereby the derivatives comprise single or multiple ribonucleotide (A,U, G, C) to 2′-deoxyribonucleotide (dA, dT, dG, dC) substitutions;

FIG. 2 shows the results of the competitive spiegelmer pull-down assayof ribo- to 2′-deoxyribonucleotide substituted 215-F9-002 (also referedto as L-S1P-215-F9-002) derivatives: 0.3 nM radioactively labeledL-S1P-215-F9-002-5′diD-G binding to 8 nM biotinylated D-e-S1P at 37° C.competed by 50 nM unlabeled spiegelmer (triplicates) as indicated;

FIG. 3 shows the results of the competitive spiegelmer pull-down assayof ribo- to 2′-deoxyribonucleotide substituted 215-F9-002 (also referedto as L-S1P-215-F9-002) derivatives, whereby

-   -   (A) 0.3 nM radioactively labeled L-SIP-215-F9-002-5′diD-G        binding to 8 nM biotinylated D-e-S-1-P for 3 h at 37° C.        competed by 36 nM unlabeled Spiegelmer (triplicates) as        indicated;    -   (B) 0.5 nM radioactively labeled L-S1P-215-F9-002-5′diD-G        binding to 7 nM biotinylated D-e-S-1-P for 2.5 h at 37° C.        competed by titrating concentrations of 5′-40        kDa-PEG-L-S1P-215-F9-002 (circles) and 5′-40        kDa-PEG-L-S1P-215-F9-002-D01-19-21-32 (squares);

FIG. 4 shows the results of the inhibition of (Mean values of triplicatecultures±SD are shown):

-   -   10 nM D-e-S1P-induced β-arrestin recruitment in a reporter cell        line expressing EDG1 by:        -   (A) 5′-40 kDa-PEG-L-S1P-215-F9-002 and        -   (B) 5′-40 kDa-PEG-L-S1P-215-F9-002-D01-19-21-32 (also            referred to as NOX-S93)

FIG. 5A-E shows nucleic acid molecule 226-F2-002 consisting ofribonucleotides and derivatives of nucleic acid molecule 226-F2-002,whereby the derivatives comprise single ribonucleotide (A, U, G, C) to2′-deoxyribonucleotide (dA, dT, dG, dC) substitutions;

FIG. 6 shows a plot of the determined changes in affinity in respect tothe parental Spiegelmer 226-F2-001 as determined by Biacore measurement;

FIG. 7 shows nucleic acid molecule 226-F2-002 consisting ofribonucleotides and the derivatives 226-F2-002-41, 226-F2-002-44 and226-F2-002-41/44 of nucleic acid molecule 226-F2-002, whereby thederivatives comprise ribonucleotides (A, U, G, C) and one or two2′-deoxyribonucleotides (dC);

FIG. 8A shows the kinetic evaluation by Biacore measurement of CGRPbinding Spiegelmers 226-F2-001 and 226-F2-001-D41 to human CGRP;

FIG. 8B shows the kinetic evaluation by Biacore measurement of CGRPbinding Spiegelmers 226-F2-001 and 226-F2-001-D44 to human CGRP;

FIG. 9 shows the kinetic evaluation by Biacore measurement of CGRPbinding Spiegelmers 226-F2-001-D41 and 226-F2-001-D41/44 to human CGRP;

FIG. 10 shows shows inhibition of human CGRP-induced cAMP production byCGRP binding Spiegelmers 226-F2-001-5′40 kDa-PEG (black circles) andNOX-L41 (also referred to as 226-F2-001-D41-5′40 kDa-PEG, blacksquares), whereby the results are shown as relative amounts of cAMPproduced in comparison to control (percent of control);

FIG. 11A-E shows nucleic acid molecule NOX-D19001 consisting ofribonucleotides and derivatives of nucleic acid molecule NOX-D19001,whereby the derivatives comprise single ribonucleotide (A, U, G, C) to2′-deoxyribonucleotide (dA, dU, dG, dC) substitutions;

FIG. 12 shows a plot of the determined changes in affinity in respect tothe parental Spiegelmer NOX-D19001 as determined by Biacore measurement;

FIG. 13 shows the kinetic evaluation by Biacore measurement ofSpiegelmers 226-F2-NOX-D19001 and derivatives NOX-D19001-D09,NOX-D19001-D16, NOX-D1900-D017, NOX-D19001-D30, NOX-D19001-D32 andNOX-D19001-D40 to human C5a;

FIG. 14 shows derivatives of nucleic acid molecule NOX-D19001, wherebythe derivatives comprise multiple ribonucleotide (A, U, G, C) to2′-deoxyribonucleotide (dA, dU, dG, dC) substitutions;

FIG. 15 shows the kinetic evaluation by Biacore measurement ofSpiegelmers 226-F2-NOX-D19001 and NOX-D19001-D09-16-17-30-32-40 to humanC5a;

FIG. 16 shows the efficacy of 5′-terminal 40 kDa PEGylated SpiegelmerNOX-D19001-5′PEG (also referred as NOX-D19) and SpiegelmerNOX-D19001-6×DNA in chemotaxis assays, wherein cells were allowed tomigrate towards 0.1 nM huC5a preincubated at 37° C. with various amountsof Spiegelmers;

FIG. 17 shows derivatives of nucleic acid molecule NOX-D19001, wherebythe derivatives comprise multiple ribonucleotide (A, U, G, C) to2′-deoxyribonucleotide (dA, dU, dG, dC) substitutions;

FIGS. 18A-E shows nucleic acid molecule NOX-G11stabi2 consisting ofribonucleotides and derivatives of the nucleic acid molecule NOX-G11stabi2, whereby the derivatives comprise single or multipleribonucleotide (A, C, G, U) to 2′-deoxyribonucleotide (dA, dC, dG, dT)substitutions;

FIG. 19 shows a plot of the determined changes in affinity in respect tothe parental Spiegelmer NOX-G11 stabi2 as determined by Biacoremeasurement;

FIG. 20 shows the kinetic evaluation by Biacore measurement ofspiegelmers NOX-G11stabi2, NOX-G11-D07, NOX-G11-D16, NOX-G11-D19,NOX-G11-D21, NOX-G11-D22 to immobilized biotinylated human glucagon,

FIGS. 21A-E show nucleic acid molecule 259-H6-002 consisting ofribonucleotides and derivatives of nucleic acid molecule 259-H6-002,whereby the derivatives comprise single or multiple deoxyribonucleotide(A, T, G, C) to ribonucleotide (rA, rU, rG, rC) to 2′-substitutions;

FIG. 22 shows a plot of the determined changes in affinity in respect tothe parental Spiegelmer 259-H6-002 as determined by Biacore measurement;

FIG. 23 shows the kinetic evaluation by Biacore measurement ofspiegelmers 259-H6-002, 259-H6-002R13, 259-H6-002R24 and 259-H6-002-R36to immobilized biotinylated human glucagon,

FIG. 24 shows the kinetic evaluation by Biacore measurement ofspiegelmers 259-H6-002, 259-H6-002R13, 259-H6-002R13-R24,259-H6-002R13-R36 and 259-H6-002R13-R24-R36 to immobilized biotinylatedhuman glucagon,

FIG. 25 shows inhibition of glucagon-induced production of cAMP bySpiegelmer 259-H6-002 and its derivatives 259-H6-002-R13 and259-H6-002-R13-R24-R36 (also referred to as 259-H6-002-R13/24/36),whereby a) the generated amounts of cAMP per well were normalized to thelargest value of each data set and depicted as per cent activity againstSpiegelmer concentration, b) the Spiegelmer concentrations at which cAMPproduction is inhibited by 50% (IC₅₀) were calculated using nonlinearregression (four parameter fit) with Prism5 software, c) the Spiegelmersused were 259-H6-002 (176 nM), 259-H6-002-R13 (12.5 nM) and259-H6-002-R13-R24-R36 (6.2 nM) with the respective IC₅₀ values given inbrackets.

FIG. 26 shows the kinetic evaluation by Biacore measurement ofspiegelmers 259-H6-002R13-R24-R30-R36 to immobilized biotinylated humanglucagon,

FIGS. 27A-E shows nucleic acid molecule 257-E1-001 consisting of2′-desoxyribonucleotides and derivatives of the nucleic acid molecule257-E1-001, whereby the derivatives comprise single or multiple2′-deoxyribonucleotide (A, C, G, T) to ribonucleotide (rA, rC, rG, rU))substitutions;

FIG. 27F shows derivatives of nucleic acid molecule 257-E1-6xR-001consisting of 2′-deoxyribonucleotides and ribonucleotides;

FIG. 28 shows the results of competitive pull-down assays of nucleicacid molecule 257-E1-001 and its derivatives 257-E1-R15-001,257-E1-R29-001, 257-E1-6xR-001 and 257-E1-7xR-03 to biotinylatedglucagon.

EXAMPLE 1: NUCLEIC ACID MOLECULE HAVING INCREASED BINDING AFFINITY TOTHE TARGET Molecule S1P

Starting from a nucleic acid molecule binding to S1P which was theresult of a development process involving as a starting point theimmediate screening product of the SELEX process, the method of thepresent invention was used in order to improve the binding affinity ofthe nucleic acid molecule to its target. In the instant case, thenucleic acid molecule binding to S1P was nucleic acid moleculeL-S1P-215-F9-002.

Nucleic acid molecule L-S1P-215-F9-002 is a Spiegelmer, i.e. anL-nucleic acid molecule, which is capable of binding to S1P, has of anucleotide sequence according to SEQ ID NO: 5 and consists of 44ribonucleotides.

The binding characteristics of nucleic acid molecule L-S1P-215-F9-002was determined by competitive Spiegelmer pull-down assay (as describedin Example 9). Nucleic acid molecule L-S1P-215-F9-002 binds S1P with anaffinity of 31.5 nM (FIG. 1 and FIG. 3B).

In order to improve the binding characteristics of nucleic acid moleculeL-S1P-215-F9-002, derivatives of nucleic acid molecule L-S1P-215-F9-002were synthesized. Said derivatives were L-nucleic acid molecules havingthe same sequence of nucleobases—guanine, cytosine, adenine, and uracilor thymine (in the case of a 2′deoxyribonucleotide)—as nucleic acidmolecule L-S1P-215-F9-002, however, differed at a single position as tothe sugar moiety of the nucleotide which was a 2′-deoxyribonucleotiderather than a ribonucleotide. In accordance therewith, derivative 1 hada 2′-deoxyribonucleoside at position 1 of the nucleotide sequenceaccording to SEQ ID NO: 6, derivative 2 had a 2′-deoxyribonucleotide atposition 2 of the nucleotide sequence according to SEQ ID NO: 7, etc.Because nucleic acid molecule L-SIP-215-F9-002 consists of 44nucleotides a total of 44 derivatives was synthesized in order toprovide a complete set of all possible derivatives of nucleic acidmolecule L-S1P-215-F9-002 carrying a single ribonucleotide to2′-deoxyribonucleotide substitution. Said complete set of derivatives isshown in FIG. 1A-C. In the case of uracil in the sequence of moleculeL-S1P-215-F9-002, uridine-5′-phosphate was replaced bythymidine-5′-phosphate.

The binding affinity to S1P of each derivative of said complete set ofderivatives of nucleic acid molecule L-S1P-215-F9-002 was determinedusing the competitive pull-down assay described in Example 9, andcompared to the binding affinity of nucleic acid moleculeL-S1P-215-F9-002 (FIG. 1 A-C).

As may be taken from FIG. 1 A-C, depending on the position within theSpiegelmer L-S1P-215-F9-002 ribonucleotide to 2′-deoxyribonucleotidesubstitution may have different impact on binding affinity for thetarget. Surprisingly, a single substitution of a ribonucleotide by a2′deoxyribonucleotide at some positions within nucleic acid moleculeL-S1P-215-F9-002 resulted in an improved binding affinity to S1P,whereas substitution at other positions did not result in significantchanges in binding affinity to S1P, or even decreased the bindingaffinity to S1P. The individual derivatives and relative changes oftheir binding affinities compared to the binding affinity of nucleicacid molecule 215-F9-002 to S1P are indicated in FIG. 1 A-C.

As may be taken from said figures, derivatives L-S1P-215-F9-002-D01,L-S1P-215-F9-002-D11, L-S1P-215-F9-002-D19, L-S1P-215-F9-002-D21,L-S1P-215-F9-002-D22, L-S1P-215-F9-002-D32 which have a2′-deoxyribonucleotide at positions 1, 11, 19, 21, 22, and 32,respectively, belong to the first group of derivatives, i.e. derivativesof nucleic acid molecule L-S1P-215-F9-002 where substitution of aribonucleotide by a 2′-deoxyribonucletoide results in an improvedbinding affinity for S1P (FIG. 1 A-C and FIG. 2). The best bindingaffinity of said derivatives was shown for derivativeL-S1P-215-F9-002-D19 and L-S1P-215-F9-002-D21 (FIG. 1 A-C and FIG. 2).Accordingly, positions 1, 11, 19, 21, 22, and 32, preferably 19 and 21,are suitable to confer improved binding affinity for S1P to nucleic acidmolecule L-S1P-215-F9-002. Adenosine-5′-phosphate to2′-deoxyadenosine-5′-phosphate substitution at position 19 andguanosine-5′-phosphate to 2′-deoxyguanosine-5′-phosphate substitution atposition 21 resulted in an improved binding affinity of 16 nM and 11.3nM, respectively, compared to L-S1P-215-F9-002 (K_(D) of 31.5 nM) (FIG.1 A-C).

Derivatives L-S1P-215-F9-002-D05, L-S1P-215-F9-002-D12,L-S1P-215-F9-002-D13, L-S1P-215-F9-002-D14, L-S1P-215-F9-002-D15,L-S1P-215-F9-002-D16, L-S1P-215-F9-002-D39, L-S1P-215-F9-002-D40,L-S1P-215-F9-002-D41, L-S1P-215-F9-002-D42 and L-S1P-215-F9-002-D43which have a 2′-deoxyribonucleotide at positions 5, 12, 13 14, 15, 16,39, 40, 41, 42 and 43, respectively, belong to the second group ofderivatives, i.e. derivatives where substitution of a ribonucleotide bya 2′-deoxyribonucletoide does not affect the binding affinity for S1P.Accordingly, positions 5, 12, 13, 14, 15, 16, 39, 40, 41, 42 and 43 arenot suitable to confer improved binding affinity nor do they havenegative impact on binding affinity to S1P compared to nucleic acidmolecule L-S1P-215-F9-002 (FIG. 1 A-C).

Finally, derivatives were obtained which resulted in reduced bindingaffinity or a profound loss of binding. These derivatives, namelyL-S1P-215-F9-002-D02, L-S1P-215-F9-002-D03, L-S1P-215-F9-002-D04,L-S1P-215-F9-002-D06, L-S1P-215-F9-002-D07, L-S1P-215-F9-002-D08,L-S1P-215-F9-002-D09, L-S1P-215-F9-002-D10, L-S1P-215-F9-002-D17,L-S1P-215-F9-002-D18, L-S1P-215-F9-002-D20, L-S1P-215-F9-002-D23,L-S1P-215-F9-002-D24, L-S1P-215-F9-002-D25, L-S1P-215-F9-002-D26,L-S1P-215-F9-002-D27, L-S1P-215-F9-002-D28, L-S1P-215-F9-002-D29,L-S1P-215-F9-002-D30, L-S1P-215-F9-002-D31, L-S1P-215-F9-002-D33,L-S1P-215-F9-002-D34, L-S1P-215-F9-002-D35, L-S1P-215-F9-002-D36,L-S1P-215-F9-002-D37, L-S1P-215-F9-002-D38 and L-S1P-215-F9-002-D44which have a 2′-deoxyribonucletoide at position 2, 3, 4, 6, 7, 8, 9, 10,17, 18, 20, 23, 24, 25, 26, 27, 28, 29, 30, 31, 33, 34, 35, 36, 37, 38and 44, respectively, belong to the third group of derivatives, i.e.derivatives of nucleic acid molecule L-S1P-215-F9-002 where substitutionof a ribonucleotide by a 2′-deoxyribonucletoide negatively affects thebinding affinity to S1P (FIG. 1 A-C).

In order to assess whether the binding affinity of the derivatives ofnucleic acid molecule L-S1P-215-F9-002 can be further increased byintroducing more than one substitution a group of further derivativeswas generated (FIG. 1C). Said group of further derivatives started fromthe first group of derivatives where substitution of a ribonucleotide bya 2′-deoxyribonucletoide resulted in an improved binding affinity forS1P. Starting from nucleic acid molecule L-S1P-215-F9-002, thederivatives had at least two substitutions of ribonucleotides by2′-deoxyribonucleotides at position 19, 21 and/or 22. Ribonucleotide to2′-deoxyribonucleotide substitution at position 19 and 21 conferred thestrongest improvements in binding affinity for S1P to nucleic acidmolecule L-S1P-215-F9-002 while substitution at position 22 had only aweak effect (FIG. 2).

Competitive Spiegelmer pull-down assays of these derivatives showed thatcombining ribonucleotide to 2′-deoxyribonucleotide substitutions atmultiple positions of the L-S1P-215-F9-002 Spiegelmer resulted in afurther improvement of binding affinity for S1P. A Spiegelmer containingtwo substitutions, namely adenosine-5′-phosphate to 2deoxyadenosine-5′-phosphate at position 19 and guanosine-5′-phosphate to2′-deoxyguanosine-5′-phosphate at position 21 (termedL-S1P-215-F9-002-D21-19) showed improved binding affinity compared toL-S1P-215-F9-002 and as well to L-S1P-215-F9-002-D21 containing a singlesubstitution, namely guanosine-5′-phosphate to2′-deoxyguanosine-5′-phosphate at position 21 (FIG. 3A). Additionalsubstitution of cytidine-5′-phosphate to 2′-deoxycytidine-5′-phosphateat position 22 did not result in further improvement asL-S1P-215-F9-002-D21 and L-S1P-215-F9-002-D21-22 as well asL-S1P-215-F9-002-D21-19 and L-S1P-215-F9-002-D21-19-22 showed similarbinding affinities for S1P, respectively (FIG. 1C and FIG. 3A). Incontrast, a Spiegelmer containing four substitutions, namely guanosineto 2′-deoxyguanosine at position 01, guanosine-5′-phosphate to2′-deoxyguanosine-5 phosphate at position 21 and adenosine-5′-phosphateto 2′-deoxyadenosine-5′-phosphate at position 19 and 32 (termedL-S1P-215-F9-002-D01-19-21-32) showed significantly improved bindingaffinity in comparison to Spiegelmer L-S1P-215-F9-002-D21-19 whichcontains only two substitutions (FIG. 1C and FIG. 3A). In comparison tothe parental molecule L-S1P-215-F9-002 (K_(D) of 31.5 nM) substitutionat four positions of ribonucleotides to 2′-deoxyribonucleotides inL-S1P-215-F9-002-D01-19-21-32 (K_(D) of 5 nM) resulted in a 6.3-foldimprovement of the binding affinity for S1P (FIG. 3B). An additionalsubstitution of cytidine-5′-phosphate to 2′-deoxycytidine-5′-phosphateat position 11 of L-S1P-215-F9-002-D01-19-21-32 had no further positiveeffect on the binding affinity for S1P (FIG. 1C and FIG. 3A).

In order to prove and compare the functionality of SpiegelmersL-S1P-215-F9-002 and L-S1P-215-F9-002-D01-19-21-32 both nucleic acidmolecules were synthesized comprising an amino-group at their 5′-ends.To the amino-modified Spiegelmers a 40 kDa PEG-moiety was coupledleading to Spiegelmers 5′-40 kDa-PEG-L-S1P-215-F9-002 and 5′-40kDa-PEG-L-S1P-215-F9-002-D01-19-21-32 (also referred to as NOX-S93).Synthesis and PEGylation of the Spiegelmer is described in Example 7.

An in vitro cell-culture assay (protocol see Example 11) confirmed thatimproved affinity to S1P translates into an enhanced inhibition of S1Pfunction. 5′-40 kDa-PEG-L-S1P-215-F9-002 and 5′-40kDa-PEG-L-S1P-215-F9-002-D01-19-21-32 (also referred to as NOX-S93)inhibited S1P-induced arrestin recruitment in a reporter cell lineexpressing human S1P-receptor EDG1 with IC₅₀ values of 22.5 nM and 10.3nM, respectively (FIG. 4A, 4B). Thus, competitive Spiegelmer pull-downassays (Example 9, FIG. 3B) and in vitro cell culture experiments(Example 11, FIG. 4) unanimously showed that substitutions ofribonucleotides to 2′-deoxyribonucleotides significantly improved thebinding affinity and the inhibitory activity of S1P-binding Spiegelmer226-F2-001.

EXAMPLE 2: NUCLEIC ACID MOLECULE HAVING INCREASED BINDING AFFINITY TOTHE TARGET MOLECULE HUMAN CGRP

Starting from a nucleic acid molecule binding to CGRP which was theresult of a development process involving as a starting point theimmediate screening product of the SELEX process, the method of thepresent invention was used in order to improve the binding affinity ofthe nucleic acid molecule to its target. In the instant case, thenucleic acid molecule binding to human CGRP was nucleic acid molecule226-F2-001.

Nucleic acid molecule 226-F2-001 is a Spiegelmer, i.e. a L-nucleic acidmolecule, which is capable of binding to human CGRP, has a nucleotidesequence according to SEQ ID NO: 55 and consists of 50 ribonucleotides.

The binding characteristics of nucleic acid molecule 226-F2-001 weredetermined by surface plasmon resonance measurement (as described inExample 8). Nucleic acid molecule 226-F2-001 binds human CGRP with anaffinity of 2.6 nM (FIG. 7, FIGS. 8A and 8B).

In order to improve the binding characteristics of nucleic acid molecule226-F2-001, derivatives of nucleic acid molecule 226-F2-001 weresynthesized. Said derivatives were L-nucleic acid molecules having thesame sequence of nucleobases—guanine, cytosine, adenine, and uracil orthymine (in the case of a 2′deoxyribonucleotide)—as nucleic acidmolecule 226-F2-001, however, differed at a single position as to thesugar moiety of the nucleotides which was a 2′-deoxyribonucleotiderather than a ribonucleotide. In accordance therewith, derivative 1(termed 226-F2-001-D01) had a 2′-deoxyribonucleoside at position 1 ofthe nucleotide sequence according to SEQ ID NO: 56, derivative 2 (termed226-F2-001-D02) had a 2′-deoxyribonucleotide at position 2 of thenucleotide sequence according to SEQ ID NO: 57, etc. Because nucleicacid molecule 226-F2-001 consisting of 50 nucleotides a total of 50derivatives were synthesized in order to provide a complete set of allpossible derivatives of nucleic acid molecule 226-F2-001 carrying asingle ribonucleotide to 2′-deoxyribonucleotide substitution. Saidcomplete set of derivatives is shown in FIG. 5 A-E. In the case ofuracil in the sequence of molecule 226-F2-001, the uridine-5′-phosphatewas replaced by thymidine-5′-phosphate.

The binding affinity to human CGRP of each derivative of said completeset of derivatives of nucleic acid molecule 226-F2-001 was determined bysurface plasmon resonance measurement described in Example 8, andcompared to the binding affinity of nucleic acid molecule 226-F2-001.From a set of at least 5 individually determined K_(D) values of226-F2-001 the mean value was calculated (mean+/− standard error). K_(D)values of individual derivatives were determined and changes in affinityare given as x-fold improvement compared to mean K_(D) of 226-F2-001,wherein the value of x-fold improvement is the quotient of the K_(D) of226-F2 001 and the derivative of 226-F2 001. The determined standarderror indicates a cutting point for positive hits. The data of thex-fold improved affinities is indicated in FIG. 5 A-E and plotted inFIG. 6.

As may be taken from FIG. 5A-E, depending on the position within theSpiegelmer ribonucleotide to 2′-deoxyribonucleotide substitutions mayhave different impact on binding affinity for the target. Surprisingly,at some positions within nucleic acid molecule 226-F2-001 a singleribonucleotide to 2′-deoxyribonucleotide substitution resulted in animproved binding affinity to human CGRP, whereas substitutions at otherpositions did not result in significant changes in binding affinity tohuman CGRP, or even decreased the binding affinity to human CGRP. Theindividual derivatives and the relative changes of their bindingaffinity to human CGRP compared to nucleic acid molecule 226-F2-001 areshown in FIG. 5 A-E and FIG. 6.

As may be taken from said figures, derivatives 226-F2-001-D03,226-F2-001-D05, 226-F2-001-D08, 226-F2-001-D09, 226-F2-001-D14,226-F2-001-D16, 226-F2-001-D19, 226-F2-001-D22, 226-F2-001-D23,226-F2-001-D24, 226-F2-001-D25, 226-F2-001-D26, 226-F2-001-D28,226-F2-001-D30, 226-F2-001-D33, 226-F2-001-D34, 226-F2-001-D37,226-F2-001-D39, 226-F2-001-D41, 226-F2-001-D42, 226-F2-001-D44,226-F2-001-D45, 226-F2-001-D46, 226-F2-001-D47, 226-F2-001-D48,226-F2-001-D49, 226-F2-001-D50 which have a 2′-deoxyribonucleotide atposition 03, 05, 08, 09, 14, 16, 19, 22, 23, 24, 25, 26, 28, 30, 33, 34,37, 39, 41, 42, 44, 45, 46, 47, 48, 49, 50, respectively, belong to thefirst group of derivatives, i.e. derivatives of nucleic acid molecule226-F2-001 where substitution of a ribonucleotide by a2′-deoxyribonucletoide results in an improved binding affinity for humanCGRP (FIG. 5A-E and FIG. 6). The best binding affinity of saidderivatives was shown for 226-F2-001-D19, 226-F2-001-D41 and226-F2-001-D44 (FIG. 5A-E and FIG. 6). Accordingly, positions 19, 41 and44, are suitable to confer to nucleic acid molecule 226-F2-001 animproved binding affinity to human CGRP. Only the nucleic acid molecules226-F2-001-D41 and 226-F2-001-D44 were further characterized by surfaceplasmon resonance measurement. Single cytidine-5′-phosphate to2′-deoxycytidine-5′-phosphate substitutions at position 41 and 44resulted in an improved binding affinity with a K_(D) of 0.55 nM and0.52 nM, respectively, compared to a K_(D) of 2.6 nM for 226-F2-001(FIG. 7 and FIG. 8A, B).

Derivatives 226-F2-001-D04 and 226-F2-001-D27 which have a2′-deoxyribonucleotide at position 4 and 27, respectively, belong to thesecond group of derivatives, i.e. derivatives where the substitution ofa ribonucleotide by a 2′-deoxyribonucletoide does not affect the bindingaffinity for human CGRP. Accordingly, positions 4 and 27 are notsuitable to confer improved binding affinity nor do they have a negativeimpact on binding affinity to human CGRP compared to nucleic acidmolecule 226-F2-001 (FIG. 5A-E and FIG. 6).

Finally, derivatives were obtained which resulted in reduced bindingaffinity or a profound loss of binding. These derivatives, namely226-F2-001-D01, 226-F2-001-D02, 226-F2-001-D06, 226-F2-001-D07,226-F2-001-D10, 226-F2-001-D11, 226-F2-001-D12, 226-F2-001-D13,226-F2-001-D15, 226-F2-001-D17, 226-F2-001-D18, 226-F2-001-D20,226-F2-001-D21, 226-F2-001-D29, 226-F2-001-D31, 226-F2-001-D32,226-F2-001-D35, 226-F2-001-D36, 226-F2-001-D38, 226-F2-001-D40 and226-F2-001-D43, which have a 2′-deoxyribonucleotide at position 1, 2, 6,7, 10, 11, 12, 13, 15, 17, 18, 20, 21, 29, 31, 32, 35, 36, 38, 40 and43, respectively, belong to the third group of derivatives, i.e.derivatives of nucleic acid molecule 226-F2-001 where substitution of aribonucleotide by a 2′-deoxyribonucletoide negatively affects thebinding affinity to human CGRP (FIG. 5A-E and FIG. 6).

In order to assess whether the binding affinity of the derivatives ofnucleic acid molecule 226-F2-001 can be further increased by introducingmore than one substitution another derivative was generated. Saidderivative started from the first group of derivatives wheresubstitution of a ribonucleotide by a 2′-deoxyribonucletoide resulted inan improved binding affinity for human CGRP. Starting from nucleic acidmolecule 226-F2-001, the derivative had substitutions of ribonucleotidesby 2′-deoxyribonucleotides at the two positions 41 and 44 (referred toas 226-F2-001-D41/D44), i.e. those positions that—besides position19—conferred the strongest improvement in binding affinity to nucleicacid molecule 226-F2-001.

Surface plasmon resonance measurement of 226-F2-001-D41/44 showed thatcombining ribonucleotide to 2′-deoxyribonucleotide substitutions at morethan one position of 226-F2-001, namely cytidine-5′-phosphate to2′-deoxycytidine-5′-phosphate at position 41 and 44, resulted in afurther improvement of binding affinity to human CGRP compared toderivatives containing a single substitution, i.e. 226-F2-001-D41 or226-F2-001-D44 (FIG. 7, FIG. 8A, B and FIG. 9). Compared to the parentalnucleic acid molecule 226-F2-001 (K_(D)=2.6 nM) substitution of tworibonucleotides by 2′-deoxyribonucleotides in 226-F2-001-D41/44(K_(D)=0.2 nM) resulted in a 13-fold improvement of binding affinity tohuman CGRP as measured by surface plasmon resonance (FIG. 7 and FIG. 9).

In order to prove and compare the functionality of Spiegelmers226-F2-001 and 226-F2-001-D41 both nucleic acid molecules weresynthesized comprising an amino-group at their 5′-ends. To theamino-modified Spiegelmers a 40 kDa PEG-moiety was coupled leading toSpiegelmers 226-F2-001-5′40 kDa-PEG and 226-F2-001-D41-5′40 kDa-PEG(also referred to as NOX-L41). Synthesis and PEGylation of theSpiegelmer is described in Example 7.

An in vitro cell-culture assay (protocol see Example 12) confirmedfunctionality for both Spiegelmers by showing that they effectivelyinhibited human CGRP-induced cAMP production in a reporter cell lineexpressing human CGRP-receptor (FIG. 10). 226-F2-001-5′40 kDa-PEG and226-F2-001-D41-5′40 kDa-PEG (NOX-L41) inhibited the function of humanCGRP-induced with IC₅₀ values of 3.8 nM and 0.39 nM, respectively. Thus,surface plasmon resonance measurement (Example 8, FIG. 8A) and in vitrocell culture experiments (Example 12, FIG. 10) unanimously showed thatsubstitution of a single ribonucleotide by a 2′-deoxyribonucleotide wassufficient to significantly improve the binding affinity and theinhibitory activity of CGRP binding Spiegelmer 226-F2-001. The affinitycan be further improved by ribonucleotide to 2′-deoxyribonucleotidesubstitutions at more than one position, as shown for 226-F2-001-D41/44(FIG. 7 and FIG. 9).

EXAMPLE 3: NUCLEIC ACID MOLECULE HAVING INCREASED BINDING AFFINITY TOTHE TARGET MOLECULE HUMAN C5A

Starting from a nucleic acid molecule binding to C5a which was theresult of a development process involving as a starting point theimmediate screening product of the SELEX process, the method of thepresent invention was used in order to improve the binding affinity ofthe nucleic acid molecule to its target. In the instant case, thenucleic acid molecule binding to human C5a was nucleic acid moleculeNOX-D19001.

Nucleic acid molecule NOX-D19001 is Spiegelmer, i.e. an L-nucleic acidmolecule, which is capable of binding to human C5a, has of a nucleotidesequence according to SEQ ID NO: 107 and consists of 44 ribonucleotides.

The binding characteristics of nucleic acid molecule NOX-D19001 wasdetermined by surface plasmon resonance measurement (as described inExample 8). Nucleic acid molecule NOX-D19001 binds human C5a with anaffinity of 1.4 nM as also shown in FIG. 13.

In order to improve the binding characteristics of nucleic acid moleculeNOX-D19001, derivatives of nucleic acid molecule NOX-D19001 weresynthesized. Said derivatives were L-nucleic acid molecules having thesame sequence of nucleobases—guanine, cytosine, adenine, and uracil—asnucleic acid molecule NOX-D19001, however, differed at a single positionas to the sugar moiety of the nucleotides which was a2′-deoxyribonucleotide rather than a ribonucleotide. In accordancetherewith, derivative 1 (termed NOX-D19001-D01) had a2′-deoxyribonucleoside at position 1 of the nucleotide sequenceaccording to SEQ ID NO: 108 derivative 2 (termed NOX-D19001-D02) had a2′-deoxyribonucleotide at position 2 of the nucleotide sequenceaccording to SEQ ID NO: 109 etc. Because of nucleic acid moleculeNOX-D19001 consisting of 44 nucleotides a total of 44 derivatives weresynthesized in order to provide a complete set of all possiblederivatives of nucleic acid molecule meeting the above requirement of asingle substitution of a ribonucleotide by a 2′-deoxyribonucleotide.Said complete set of derivatives is shown in FIG. 11 A-E. In the case ofuracil in the sequence of molecule NOX-D19001, the uridine-5′-phosphatewas replaced by 2′-deoxyuridine-5′-phosphate.

The binding affinity to human C5a of each derivative of said completeset of derivatives of nucleic acid molecule NOX-D19001 was determined bysurface plasmon resonance measurement described in Example 8, andcompared to the binding affinity of nucleic acid molecule NOX-D19001.From a set of at least 5 individual determined K_(D) values ofNOX-D19001 the mean value was calculated (mean±standard error). K_(D)values of individual derivatives were determined and changes in affinityare given as x-fold improvement compared to mean NOX-D19001, wherein thevalue of the x-fold improvement is the quotient of the K_(D) ofNOX-D19001 and the derivative of NOX-D19001. The determined standarderror indicates a cutting point for positive hits. The data of thex-fold improved affinity is indicated in FIGS. 11 A-E and plotted inFIG. 12.

As may be taken from FIG. 11 A-E, depending on the position within thespiegelmer x-fold improved affinity ribo- to 2′-deoxyribonucleotidesubstitutions may have different impacts on binding affinity for thetarget. Surprisingly, a single substitution of a ribonucleotide by a2′-deoxyribonucleotide at some positions within nucleic acid moleculeNOX-D19001 resulted in an improved, i.e. lower binding affinity to humanglucagon, whereas substitution at other positions of a ribonucleotide bya 2′-deoxyribonucleotide at some positions within nucleic acid moleculeNOX-D19001 did not result in a significant change of the bindingaffinity to human C5a, or even decreased the binding affinity to humanC5a. The individual derivatives, their binding affinity to human C5a andthe relative change of their binding affinity compared to the bindingaffinity of nucleic acid molecule NOX-D19001 to human C5a is indicatedin FIG. 11 A-E.

As may be taken from said figures, derivatives NOX-D19001-D01,NOX-D19001-D02, NOX-D19001-D09, NOX-D19001-D16, NOX-D19001-D17,NOX-D19001-D22, NOX-D19001-D25, NOX-D19001-D29, NOX-D19001-D30,NOX-D19001-D32, NOX-D19001-D40, NOX-D19001-D42, and NOX-D19001-D43 whichhave a 2′-deoxyribonucleotide at positions 1, 2, 9, 16, 17, 22, 25, 29,30, 32, 40, 42, and 43, respectively, belong to the first group ofderivatives, i.e. derivatives where the substitution of a ribonucleotideby a 2′-deoxyribonucletoide results in an improved binding affinity forhuman C5a (FIG. 11 A-E, FIG. 12). The best binding affinity of saidderivatives was shown for derivative NOX-D19001-D09, NOX-D19001-D16,NOX-D19001-D17, NOX-D19001-D30, NOX-D19001-D32 and NOX-D19001-D40 (FIG.11 A-E, FIG. 12). Accordingly, positions 9, 16, 17, 30, 32 and 40 aresuitable to confer to nucleic acid molecule NOX-D19001 an improvedbinding affinity to human C5a. The nucleic acid moleculesNOX-D19001-D09, NOX-D19001-D16, NOX-D19001-D17, NOX-D19001-D30,NOX-D19001-D32 and NOX-D19001-D40 were further characterized by surfaceplasmon resonance measurement, whereby the binding affinities weredetermined (FIG. 13). Uridine-5′-phosphate to2′-deoxy-uridine-5′-phosphate substitution at position 09 resulted in animproved of binding affinity by a factor of two (FIG. 13).

Derivatives NOX-D19001-D03, NOX-D19001-D23, NOX-D19001-D26,NOX-D19001-D35, NOX-D19001-D38, NOX-D19001-D39 and NOX-D19001-D44 whichhave a 2′-deoxyribonucleotide at positions 3, 23, 26, 35, 38, 39 and 44,respectively, belong to the second group of derivatives, i.e.derivatives where the substitution of a ribonucleotide by a2′-deoxyribonucleotide does not change or affect the binding affinityfor human C5a. The positions 35 and 44 result in an improved bindingaffinity of NOX-D19001 for human C5a. Accordingly, positions 3, 23, 38,and 39 are not suitable to confer to nucleic acid molecule NOX-D19001 animproved binding affinity to human C5a, however, do not have a negativeimpact on binding affinity of nucleic acid molecule NOX-D19001 to humanC5a either.

Finally, derivatives were obtained which resulted in reduced bindingaffinity or a profound loss of binding affinity. These derivatives,namely NOX-D19001-D04, NOX-D19001-D05, NOX-D19001-D06, NOX-D19001-D07,NOX-D19001-D08, NOX-D19001-D10, NOX-D19001-D11, NOX-D19001-D12,NOX-D19001-D13, NOX-D19001-D14, NOX-D19001-D15, NOX-D19001-D18,NOX-D19001-D19, NOX-D19001-D20, NOX-D19001-D21, NOX-D19001-D24,NOX-D19001-D27, NOX-D19001-D28, NOX-D19001-D31, NOX-D19001-D33,NOX-D19001-D34, NOX-D19001-D36, NOX-D19001-D38 and NOX-D19001-D41,accordingly, belong to the third group of derivatives, i.e. thosederivatives of nucleic acid molecule NOX-D19001 where the substitutionof a ribonucleotide by a 2′-deoxyribonucletoide—negatively—affects thebinding affinity for human C5a. Accordingly, positions 4, 5, 6, 7, 8,10, 11, 12, 13, 14, 15, 18, 19, 20, 21, 24, 27, 28, 31, 33, 34, 36 and41, have a negative impact on the binding affinity of nucleic acidmolecule NOX-D19001 to human C5a.

In order to assess whether the binding affinity of the derivatives ofnucleic acid molecule L-NOX-D19001 can be further increased byintroducing more than one substitution a group of further derivativeswas generated. Such group of further derivatives started from the abovefirst group of derivatives comprising derivatives where the substitutionof a ribonucleotide by a 2′-deoxyribonucletoide resulted in an improvedbinding affinity for human C5a. Starting from nucleic acid moleculeNOX-D19001, the derivatives of the further group of derivatives had asubstitution of a ribonucleotide by a 2′-deoxyribonucleotide at at leasttwo of positions 9, 30, 32 and 40, i.e. those positions which have beenproven to be suitable to confer to nucleic acid molecule NOX-D19001 animproved binding affinity to human C5a.

Surface plasmon resonance measurement of these representative exampleshowed, as depicted in FIGS. 8 and 9, that combining ribonucleotide to2′-deoxyribonucleotide substitutions at multiple positions of thespiegelmer NOX-D19001 resulted in an improvement of binding affinity.

Spiegelmers NOX-D19001-D09-30, NOX-D19001-D09-32, NOX-D19001-D09-40,NOX-D19001-D30-32, NOX-D19001-D30-40 and NOX-D19001-D32-40 allcontaining two substitutions, namely uridine-5′-phosphate to2′-deoxy-uridine-5′-phosphate at position 9/30, 9/32, 9/40, 30/32, 30/40and 32/40 showed better binding affinity as the molecules containing onesubstitution, namely uridine-5′-phosphate to2′-deoxy-uridine-5′-phosphate at position 9, 30, 32 or 40 (FIG. 14).

Spiegelmers NOX-D19001-D09-30-32, NOX-D19001-D09-30-40,NOX-D19001-D09-32-40 and NOX-D19001-D30-32-40 were synthesized to testwhether three substitutions in the nucleic acid molecule NOX-D19001,namely uridine-5′-phosphate to 2′-deoxy-uridine-5′-phosphate at position9/30/32, 9/30/40, 9/32/40 and 30/32/40 led to further improved bindingaffinity in comparison to the NOX-D19001-D09-30, NOX-D19001-D09-32,NOX-D19001-D09-40, NOX-D19001-D30-32, NOX-D19001-D30-40 andNOX-D19001-D32-40 all containing two substitutions. SpiegelmersNOX-D19001-D09-30-40 and NOX-D19001-D09-32-40 all containing threesubstitutions, namely uridine-5′-phosphate to2′-deoxy-uridine-5′-phosphate at position 9/30/40 and 9/32/40 showedbetter binding affinity as the molecules containing two substitution,namely uridine-5′-phosphate to 2′-deoxy-uridine-5′-phosphate at position9, 30, 32 or 40 (FIG. 14).

Combining the four positions 9, 30, 32 or 40 (nucleic acid moleculeNOX-D19001-D09-30-32-40) for substitution, namely uridine-5′-phosphateto 2′-deoxy-uridine-5′-phosphate at position 9/30/32/40 led to furtherimprovement in comparison to the Spiegelmers NOX-D19001-D09-30-40 andNOX-D19001-D09-32-40 all containing three substitutions (FIG. 14).

Substitution of an additional ribonucleotide by 2′-deoxyribonucleotideat position 16 or 17 of NOX-D19001-D09-30-32-40 had a further positiveeffect on the binding affinity to human C5a (seeNOX-D19001-D09-16-30-32-40 and see NOX-D19001-D09-17-30-32-40 FIG. 14).Substitution of two additional ribonucleotides by2′-deoxyribonucleotides at position 16 or 17 of NOX-D19001-D09-30-32-40had a no further positive effect on the binding affinity to human C5a(see NOX-D19001-D09-16-17-30-32-40, also referred to asNOX-D19001-6×DNA, FIGS. 14 and 15). In comparison to nucleic acidmolecule NOX-D19001 nucleic acid molecule NOX-D19001-6×DNA shows animprovement of binding to human C5a by a factor of 4.2 (FIG. 15).

In order to prove and compare the functionality of spiegelmersNOX-D19001 and NOX-D19001-6×DNA both nucleic acid molecules were in anin vitro cell-culture assay (protocol see Example 14). As shown in FIG.16, the in vitro cell-culture assay confirmed that improved affinity tohuman C5a translates into an enhanced inhibition of C5a function. ThePEGylated Spiegelmers NOX-D19 and NOX-D19-6×DNA inhibited C5a-inducedchemotaxis with IC50 values of 2.39 nM and 0.27 nM, respectively (FIG.16).

As shown before, the substitution of multiple ribonucleotides by2′-deoxyribonucleotides in the nucleic acid molecule NOX-D19-001 led toimproved affinity to human C5a. However, such improvement can only bereached if the multiple substitutions are the result of singlesubstitutions that already lead an improvement in binding to human C5a.The substitution of the ribonucleotide at position 7 by a2′-deoxyribonucleotides led to reduced affinity (see FIG. 17). Thisreduced affinity can be ‘healed’ a little bit by additionalsubstitutions at other positions, for example 16, 17, 30, 32 and 40 (seeNOX-D19001-D07-16-17-30-32-40 in comparison to NOX-D19001-D07-30, FIG.17).

EXAMPLE 4: DERIVATIVES OF NUCLEIC ACID MOLECULE NOX-G11STABI2 HAVINGINCREASED BINDING AFFINITY TO THE TARGET MOLECULE GLUCAGON

Starting from a nucleic acid molecule binding to glucagon which was theresult of a development process involving as a starting point theimmediate screening product of the SELEX process, the method of thepresent invention was used in order to improve the binding affinity ofthe nucleic acid molecule to its target. In the instant case, thenucleic acid molecule binding to human glucagon was nucleic acidmolecule NOX-G11stabi2.

Nucleic acid molecule NOX-G11stabi2 is a spiegelmer, i.e. an L-nucleicacid molecule, which is capable of binding to human glucagon, has of anucleotide sequence according to SEQ ID NO: 172 and consists of 54ribonucleotides.

The binding characteristics of nucleic acid molecule NOX-G11 stabi2 wasdetermined by surface plasmon resonance measurement (as described inExample 8). Nucleic acid molecule NOX-G11 stabi2 binds human glucagonwith an affinity of 67.1 nM as also shown in FIG. 20.

In order to improve the binding characteristics of nucleic acid moleculeNOX-G11 stabi2, derivatives of nucleic acid molecule NOX-G11 stabi2 weresynthesized. Said derivatives were L-nucleic acid molecules having thesame sequence of nucleobases—guanine, cytosine, adenine, and uracil oralternatively thymine (in the case of a 2′deoxyribonucleotide)—asnucleic acid molecule NOX-G11 stabi2, however, differed at a singleposition as to the sugar moiety of the nucleotides which was a2′-deoxyribonucleotide rather than a ribonucleotide. In accordancetherewith, derivative 1 (termed NOX-G11-D01) had a2′-deoxyribonucleoside at position 1 of the nucleotide sequenceaccording to SEQ ID NO: 172 derivative 2 (termed NOX-G11-D02) had a2′-deoxyribonucleotide at position 2 of the nucleotide sequenceaccording to SEQ ID NO: 173 etc. Because of nucleic acid moleculeNOX-G11 stabi2 consisting of 54 nucleotides a total of 54 derivativeswere synthesized in order to provide a complete set of all possiblederivatives of nucleic acid molecule meeting the above requirement of asingle substitution of a 2′-ribonucleotide by a 2′-deoxyribonucleotide.Said complete set of derivatives is shown in FIG. 18 A-E. In the case ofuracil in the sequence of molecule NOX-G11stabi2, theuridine-5′-phosphate was replaced by thymidine-5′-phosphate.

The binding affinity to human Glucagon of each derivative of saidcomplete set of derivatives of nucleic acid molecule NOX-G11 stabi2 wasdetermined by surface plasmon resonance measurement described in Example8, and compared to the binding affinity of nucleic acid molecule NOX-G11stabi2. From a set of at least 5 individual determined K_(D) values ofNOX-G11stabi2 the mean value was calculated (mean±standard error). K_(D)values of individual derivatives were determined and changes in affinityare given as x-fold improvement compared to mean NOX-G11stabi2, whereinthe value of the x-fold improvement is the quotient of the K_(D) ofNOX-G11stabi2 and the derivative of NOX-G11stabi2. The determinedstandard error indicates a cutting point for positive hits. The data ofthe x-fold improved affinity is indicated in FIGS. 18 A-E.

As may be taken from FIG. 18 A-E, depending on the position within thespiegelmer x-fold improved affinity ribo- to 2′-deoxyribonucleotidesubstitutions may have different impacts on binding affinity for thetarget. Surprisingly, a single substitution of a 2′ ribonucleotide by a2′deoxyribonucleotide at some positions within nucleic acid moleculeNOX-G11 stabi2 resulted in an improved, i.e. lower binding affinity tohuman glucagon, whereas substitution at other positions of a 2′ribonucleotides by a 2′deoxyribonucleotide at some positions withinnucleic acid molecule NOX-G11stabi2 did not result in a significantchange of the binding affinity to human Glucagon, or even decreased thebinding affinity to human Glucagon. The individual derivatives, theirbinding affinity to human Glucagon and the relative change of theirbinding affinity compared to the binding affinity of nucleic acidmolecule NOX-G 11 stabi2 to glucagon is indicated in FIG. 18 A-E.

As may be taken from said figures, derivatives NOX-G11-D01, NOX-G11-D02,NOX-G11-D03, NOX-G11-D04, NOX-G11-D05, NOX-G11-D06, NOX-G11-D07,NOX-G11-D08, NOX-G11-D09, NOX-G11-D10, NOX-G11-D12, NOX-G11-D13,NOX-G11-D14, NOX-G11-D15, NOX-G11-D16, NOX-G11-D18, NOX-G11-D19,NOX-G11-D20, NOX-G11-D21, NOX-G11-D22, NOX-G11-D23, NOX-G11-D24,NOX-G11-D25, NOX-G11-D26, NOX-G11-D27, NOX-G11-D28, NOX-G11-D29,NOX-G11-D30, NOX-G11-D32, NOX-G11-D36, NOX-G11-D38, NOX-G11-D44,NOX-G11-D46, NOX-G11-D48 and NOX-G11-D53 which have a2′-deoxyribonucleotide at positions 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12,13, 14, 15, 16, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 32,36, 38, 44, 46, 48 and 53, respectively, belong to the first group ofderivatives, i.e. derivatives where the substitution of a ribonucleotideby a 2′-deoxyribonucletoide results in an improved binding affinity forhuman glucagon (FIG. 11 A-E, FIG. 19). The best binding affinity of saidderivatives was shown for derivative NOX-G11-D07, NOX-G11-D16,NOX-G11-D19, NOX-G11-D19, NOX-G11-D21 and NOX-G11-D22 (FIG. 11 A-E, FIG.20). Accordingly, positions 7, 16, 19, 21 and 22 are suitable to conferto nucleic acid molecule NOX-G11 stabi2 an improved binding affinity tohuman glucagon. The nucleic acid molecules NOX-G11-D07, NOX-G11-D16,NOX-G11-D19, NOX-G11-D19, NOX-G11-D21 and NOX-G11-D22 were furthercharacterized by surface plasmon resonance measurement, whereby thebinding affinities were determined (FIG. 20).

Derivatives NOX-G11-D11, NOX-G11-D17, NOX-G11-D31, NOX-G11-D33,NOX-G11-D34, NOX-G11-D35, NOX-G11-D39, NOX-G11-D40, NOX-G11-D43,NOX-G11-D45, NOX-G11-D50 and NOX-G11-D52, which have a2′-deoxyribonucleotide at positions 11, 17, 31, 33, 34, 35, 39, 40, 43,45, 50 and 52, respectively, belong to the second group of derivatives,i.e. derivatives where the substitution of a ribonucleotide by a2′-deoxyribonucletoide does not change or affect the binding affinityfor human glucagon. Accordingly, positions 11, 17, 31, 33, 34, 35, 39,40, 43, 45, 50 and 52 are not suitable to confer to nucleic acidmolecule NOX-G11stabi2 an improved binding affinity to human glucagon,however, do not have a negative impact on binding affinity of nucleicacid molecule NOX-G11stabi2 to human glucagon either.

Finally, derivatives were obtained which resulted in reduced bindingaffinity or a profound loss of binding affinity. These derivatives,namely NOX-G11-D37, NOX-G11-D41, NOX-G11-D42, NOX-G11-D47, NOX-G11-D49,NOX-G11-D51 and NOX-G11-D54, accordingly, belong to the third group ofderivatives, i.e. those derivatives of nucleic acid moleculeNOX-G11stabi2 where the substitution of a ribonucleotide by a2′-deoxyribonucletoide—negatively —affects the binding affinity forhuman Glucagon. Accordingly, positions 37, 41, 42, 47, 49, 51 and 54,have a negative impact on the binding affinity of nucleic acid moleculeNOX-G11stabi2 to human Glucagon.

EXAMPLE 5: DERIVATIVES OF NUCLEIC ACID MOLECULE 259-H6-002 HAVINGINCREASED BINDING AFFINITY TO THE TARGET MOLECULE GLUCAGON

Starting from a nucleic acid molecule binding to glucagon which was theresult of a development process involving as a starting point theimmediate screening product of the SELEX process, the method of thepresent invention was used in order to improve the binding affinity ofthe nucleic acid molecule to its target. In the instant case, thenucleic acid molecule binding to human glucagon was nucleic acidmolecule 259-H6-002.

Nucleic acid molecule 259-H6-002, a Spiegelmer, i.e. an L-nucleic acidmolecule, which is capable of binding to human glucagon, has anucleotide sequence according to SEQ ID NO: 287 and consists of 462′-deoxyribonucleotides.

The binding characteristics of nucleic acid molecule 259-H6-002 wasdetermined by surface plasmon resonance measurement (as described inExample X). Nucleic acid molecule 259-H6-002 binds human glucagon withan affinity of 10.9 nM as also shown in FIG. 23.

In order to improve the binding characteristics of nucleic acid molecule259-H6-002, derivatives of nucleic acid molecule 259-H6-002 weresynthesized. Said derivatives were L-nucleic acid molecules having thesame sequence of nucleobases—guanine, cytosine, adenine, and uracil—asnucleic acid molecule 259-H6-002, however, differed at a single positionas to the sugar moiety of the nucleotides which was a 2′-ribonucleotiderather than a desoxyribonucleotide. In accordance therewith, derivative1 (termed 259-H6-002-R01) had a ribonucleoside at position 1 of thenucleotide sequence according to SEQ ID NO: 288 derivative 2 (termed259-H6-002-R02) had a 2′-ribonucleotide at position 2 of the nucleotidesequence according to SEQ ID NO: 289 etc. Because of nucleic acidmolecule 259-H6-002 consisting of 46 nucleotides a total of 46derivatives were synthesized in order to provide a complete set of allpossible derivatives of nucleic acid molecule meeting the aboverequirement of a single substitution of a 2′-deoxyribonucleotide by aribonucleotide. Said complete set of derivatives is shown in FIG. 21A-E. In the case of thymidine in the sequence of molecule 259-H6-002,the thymidine-5′phosphate was replaced by uridine 5′ phosphate.

The binding affinity to human glucagon of each derivative of saidcomplete set of derivatives of nucleic acid molecule 259-H6-002 wasdetermined by surface plasmon resonance measurement described in Example8, and compared to the binding affinity of nucleic acid molecule259-H6-002, whereby the binding affinity to human glucagon of eachderivative of said complete set of derivatives of nucleic acid molecule259-H6-002 was determined by surface plasmon resonance measurementdescribed in Example 8, and compared to the binding affinity of nucleicacid molecule 259-H6-002. From a set of at least 5 individual determinedK_(D) values of 259-H6-002 the mean value was calculated(mean+/−standard error). K_(D) values of individual derivatives weredetermined and changes in affinity are given as x-fold improvementcompared to mean 259-H6-002, wherein the value of the x-fold improvementis the quotient of the K_(D) of 259-H6-002 and the derivative of259-H6-002. The determined standard error indicates a cutting point forpositive hits. The data of the x-fold improved affinity is indicated inFIGS. 21 A-D and plotted in FIG. 22.

As may be taken from FIG. 21 A-D, depending on the position within thespiegelmer 2′-deoxyribonucleotide to ribonucleotide substitutions mayhave different impacts on binding affinity for the target. Surprisingly,a single substitution of a 2′-deoxyribonucleotide by a ribonucleotide atsome positions within nucleic acid molecule 259-H6-002 resulted in animproved, i.e. higher binding affinity to human glucagon, whereassubstitution at other positions of a 2′-deoxyribonucleotide by aribonucleotide within nucleic acid molecule 259-H6-002 did not result ina significant change of the binding affinity to human glucagon, or evendecreased the binding affinity to human glucagon. The individualderivatives and the relative change of their binding affinity comparedto the binding affinity of nucleic acid molecule 259-H6-002 to glucagonis indicated in FIG. 21 A-D.

As may be taken from said figures, derivatives 259-H6-002-R8,259-H6-002-R13, 259-H6-002-R22, 259-H6-002-R24, 259-H6-002-R30,259-H6-002-R31, 259-116-002-R36, 259-H6-002-R38, 259-H6-002-R39, and259-H6-002-R44, which have a ribonucleotide at positions 8, 13, 22, 24,30, 31, 36, 38, 39, and 44, respectively, belong to the first group ofderivatives, i.e. derivatives where the substitution of a2′-deoxyribonucleotide by a ribonucleotide results in an improvedbinding affinity for human glucagon (FIG. 21 A-D, FIG. 22). The bestbinding affinity of said derivatives was shown for derivative259-H6-002-R13, 259-H6-002-R24, 259-H6-002-R30 and 259-H6-002-R36 withimprovement factors between 2.1 and 5.8 (FIG. 21 A-D, FIG. 22).Accordingly, positions 13, 24, 30 and 36 are suitable to confer tonucleic acid molecule 259-H6-002 an improved binding affinity to humanglucagon. The nucleic acid molecules 259-H6-002-R13, 259-H6-002-R24, and259-H6-002-R36 were further characterized by surface plasmon resonancemeasurement, whereby the binding affinities were determined (FIG. 23).

Derivatives 259-H6-002-R04, 259-H6-R06, and 259-H6-R46 . . . which havea 2′-ribonucleotide at positions 4, 6, and 46 respectively, belong tothe second group of derivatives, i.e. derivatives where the substitutionof a 2′desoxyribonucleotide by a 2′-ribonucleotide does notsignificantly change or affect the binding affinity for human glucagon.Accordingly, positions 4, 6, and 46 are not suitable to confer tonucleic acid molecule 259-H6-002 an improved binding affinity to humanglucagon, however, do not have a negative impact on binding affinity ofnucleic acid molecule 259-H6-002 to human glucagon either.

Derivatives 259-H6-R09 and 259-H6-R45 show a biphasic binding behaviouron the Biacore. Therefore the improvement factor were judged to beartificial and positions 9 and 45 were not further considered forimprovement of binding affinity.

Finally, 31 derivatives were obtained which resulted in reduced bindingaffinity or a profound loss of binding affinity. These derivatives,namely 259-H6-002-R01, 259-H6-002-R02, 259-H6-002-R03, 259-H6-002-R05,259-H6-002-R07, 259-H6-002-R10, 259-H6-002-R11, 259-H6-002-R12,259-H6-002-R14, 259-H6-002-R15, 259-H6-002-R16, 259-H6-002-R17,259-116-002-R18, 259-H6-002-R19, 259-H6-002-R20, 259-H6-002-R21,259-H6-002-R23, 259-H6-002-R25, 259-H6-002-R26, 259-H6-002-R27,259-H6-002-R28, 259-H6-002-R29, 259-H6-002-R32, 259-H6-002-R33,259-H6-002-R34, 259-H6-002-R35, 259-H6-002-R37, 259-H6-002-R40,259-H6-002-R41, 259-H6-002-R42, 259-H6-002-R43 accordingly, belong tothe third group of derivatives, i.e. those derivatives of nucleic acidmolecule 259-H6-002 where the substitution of a 2′-deoxyribonucleotideby a ribonucleotide—negatively—affects the binding affinity for humanglucagon. Accordingly, positions 1, 2, 3, 5, 7, 10, 11, 12, 14, 15, 16,17, 18, 19, 20, 21, 23, 25, 26, 27, 28, 29, 32, 33, 34, 35, 37, 40, 41,42, and 43 have a negative impact on the binding affinity of nucleicacid molecule 259-H6-002 to human glucagon.

In order to assess whether the binding affinity of the derivatives ofnucleic acid molecule L-259-H6-002 can be further increased byintroducing more than one substitution a group of further derivativeswas generated. Such group of further derivatives started from the abovefirst group of derivatives comprising derivatives where the substitutionof a 2′-deoxyribonucleotide by a ribonucleotide resulted in an improvedbinding affinity for human glucagon. Starting from nucleic acid molecule259-H6-002, the derivatives of the further group of derivatives had asubstitution of a 2′-deoxyribonucleotide by a ribonucleotide at at leasttwo of positions 13, 24, 30 and 36, i.e. those positions which have beenproven to be suitable to confer to nucleic acid molecule 259-H6-002 animproved binding affinity to human glucagon.

Surface plasmon resonance measurement of these representative exampleshowed, as depicted in FIG. 24, that combining 2′-deoxyribonucleotide bya ribonucleotide substitutions at multiple positions of the spiegelmer259-H6-002 resulted in an improvement of binding affinity.

Spiegelmers 259-H6-002-R13_R24 and 259-H6-002-R13_R36, all containingtwo substitutions, namely deoxyadenosine-5′-phosphate toadenosine-5′-phosphate at position 13, deoxyguanosine toguanosine-5′-phosphate at position 24 and/or thymidine-5′-phosphate touridine-5′-phosphate at position 36, showed better binding affinity asthe molecules containing one substitution (FIG. 24).

Spiegelmer 259-H6-002-R13_R24_R36 was synthesized to test whether threesubstitutions in the nucleic acid molecule 259-H6-002, namelydeoxyadenosine-5-phosphate to adenosine-5′-phosphate at position 13,deoxyguanosine-5′-phosphate to guanosine-5′-phosphate at position 24 andthymidine-5′-phosphate to uridine-5′-phosphate at position 36, led tofurther improved binding affinity in comparison to the spiegelmers259-H6-002-R13_R24 and 259-H6-002-R13_R36, all containing twosubstitutions (FIG. 24).

Combining the four positions 13, 24, 30 and 36 (nucleic acid molecule259-H6-002-R13_R24_R30_R36) for substitution, namelydeoxyadenosine-5′-phosphate to adenosine-5′-phosphate at position 13,deoxyguanosine-5-phosphate to guanosine-5′-phosphate at position 24 and30 and thymidine-5′-phosphate to uridine-5′-phosphate at position 36,led to a slight improvement in comparison to the Spiegelmer259-H6-002-R13_R24_R36 containing three substitutions (FIG. 26).

In order to prove and compare the functionality of Spiegelmers259-H6-002, 259-H6-002-R13 and 259-H6-002-R13_R24_R36 all nucleic acidmolecules were tested in an in vitro cell-culture assay (protocol seeExample 14). As shown in FIG. 25, the in vitro cell-culture assayconfirmed that improved affinity to human glucagon translates into anenhanced inhibition of human glucagon function. Spiegelmers 259-H6-002,259-H6-002-R13 and 259-H6-002-R13_R24_R36 inhibited glucagon inducedformation of intracellular cAMP with IC₅₀ values of 176 nM, 12.5 nM and6.2 nM, respectively (FIG. 25).

EXAMPLE 6: DERIVATIVES OF NUCLEIC ACID MOLECULE 257-E1-001 HAVINGINCREASED BINDING AFFINITY TO THE TARGET MOLECULE GLUCAGON

Starting from a nucleic acid molecule binding to glucagon which was theresult of a development process involving as a starting point theimmediate screening product of the SELEX process, the method of thepresent invention was used in order to improve the binding affinity ofthe nucleic acid molecule to its target. In the instant case, thenucleic acid molecule binding to human glucagon was nucleic acidmolecule 257-E1-001.

Nucleic acid molecule 257-E1-001 is a Spiegelmer, i.e. a L-nucleic acidmolecule, which is capable of binding to human glucagon, has anucleotide sequence according to SEQ ID NO: 27 and consists of 472′-deoxyribonucleotides.

The binding characteristics of nucleic acid molecule 257-E1-001 weredetermined in the competitive pull-down assay format (as described inExample 10). Nucleic acid molecule 257-E1-001 binds human glucagon withan affinity of 186 nM as also shown in FIG. 28.

In order to improve the binding characteristics of nucleic acid molecule257-E1-001, derivatives of nucleic acid molecule 257-E1-001 weresynthesized (as described in Example 7). Said derivatives were L-nucleicacid molecules having the same sequence of nucleobases—guanine,cytosine, adenine, and uracil or alternatively thymine (in the case of a2′deoxyribonucleotide)—as nucleic acid molecule 257-E1-001, however,differed at a single position as to the sugar moiety of the nucleotideswhich was a ribonucleotide rather than a 2′-deoxyribonucleotide. Inaccordance therewith, derivative 1 (termed 257-E1-R1-001) had aribonucleoside at position 1 of the nucleotide sequence according to SEQID NO: 228, derivative 2 (termed 257-E1-R2-001) had a ribonucleotide atposition 2 of the nucleotide sequence according to SEQ ID NO: 229 etc.Because of nucleic acid molecule 257-E1-001 consisting of 47 nucleotidesa total of 47 derivatives was synthesized in order to provide a completeset of all possible derivatives of nucleic acid molecules meeting theabove requirement of a single substitution of a 2′-deoxyribonucleotideby a ribonucleotide. Said complete set of derivatives is shown in FIGS.27 A-D. In the case of a thymidine-5′-phosphate in the sequence ofmolecule 257-E1-001, the thymidine-5′-phosphate was replaced by theuridine-5′-phosphate.

The binding characteristics to human glucagon of each derivative of saidcomplete set of derivatives of nucleic acid molecule 257-E1-001 wasdetermined in competitive pull-down assays described in Example 10, andcompared to the binding affinity of nucleic acid molecule 257-E1-001. Asmay be taken from FIGS. 27 A-D, depending on the position within theSpiegelmer 2′-deoxyribonucleotide to ribonucleotide substitutions mayhave different impacts on binding affinity for the target. Surprisingly,a single substitution of a 2′-deoxyribonucleotide by a ribonucleotide atsome positions within nucleic acid molecule 257-E1-001 resulted in animproved, i.e. higher binding affinity to human glucagon, whereas thesubstitution of a 2′deoxyribonucleotide by a ribonucleotide at otherpositions within nucleic acid molecule 257-E1-001 did not result in asignificant change of the binding affinity to human glucagon, or evendecreased the binding affinity to human glucagon. The individualderivatives, and the relative change of their binding affinity comparedto the binding affinity of nucleic acid molecule 257-E1-001 to glucagonis indicated in FIG. 27 A-D.

As may be taken from said figures, derivatives 257-E1-R9-001,257-E1-R15-001, 257-E1-R18-001, 257-E1-R19-001, 257-E1-R29-001, and257-E1-R30-001 which have a ribonucleotide at position 9, 15, 18, 19,29, or 30, respectively, belong to the first group of derivatives, i.e.derivatives where the substitution of a 2′-deoxyribonucleotide by aribonucleotide results in an improved binding affinity for humanglucagon (FIGS. 27 A-C, 28). The best binding affinity of saidderivatives was shown for derivatives 257-E1-R15-001, 257-E1-R29-001,and 257-E1-R30-001 (FIG. 27 B-C, 28). Accordingly, positions 15, 29, and30 are suitable to confer to nucleic acid molecule 257-E1-001 animproved binding affinity to human glucagon. The nucleic acid molecules257-E1-R15-001, and 257-E1-R29-001 were further characterized incompetitive pull-down assays, whereby the binding affinities weredetermined (FIG. 28).

Derivatives 257-E1-R26-001 and 257-E1-R46-001, which have aribonucleotide at positions 26 and 46, respectively, belong to thesecond group of derivatives, i.e. derivatives where the substitution ofa 2′-deoxyribonucleotide by a ribonucleotide does not change or affectthe binding affinity for human glucagon. Accordingly, positions 26 and46 are not suitable to confer to nucleic acid molecule 257-E1-001 animproved binding affinity to human glucagon, however, do not have anegative impact on binding affinity of nucleic acid molecule 257-E1-001to human glucagon either.

Finally, derivatives were obtained which resulted in reduced bindingaffinity or a profound loss of binding affinity. These derivatives,namely 257-E1-R1-001, 257-E1-R2-001, 257-E1-R3-001, 257-E4-R1-001,257-E5-R1-001, 257-E1-R6-001, 257-E1-R7-001, 257-E1-R8-001,257-E1-R10-001, 257-E1-R11-001, 257-E1-R12-001, 257-E1-R13-001,257-E1-R14-001, 257-E1-R16-001, 257-E1-R17-001, 257-E1-R20-001,257-E1-R21-001, 257-E1-R22-001, 257-E1-R23-001, 257-E1-R24-001,257-E1-R25-001, 257-E1-R27-001, 257-E1-R28-001, 257-E1-R31-001,257-E1-R32-001, 257-E1-R33-001, 257-E1-R34-001, 257-E1-R35-001,257-E1-R36-001, 257-E1-R37-001, 257-E1-R38-001, 257-E1-R39-001,257-E1-R40-001, 257-E1-R41-001, 257-E1-R42-001, 257-E1-R43-001,257-E1-R44-001, 257-E1-R45-001, 257-E1-R47-001, accordingly, belong tothe third group of derivatives, i.e. those derivatives of nucleic acidmolecule 257-E1-001 where the substitution of a 2′-deoxyribonucleotideby a ribonucleotide—negatively—affects the binding affinity for humanglucagon. Accordingly, positions 1, 2, 3, 4, 5, 6, 7, 8, 10, 11, 12, 13,14, 16, 17, 20, 21, 22, 23, 24, 25, 27, 28, 31, 32, 33, 34, 35, 36, 37,38, 39, 40, 41, 42, 43, 44, 45, 47, have a negative impact on thebinding affinity of nucleic acid molecule 257-E1-001 to human glucagon.

In order to assess whether the binding affinity of the derivatives ofnucleic acid molecule 257-E1-001 can be further increased by introducingmore than one substitution a group of further derivatives was generated.Such group of further derivatives started from the above first group ofderivatives comprising derivatives where the substitution of a2′-deoxyribonucleotide by a ribonucleotide resulted in an improvedbinding affinity for human glucagon. Starting from nucleic acid molecule257-E1-001, the derivatives of the further group of derivatives had asubstitution of a 2′-deoxyribonucleotide by a ribonucleotide at least attwo of positions 9, 15, 18, 19, 29, and 30, i.e. those positions whichhave been proven to be suitable to confer to nucleic acid molecule257-E1-001 an improved binding affinity to human glucagon.

In competitive pull-down assays representative examples showed, asdepicted in FIGS. 27E, F and 28, that combining 2′-deoxyribonucleotideby ribonucleotide substitutions at multiple positions of the Spiegelmer257-E1-001 resulted in an improvement of binding affinity. The bindingaffinity to human glucagon of derivatives, containing combinations of atleast two 2′-deoxyribonucleotide to ribonucleotide substitutions, wasdetermined in competitive pull-down assays described in Example 10, andcompared to the binding affinity of nucleic acid molecule 257-E1-001 or257-E1-6xR-001, respectively. From a set of two or ten individualdetermined K_(D) values of 257-E1-001 or 257-E1-6xR-001, respectively,the mean values were calculated (mean+/−standard error). K_(D) values ofSpiegelmers with combined substitutions were determined and changes inaffinity are given as improvement factor of affinity compared to mean of257-E1-001 or 257-E1-6xR-001, respectively, wherein the value of thex-fold improvement is the quotient of the K_(D) of 257-E1-001 and thederivative of 257-E1-001. The determined standard error indicates acutting point for improvement or decline. The improvement factors ofaffinity are indicated in FIGS. 27 E and F.

Spiegelmers 257-E1-R15/29-001 and 257-E1-R29/30-001, both containing twosubstitutions, namely 2′-deoxyguanosine-5′-phosphate toguanosine-5′-phosphate at position 15, 2′-deoxyadenosine-5′-phosphate toadenosine-5′-phosphate at position 29 and/or2′-deoxyadenosine-5′-phosphate to adenosine-5′-phosphate at position 30,showed better binding affinity as the molecules containing onesubstitution (FIG. 27E).

Spiegelmers 257-E1-R15/29/30-001 and 257-E1-R18/29/30-001 weresynthesized to test whether three substitutions in the nucleic acidmolecule 257-E1-001 led to a further improved binding affinity comparedto Spiegelmers 257-E1-R15/29-001 and 257-E1-R29/30-001, all containingtwo substitutions. Namely, the substitutions of2′-deoxyguanosine-5′-phosphate to guanosine-5′-phosphate at position 15,2′-deoxyadenosine-5′-phosphate to adenosine-5′-phosphate at position 29,and 2′-deoxyadenosine-5′-phosphate to adenosine-5′-phosphate at position30 led to further improved binding affinity compared to the Spiegelmer257-E1-R29/30-001. However, the binding affinity of the three-foldsubstituted Spiegelmer 257-E1-R15/29/30-001 to glucagon is comparable tothat of Spiegelmer 257-E1-R15/29-001, containing two substitutions. Thesubstitution of 2′-deoxyguanosine-5′-phosphate to guanosine-5′-phosphateat position 18 instead of the 2′-deoxyguanosine-5′-phosphate toguanosine-5′-phosphate substitution at position 15 in Spiegelmer257-E1-R18/29/30-001 led to an increased binding affinity compared to257-E1-R29/30-001, but to a decreased affinity compared to257-E1-R15/29/30 (FIG. 27E).

Combining the four positions 15, 18, 29 and 30 (nucleic acid molecule257-E1-R15/18/29/30-001) for substitution, namely2′-deoxyguanosine-5′-phosphate to guanosine-5′-phosphate at position 15,2′-deoxyguanosine-5′-phosphate to guanosine-5′-phosphate at position 18,2′-deoxyadenosine-5′-phosphate to adenosine-5′-phosphate at position 29,and 2′-deoxyadenosine-5′-phosphate to adenosine-5′-phosphate at position30, did not lead to further improvement in comparison to the Spiegelmer257-E1-R15/29/30-001 containing three substitutions (FIG. 27E).

Surprisingly, the combination of six 2′deoxyribonucleotide toribonucleotide substitutions at positions 9, 15, 18, 19, 29, 30(Spiegelmer 257-E1-R9/15/18/19/29/30-001=257-E1-6xR-001), namely2′-deoxyguanosine-5′-phosphate to guanosine-5′-phosphate at position 9,2′-deoxyguanosine-5′-phosphate to guanosine-5′-phosphate at position 15,2′-deoxyguanosine-5′-phosphate to guanosine-5′-phosphate at position 18,2′-deoxyguanosine-5′-phosphate to guanosine-5′-phosphate at position 19,2′-deoxyadenosine-5′-phosphate to adenosine-5′-phosphate at position 29,and 2′-deoxyadenosine-5′-phosphate to adenosine-5′-phosphate at position30, led to a further improved binding affinity to glucagon compared tothe Spiegelmers 257-E1-R15/29-001 and 257-E1-R15/18/29/30-001,containing two and four substitutions, respectively (FIGS. 27E and 28).

In order to assess whether the binding affinity to glucagon of theSpiegelmer 257-E1-6xR-001, containing six 2′-deoxyribonucleotide toribonucleotide substitutions, can be further increased by the exchangeof thymidine-5′-phosphate with 5-methyl-uridine-5′-phosphate instead ofwith uridine-5′-phosphate, derivatives of nucleic acid molecule257-E1-6xR-001 were synthesized. Said derivatives contain an additional,seventh substitution of thymidine-5′-phosphates to5-methyl-uridine-5′-phosphate and are shown in FIG. 27 F. In fact, asingle derivative nucleic acid molecule, containing seven substitutions(nucleic acid molecule 257-E1-7xR-023), namely four2′-deoxyguanosine-5′-phosphate to guanosine-5′-phosphate substitutionsat positions 9, 15, 18, and 19, one thymidine-5′-phosphate to5-methyl-uridine-5′-phosphate substitution, and two2′-deoxyadenosine-5′-phosphate to adenosine-5′-phosphate substitutionsat positions 29 and 30, resulted in a slightly improved binding affinitycompared to Spiegelmer 257-E1-6xR-001 (FIGS. 27F and 28).

Finally, the binding affinity of Spiegelmer 257-E1-7xR-023 to glucagonwas improved by a factor of 43 in comparison to the SELEX derived,unmodified Spiegelmer 257-E1-001.

EXAMPLE 7: SYNTHESIS AND DERIVATIZATION OF SPIEGELMERS Small ScaleSynthesis

Spiegelmers (L-RNA nucleic acids or L-DNA modified L-RNA nucleic acids)were produced by solid-phase synthesis with an ABI 394 synthesizer(Applied Biosystems, Foster City, Calif., USA) using 2′TBDMS RNA and DNAphosphoramidite chemistry with standard exocyclic amine protectinggroups (Damha and Ogilvie, 1993). For the RNA part of theoligonucleotide rA(N-Bz)-, rC(N-Ac)-, rG(N-ibu)-, andrU-phosphoramidites in the D-(if needed, see Ex 9/10) andL-configuration were used, while for the DNA part dA(N-Bz)-, dC(N-Ac)-,dG(N-ibu)-, and dT in the D- and L-configuration were applied. Allphosphoramidites were purchased from ChemGenes, Wilmington, Mass. Aftersynthesis and deprotection aptamers and spiegelmers were purified by gelelectrophoresis.

Large Scale Synthesis Plus Modification

Spiegelmers were produced by solid-phase synthesis with an ÄktaPilot100synthesizer (GE Healthcare, Freiburg) using 2′TBDMS RNA and DNAphosphoramidite chemistry with standard exocyclic amine protectinggroups (Damha and Ogilvie, 1993). L-rA(N-Bz)-, L-rC(N-Ac)-,L-rG(N-ibu)-, L-dA(N-Bz)-, L-dC(N-Ac)-, L-dG(N-ibu)-, andL-dT-phosphoramidites were purchased from ChemGenes, Wilmington, Mass.The 5′-amino-modifier was purchased from American InternationalChemicals Inc. (Framingham, Mass., USA). Synthesis of the unmodified ora 5′-Amino-modified spiegelmer was started on L-riboA, L-riboC, L-riboG,L-riboU, L-2′deoxyA, L-2′deoxyC, L-2′deoxyG, or L-2′deoxyT modified CPGpore size 1000 Å (Link Technology, Glasgow, UK. For coupling of the RNAand DNA phosphoramidites (15 min per cycle), 0.3 M benzylthiotetrazole(CMS-Chemicals, Abingdon, UK) in acetonitrile, and 2 equivalents of therespective 0.2 M phosphoramidite solution in acetonitrile was used. Anoxidation-capping cycle was used. Further standard solvents and reagentsfor oligonucleotide synthesis were purchased from Biosolve(Valkenswaard, NL). The Spiegelmer was synthesized DMT-ON; afterdeprotection, it was purified via preparative RP-HPLC (Wincott et al.,1995) using Source15RPC medium (Amersham). The 5′DMT-group was removedwith 80% acetic acid (30 min at RT). In case of 5′aminomodifiedSpiegelmers the 5′MMT-group was removed with 80% acetic acid (90 min atRT). Subsequently, aqueous 2 M NaOAc solution was added and theSpiegelmer was desalted by tangential-flow filtration using a 5 Kregenerated cellulose membrane (Millipore, Bedford, Mass.).

Pegylation of Spiegelmers

In order to prolong the Spiegelmer's plasma residence time in vivo, a 40kDa polyethylene glycol (PEG) moiety was covalently coupled at the5′-end of the spiegelmers.

For PEGylation (for technical details of the method for PEGylation seeEuropean patent application EP 1 306 382), the purified 5′-aminomodified Spiegelmer was dissolved in a mixture of H₂O (2.5 ml), DMF (5ml), and buffer A (5 ml; prepared by mixing citric acid—H₂O [7 g], boricacid [3.54 g], phosphoric acid [2.26 ml], and 1 M NaOH [343 ml] andadding water to a final volume of 11; pH=8.4 was adjusted with 1 M HCl).

The pH of the Spiegelmer solution was brought to 8.4 with 1 M NaOH.Then, 40 kDa PEG-NHS ester (Jenkem Technology, Allen, Tex., USA) wasadded at 37° C. every 30 min in six portions of 0.25 equivalents until amaximal yield of 75 to 85% was reached. The pH of the reaction mixturewas kept at 8-8.5 with 1 M NaOH during addition of the PEG-NHS ester.

The reaction mixture was blended with 4 ml urea solution (8 M), and 4 mlbuffer B (0.1 M triethylammonium acetate in H₂O) and heated to 95° C.for 15 min. The PEGylated Spiegelmer was then purified by RP-HPLC withSource 15RPC medium (Amersham), using an acetonitrile gradient (bufferB; buffer C: 0.1 M triethylammonium acetate in acetonitrile). Excess PEGeluted at 5% buffer C, PEGylated Spiegelmer at 10-15% buffer C. Productfractions with a purity of >95% (as assessed by HPLC) were combined andmixed with 40 ml 3 M NaOAC. The PEGylated Spiegelmer was desalted bytangential-flow filtration (5 K regenerated cellulose membrane,Millipore, Bedford Mass.).

EXAMPLE 8: BIACORE MEASUREMENT Biacore Assay Setup

The Biacore 2000 instrument (Biacore AB, Sweden) was set to a constanttemperature of 37° C. The instrument was cleaned using the DESORB methodbefore the start of each experiment/immobilization of a new chip: Afterdocking a maintenance chip, the instrument was consecutively primed withdesorb solution 1 (0.5% sodium dodecyl sulphate, SDS), desorb solution 2(50 mM glycine, pH 9.5) and HBS-EP pH 7.4 buffer. Finally, the systemwas primed with HBS-EP pH 7.4 buffer. All reagents were purchased fromGE Healthcare unless otherwise indicated.

Target Immobilization

The target immobilization procedure was established individually foreach target. Examples for the targets described herein are listed below:

Immobilization of Biotinylated Human L-Glucagon

The immobilization buffer was HBS-EP pH 7.4 buffer. Syntheticbiotinylated human L-glucagon (glucagon1-29-AEEAc-AEEAc-biotin, customsynthesis by BACHEM, Switzerland) was immobilized on a carboxymethylateddextran-coated sensor chip (CM5, GE Healthcare) which had been preparedby covalent immobilization of soluble neutravidin (Sigma Aldrich,Germany) using a 1:1 mixture of 0.4 M EDC(1-ethyl-3-(3-dimethylaminopropyl) carbodiimide in H₂O) and 0.1 M NHS(N-hydroxysuccinimide in H₂O). The reference flow cell on the samesensor chip was blocked with biotin.

Immobilization of Human L-C5a

The immobilization buffer was HBS-EP pH 7.4 buffer. Recombinant humanL-C5a (Sigma Aldrich) in 10 mM NaOAc pH 5.5 was immobilized by aminecoupling on a carboxymethylated dextran-coated sensor chip (CM5, GEHealthcare) which had been activated using a 1:1 mixture of 0.4 M EDC(1-ethyl-3-(3-dimethylaminopropyl) carbodiimide in H₂O) and 0.1 M NHS(N-hydroxysuccinimide in H₂O).

Immobilization of Human L-Alpha-CGRP

The immobilization buffer was HBS-EP pH 7.4 buffer. Synthetic humanL-αCGRP (Bachem) in 10 mM NaOAc pH 5.5 was immobilized by amine couplingon a carboxymethylated dextran-coated sensor chip (CM5, GE Healthcare)which had been activated using a 1:1 mixture of 0.4 M EDC(1-ethyl-3-(3-dimethylaminopropyl) carbodiimide in H₂O) and 0.1 M NHS(N-hydroxysuccinimide in H₂O).

Identification of Spiegelmer Derivatives with Improved Binding Affinity

Binding analysis and kinetic parameter assessment of the individualsingle-position modified spiegelmer derivatives was performed byinjecting Spiegelmer at a concentration of 1 μM at a device temperatureof 37°. Before and after the total injection series, as well as everytenth injection an injection of blank running buffer and of a Spiegelmerreference were injected to monitor sensor chip decay, due to theregeneration procedure or/and limited peptide stability on the sensorchip surface.

From at least 5 individually determined K_(d) values of the parent(all-DNA or all-RNA) spiegelmer the mean value was calculated(mean±standard error). K_(d) values of individual derivatives weredetermined and changes in affinity are given as x-fold improvementcompared to the mean of the parent molecule, wherein the value of thex-fold improvement is the quotient of the K_(D) of the parent moleculeand the derivative of the parent molecule. The determined standard errorindicates a cutting point for positive hits.

Data analysis and calculation of dissociation constants (K_(d)) was donewith the BLAevaluation 3.1.1 software (BIACORE AB, Uppsala, Sweden) andPrism 5.0 (GraphPad) software for calculation of mean values andstandard errors.

Derivatives of the parent molecule that showed improved bindingproperties in respect of the target recognition (association constantk_(a)) or/and Spiegelmer target complex stability (dissociation constantk_(d)) resulting in an overall improved affinity (dissociation constantK_(d)) were characterized by measuring detailed binding kinetics(injection of a concentration series of the respective Spiegelmer).

Detailed Kinetic Evaluation of Selected Derivatives of the ParentMolecule

Kinetic parameters and dissociation constants were evaluated by a seriesof Spiegelmer injections at concentrations of2,000-1,000-500-200-125-62.5-31.3-15.6(2x)-7.8-3.9-1.95-0.98-0.48-0.24-0.12-0 nM diluted in running buffer,starting with the lowest concentration. In all experiments, the analysiswas performed at 37° C. using the Kinject command defining anassociation time of 240 to 360 seconds and a dissociation time of 240 to360 seconds at a flow of 30 μl/min. The assay was double referenced,whereas Flow Cell 1 (FC1) served as (blocked) surface control (bulkcontribution of each Spiegelmer concentration) and a series of bufferinjections without analyte determined the bulk contribution of thebuffer itself. At least one Spiegelmer concentration was injected twiceto monitor the regeneration efficiency and chip integrity during theexperiments. Data analysis and calculation of dissociation constants(K_(d)) was done with the BIAevaluation 3.1.1 software (BIACORE AB)

Combination of Identified Exchange Positions that Lead to ImprovedBinding

Finally two or more of the positive single positions for substitionswere combined and the resulting sequences were again studied withdetailed binding kinetics.

The results of the Biacore measurements are described in Examples 2 to5.

EXAMPLE 9: COMPETITIVE SPIEGELMER PULL-DOWN ASSAY OF S1P SPIEGELMERS

Affinity constants of SU′ binding spiegelmers were determined bycompetitive pull-down assays. In order to allow for radioactive labelingof the spiegelmer by T4 polynucleotide kinase two guanosine residues inthe D-configuration were added to the 5′-end of the L-S1P-215-F9-002spiegelmer. Unlabeled spiegelmers were then tested for their ability tocompete with 300-600 pM radiolabeled spiegelmer L-S1P-215-F9-002-5′diD-Gfor binding to a constant amount of biotinylated D-e-S1P, i.e.decreasing the binding signal according to the binding affinity of thenon-labeled spiegelmer to D-e-S1P. D-e-S1P was used at a concentrationof 8 nM resulting in a final binding of approximately 10% ofradiolabeled spiegelmer L-S1P-215-F9-002-5′diD-G in the absence ofcompetitor spiegelmers. Assays were performed in 250 μl selection buffer(20 mM Tris-HCl pH 7.4; 150 mM NaCl; 5 mM KCl; 1 mM MgCl₂; 1 mM CaCl₂;0.1% [w/vol] Tween-20; 4 mg/ml bovine serum albumin; 10 μg/ml Yeast-RNA)for 3-4 hours at 37° C. Biotinylated D-e-S1P and complexes of spiegelmerand biotinylated S1P were immobilized on 5 μl Neutravidin Ultralink Plusbeads (Pierce Biotechnology, Rockford, USA) which had beenpre-equilibrated with selection buffer before addition to the bindingreactions. Beads were kept in suspension for 30 min at 37° C. in athermomixer. After removal of supernatants and appropriate washing,immobilized radioactivity was quantified in a scintillation counter. Thepercentage of binding or normalized percentage of bound radiolabeledspiegelmer L-S1P-215-F9-002-5′diD-G was plotted against thecorresponding concentration of competitor spiegelmer. Dissociationconstants were obtained using GraphPad Prism software. The same assayformat was used for comparative ranking of a set of differentspiegelmers. In this case competitor spiegelmers were used at a singleconcentration as indicated.

EXAMPLE 10: DETERMINATION OF BINDING AFFINITY TO GLUCAGON (PULL-DOWNASSAY)

For binding analysis to glucagon the glucagon binding nucleic acidmolecules were synthesized as spiegelmers consisting of L-nucleotides.The binding analysis of spieglmers was done with biotinylated humanL-glucagon consisting of L-amino acids.

Direct Pull-Down Assay

Two additional adenosinresidues in the D-configuration at theSpiegelmer's 5′-end enabled 5′-phosphate labeleling by T4 polynucleotidekinase (Invitrogen, Karlsruhe, Germany) using [γ-³²P]-labeled ATP(Hartmann Analytic, Braunschweig, Germany). The specific radioactivityof labeled nucleic acids was 200,000-800,000 cpm/pmol. After de- andrenaturation (1′ 94° C., ice/H₂O) labeled nucleic acids were incubatedat 100-700 pM concentration at 37° C. in selection buffer (20 mMTris-HCl pH 7.4; 137 mM NaCl; 5 mM KCl; 1 mM MgCl₂; 1 mM CaCl₂; 0.1%[w/vol] Tween-20; 0.1% [w/vol] CHAPS) together with varying amounts ofbiotinylated human D- or L-glucagon, respectively, for 2-6 hours inorder to reach equilibrium at low concentrations. Selection buffer wassupplemented with 100 μg/ml human serum albumin (Sigma-Aldrich,Steinheim, Germany), and 10 μg/ml yeast RNA (Ambion, Austin, USA) inorder to prevent unspecific adsorption of binding partners to surfacesof used plasticware or to the immobilization matrix. The concentrationrange of biotinylated L-glucagon for Spiegelmer binding was set from0.32 nM to 5 μM; total reaction volume was 50 Biotinylated glucagon andcomplexes of nucleic acids and biotinylated glucagon were immobilized on4 μl High Capacity Neutravidin Agarose particles (Thermo Scientific,Rockford, USA) which had been preequilibrated with selection buffer.Particles were kept in suspension for 20 min at the respectivetemperature in a thermomixer. Immobilized radioactivity was quantitatedin a scintillation counter after removal the supernatant and appropriatewashing. The percentage of binding was plotted against the concentrationof biotinylated glucagon and dissociation constants were obtained byusing software algorithms (GRAFIT; Erithacus Software; Surrey U.K.)assuming a 1:1 stoichiometry.

Competitive Pull-Down Assay for Ranking of Glucagon Binding NucleicAcids

In order to compare the binding of different Spiegelmers to glucagon acompetitive ranking assay was performed. For this purpose either themost affine spiegelmer available was radioactively labeled (see above)and served as reference for glucagon binding spiegelmers, respectively.After de- and renaturation the labeled nucleic acids were incubated at37° C. with biotinylated glucagon in 50 or 100 μl selection buffer atconditions that resulted in around 5-10% binding to the biotinylatedglucagon after immobilization on 1.5 μl High Capacity NeutravidinAgarose particles (Thermo Scientific, Rockford, USA) and washing withoutcompetition. An excess of de- and renatured non-labeled spiegelmervariants was added at different concentrations together with the labeledreference spiegelmer to parallel binding reactions. De- and renaturednon-labeled Spiegelmer derivatives were applied at concentrations of 1,10, and 100 nM together with the reference Spiegelmer in parallelbinding reactions. The nucleic acids to be tested competed with thereference nucleic acid for target binding, thus decreasing the bindingsignal in dependence of their binding characteristics. The aptamer orSpiegelmer, respectively that was found most active in this assay couldthen serve as a new reference for comparative analysis of other glucagonbinding nucleic acid molecules.

Competitive Pull-Down Assay for Determination of Affinity

In addition to comparative ranking experiments the competitive pull-downassay was also performed to determine the affinity constants of glucagonbinding nucleic acids. For this purpose either a L-glucagon bindingSpiegelmer was radioactively labeled and served as reference asdescribed above. After de- and renaturation the labeled referencenucleic acid and a set of 5-fold dilutions ranging e.g. from 0.128 to2000 nM of competitor molecules were incubated with a constant amount ofbiotinylated glucagon in 0.1 or 0.2 ml selection buffer at 37° C. for2-4 hours. The chosen protein concentration should cause final bindingof approximately 5-10% of the radiolabeled reference molecule at thelowest competitor concentration. In order to measure the bindingconstants of derivative nucleic acid sequences an excess of theappropriate de- and renatured non-labeled Spiegelmer variants served ascompetitors, whereas for Spiegelmers unmodified as well as PEGylatedforms were tested. In another assay approach non-biotinylated glucagonat different concentrations competed against the biotinylated glucagonfor Spiegelmer binding. After immobilization of biotinylated glucagonand the bound nucleic acids on 1.5 μl High Capacity Neutravidin Agarosematrix, washing and scintillation counting (see above), the normalizedpercentage of bound radiolabeled Spiegelmer was plotted against thecorresponding concentration of competitor molecules. The resultingdissociation constant was calculated employing the GraFit Software.

EXAMPLE 11: INHIBITION OF β-ARRESTIN RECRUITMENT INDUCED BY S1P VIA EDG1RECEPTOR BY S1P-BINDING SPIEGELMERS

PathHunter™ eXpress EDG-1 CHO-K1 β-arrestin GPCR cells (DiscoverX) wereseeded at 1×10⁴ cells per well in a white 96 well-plate with clearbottom (Greiner) and cultivated for 48 h at 37° C. and 5% CO₂ in 100 μlCulture Medium (DiscoverX). Stimulation solutions (D-e-S1P+variousconcentrations of Spiegelmer) are made up as 11× concentrated solutionsin HBSS (Gibco) supplemented with 1 mg/ml BSA and 20 mM HEPES, mixedthoroughly and incubated at 37° C. for 30 min. 10 μl stimulationsolution were added per well (triplicates) and cells were incubated for90 min at 37° C. and 5% CO₂.

Upon receptor activation by D-e-S1P, the interaction of activated EDG1with β-arrestin leads to β-galactosidase enzyme fragmentcomplementation.

For quantification of β-galactosidase activity 55 μl Working DetectionReagent Solution (DiscoverX) were added and incubated for 90 min at roomtemperature. Luminescence was subsequently measured in a Fluostar Optimamultidetection plate reader (BMG).

To show the efficacy of anti-S1P-spiegelmers, cells were stimulated with10 nM D-e-S1P or D-e-S1P preincubated with various amounts ofspiegelmers. The results show the percentage of luminescence signalnormalized to the signal obtained without addition of spiegelmer. Meanvalues±SD from triplicate cultures are shown.

EXAMPLE 12: INHIBITION OF ALPHACGRP-INDUCED CAMP PRODUCTION IN HUMANNEUROBLASTOMA CELLS

Biological efficacy of CGRP-binding Spiegelmers was analysed as follows.

SK-N-MC human neuroblastoma cells (DSMZ, Braunschweig) were seeded at5×10e4 cells/well in a flat-bottomed 96-well plate (Greiner) andcultivated for 48 h at 37° C. and 5% CO₂ in 100 μl in DMEM (1000 mg/Lglucose, Invitrogen) supplemented with 10% heat-inactivated fetal calfserum (FCS), 4 mM L-alanyl-L-glutamine (GLUTAMAX), 50 units/mlPenicillin and 50 μg/ml Streptomycin.

Stimulation solutions (1 nM human or rat L-alphaCGRP (Bachem)+increasingconcentrations of Spiegelmer) were prepared as triplicates in HBSS(Gibco) supplemented with 1 mg/ml BSA and 20 mM HEPES using v-bottomed0.2 ml low profile 96-well plates and incubated at 37° C. for 60 min intotal. Blank values (no L-alphaCGRP, no Spiegelmer) and control values(1 nM L-alphaCGRP, no Spiegelmer) were included as triplicates. 20 minprior to stimulation 1 mM phosphodiesterase inhibitor3-Isobutyl-1-methylxanthine (IBMX, Sigma; 50 mM stock in DMSO diluted inHBSS/BSA/HEPES) was added to the cells and the stimulation solutions.For stimulation, cell culture medium was removed from the cells andsubstituted by 100 μl pre-incubated stimulation solution. Cell werestimulated for 30 min at 37° C., 5% CO₂. After removal of stimulationsolutions cells were lysed by addition of 50 μl/well assay/lysis buffer(Applied Biosystems, Tropix cAMP-Screen™ System kit) for 30 min at 37°C.

The amount of cAMP produced per well was subsequently measured using theTropix cAMP-Screen™ ELISA System kit (Applied Biosystems) according tomanufacturer's instructions. Briefly, a standard curve is prepared inassay/lysis buffer ranging from 6 nmol to 0.6 pmol cAMP/well. Celllysates diluted in assay/lysis buffer and standard curves are added tomicroplates precoated with goat anti-rabbit IgG. cAMP alkalinephosphatase conjugate and anti-cAMP antibody are added to the samplesand incubated for 60 min at room temperature. Subsequently, plates arewashed and chemiluminescent substrate is added. After 30 minchemiluminescence is measured in a FLUOstar OPTIMA plate reader unit(BMG Labtech). The cAMP-Screen™ ELISA system is a competitiveimmunoassay format. Thus, light signal intensity is inverselyproportional to the cAMP level in the sample or standard preparation.

This assay system was used to test Spiegelmers within the scope ofExamples 1 and 7 described herein. The result is illustrated in FIGS. 7and 8. Quantities of cAMP produced are given as percentage of thecontrol. The concentration of Spiegelmer required for 50% inhibition ofcAMP production relative to control defines the inhibitory constantIC₅₀.

EXAMPLE 13: DETERMINATION OF INHIBITORY CONCENTRATION IN A CHEMOTAXISASSAY

Generation of a cell line expressing the human receptor for C5a A stablytransfected cell line expressing the human receptor for C5a wasgenerated by transfecting BA/F3 mouse pro B cells with a plasmid codingfor the human C5a receptor (NCBI accession NM_001736 in pcDNA3.1+).Cells expressing C5aR were selected by treatment with geneticin andtested for expression with RT-PCR and for functionality with chemotaxisassay.

Chemotaxis Assay

The day before the experiment, cells are seeded in a new flask at0.3×10⁶/ml. For the experiment, cells were centrifuged, washed once inHBH (HBSS, containing 1 mg/ml bovine serum albumin and 20 mM HEPES) andresuspended at 1.33×10⁶ cells/ml. 75 μl of this suspension were added tothe upper compartments of a 96 well Corning Transwell plate with 5 μmpores (Costar Corning, #3388; NY, USA). In the lower compartmentsrecombinant human C5a (SEQ.ID. 50) or mouse C5a (SEQ.ID. 54) waspre-incubated together with Spiegelmers in various concentrations in 235μl HBH at 37° C. for 20 to 30 min prior to addition of cells. Cells wereallowed to migrate at 37° C. for 3 hours. Thereafter the insert plate(upper compartments) was removed and 30 μl of 440 μM resazurin (Sigma,Deisenhofen, Germany) in phosphate buffered saline was added to thelower compartments. After incubation at 37° C. for 2.5 hours,fluorescence was measured at an excitation wavelength of 544 nm and anemission wavelength of 590 nm.

Fluorescence values are corrected for background fluorescence (no C5a inwell) and plotted against Spiegelmer concentration. The IC₅₀ values aredetermined with non-linear regression (4 parameter fit) using GraphPadPrism. Alternatively, the value for the sample without Spiegelmer (C5aonly) is set 100% and the values for the samples with Spiegelmer arecalculated as per cent of this. The per cent-values are plotted againstSpiegelmer concentration and the IC₅₀-values are determined as describedabove.

Determination of the Half-Maximal Effective Concentration (EC₅₀) forHuman and Mouse C5a

After 3 hours migration of BA/F3/huC5aR cells towards various human C5aor mouse C5a concentrations, dose-response curves for human and mouseC5a were obtained, indicating half effective concentrations (EC₅₀) of0.1 nM for huC5a and 0.3 nM for mC5a. For the experiments on inhibitionof chemotaxis by Spiegelmers 0.1 nM human C5a and 0.3 nM mouse C5a wereused.

EXAMPLE 14: INHIBITION OF GLUCAGON-INDUCED CAMP PRODUCTION BYGLUCAGON-BINDING SPIEGELMERS

A stably transfected cell line expressing the human receptor forglucagon was generated by cloning the sequence coding for the humanglucagon receptor (NCBI accession NM_000160) into the pCR3.1 vector(Invitrogen). CHO cells adapted to growth in serum-free medium(UltraCHO, Lonza) were transfected with the glucagon receptor plasmidand stably transfected cells were selected by treatment with geneticin.

For an inhibition experiment CHO cells expressing the glucagon receptorwere plated on a 96 well plate (cell culture treated, flat bottom) at adensity of 4-6×10⁴/well and cultivated overnight at 37° C. 5% CO₂ inUltraCHO medium containing 100 units/ml penicillin, 100 pg/mlstreptomycin and 0.5 mg/ml geneticin. 20 min before stimulation asolution of 3-isobutyl-1-methylxanthine (IBMX) was added to a finalconcentration of 1 mM.

The stimulation solutions (glucagon+various concentrations ofSpiegelmers) were made up in Hank's balanced salt solution (HBSS)+1mg/ml BSA and were incubated for 30 min at 37° C. Shortly beforeaddition to the cells, IBMX was added to a final concentration of 1 mM.For stimulation, the medium was removed from the cells and thestimulation solutions (glucagon+Spiegelmer) were added. After incubationfor 30 min at 37° C. the solutions were removed and the cells were lysedin lysis-buffer which is a component of the cAMP-Screen™ System kit(Applied Biosystems). This kit was used for determination of the cAMPcontent following the supplier's instructions.

REFERENCES

The complete bibliographic data of the documents recited herein are, ifnot indicated to the contrary, as follows, whereby the disclosure ofsaid references is incorporated herein by reference.

-   Altschul S. F., Gish W., et al. (1990) Basic local alignment search    tool. J Mol Biol. 215(3):403-10.-   Altschul S. F., Madden T. L., et al. (1997) Gapped BLAST and    PSI-BLAST: a new generation of protein database search programs.    Nucleic Acids Res. 25(17):3389-402.-   Damha M J, Ogilvie K K. (1993) Oligoribonucleotide synthesis. The    silyl-phosphoramidite method. Methods Mol Biol. 20:81-114-   Klussmann S. (2006). The Aptamer Handbook—Functional    Oligonucleotides and their Applications. Edited by S. Klussmann.    WILEY-VCH, Weinheim, Germany, ISBN 3-527-31059-2-   Kusser W. (2000) Chemically modified nucleic acid aptamers for in    vitro selections: evolving evolution. J Biotechnol 74(1): 27-38.-   Mairal T., Ozalp V. C., Lozano Sanchez P., et al. (2008) Aptamers:    molecular tools for analytical applications. Anal Bioanal Chem.    390(4):989-1007-   McGinnis S., Madden T. L. et al. (2004) BLAST: at the core of a    powerful and diverse set of sequence analysis tools. Nucleic Acids    Res. 32 (Web Server issue):W20-5.-   Needleman and Wunsch (1970) A general method applicable to the    search for similarities in the amino acid sequence of two proteins.    J Mol Biol. 48(3):443-53.-   Pearson and Lipman (1988) Improved tools for biological sequence    comparison. Proc. Nat'l. Acad. Sci. USA 85: 2444-   Smith and Waterman (1981), Adv. Appl. Math. 2: 482-   Venkatesan N., Kim S. J., et al. (2003) Novel phosphoramidite    building blocks in synthesis and applications toward modified    oligonucleotides. Curr Med Chem 10(19): 1973-91-   Wincott F, DiRenzo A, et al. (1995). Synthesis, deprotection,    analysis and purification of RNA and ribozymes. Nucleic Acids Res.;    23(14):2677-84.

The features of the present invention disclosed in the specification,the claims and/or the drawings may both separately and in anycombination thereof be material for realizing the invention in variousforms thereof.

1.-97. (canceled)
 98. An L-nucleic acid molecule capable of binding to atarget molecule by a mechanism other than base pairing obtainable by amethod comprising the following steps: a) providing a referenceL-nucleic acid molecule, wherein the reference L-nucleic acid moleculebinds the target molecule, and wherein the reference L-nucleic acidmolecule comprises a sequence of L-nucleotides, wherein the sequence ofL-nucleotides comprises n L-nucleotides; b) preparing a first levelderivative of the reference L-nucleic acid molecule, wherein the firstlevel derivative of the reference L-nucleic acid molecule differs fromthe reference L-nucleic acid molecule at one nucleotide position;wherein the first level derivative is prepared by replacing2′-deoxyribonucleotide at the one nucleotide position by aribonucleotide in case the reference L-nucleic acid molecule has a2′-deoxyribonucleotide at the one nucleotide position; wherein the firstlevel derivative is prepared by replacing ribonucleotide at the onenucleotide position by a 2′-deoxyribonucleotide in case the referenceL-nucleic acid molecule has a ribonucleotide at the one nucleotideposition; and wherein the nucleotide position at which the replacementis made is the modified nucleotide position; c) repeating step b) foreach nucleotide position of the reference L-nucleic acid molecule,thereby preparing a group of first level derivatives of the referenceL-nucleic acid molecule, wherein the group of first level derivatives ofthe reference L-nucleic acid molecule consists of n first levelderivatives, wherein each of the first level derivatives of thereference L-nucleic acid molecule differs from the reference L-nucleicacid molecule by a single nucleotide replacement and wherein each of thefirst level derivatives of the reference L-nucleic acid molecule has asingle modified nucleotide position which is different from the singlemodified nucleotide of all of the single modified nucleotide positionsof the other first level derivatives of the group of first levelderivatives of the reference L-nucleic acid molecule; d) determining abinding characteristic of each of the n first level derivatives of thereference L-nucleic acid molecule that binds the target molecule,wherein the binding characteristic comprises binding affinity of thefirst level derivative(s) of the reference L-nucleic acid molecule thatbinds the target molecule, wherein the binding affinity is expressed asKD value; and e) identifying first level derivative(s) of the referenceL-nucleic acid molecule that binds the target molecule, comprisingbinding affinity that exceeds binding affinity of the referenceL-nucleic acid molecule that binds the target molecule, therebyobtaining L-nucleic acid molecules that bind(s) the target molecule by amechanism other than base pairing.
 99. The L-nucleic acid moleculeaccording to claim 98, wherein first level derivative(s) of thereference L-nucleic acid molecule that binds the target molecule,identified in step e) comprise a binding affinity that exceeds apredetermined threshold value.
 100. The L-nucleic acid moleculeaccording to claim 99, wherein the predetermined threshold value is Ywith Y being the quotient of(binding affinity of the reference L-nucleicacid molecule)/(binding affinity of a first level derivative) andwherein Y>1, Y≥2, Y≥5 or Y≥10.
 101. The L-nucleic acid moleculeaccording to claim 98, wherein the L-nucleic acid molecule comprises atleast one modification.
 102. The L-nucleic acid molecule according toclaim 101, wherein excretion rate of the L-nucleic acid moleculecomprising a sequence of L-nucleotides and at least one modificationgroup from an organism is decreased compared to an L-nucleic acidmolecule consisting of the sequence of L-nucleotides.
 103. The L-nucleicacid molecule according to 101, wherein the L-nucleic acid moleculecomprising a sequence of L-nucleotides and at least one modification hasan increased retention time in an organism compared to an L-nucleic acidmolecule consisting of the sequence of L-nucleotides.
 104. An L-nucleicacid molecule capable of binding to a target molecule, wherein theL-nucleic acid molecule has a binding affinity to the target molecule,wherein the binding affinity of the L-nucleic acid molecule to thetarget molecule is increased compared to the binding affinity of areference L-nucleic acid molecule to the target molecule, wherein a) theL-nucleic acid molecule comprises a sequence of nucleotides and thereference L-nucleic acid molecule comprises a sequence of L-nucleotides,or b) the L-nucleic acid molecule comprises a sequence of L-nucleotidesand at least one modification group and the reference L-nucleic acidmolecule comprises a sequence of L-nucleotides and the at least onemodification group, wherein the sequence of L-nucleotides of theL-nucleic acid molecule and the sequence of L-nucleotides of thereference L-nucleic acid molecule are at least partially identical withrespect to the nucleobase moiety of the L-nucleotides but differ withrespect to the sugar moiety of the L-nucleotides, wherein the sequenceof L-nucleotides of the L-nucleic acid molecule consists of bothL-ribonucleotides and 2′-L-deoxyribonucleotides and wherein the sequenceof L-nucleotides of the reference L-nucleic acid molecule consists ofeither L-ribonucleotides or 2′-L-deoxyribonucleotides.
 105. TheL-nucleic acid molecule according to claim 104, wherein the L-nucleicacid molecule and/or the reference L-nucleic acid molecule areantagonists of an activity mediated by the target molecule.
 106. TheL-nucleic acid molecule according to claim 104, wherein excretion rateof the L-nucleic acid molecule comprising a sequence of L-nucleotidesand at least one modification group from an organism is decreasedcompared to an L-nucleic acid molecule consisting of the sequence ofL-nucleotides.
 107. The L-nucleic acid molecule according to claim 104,wherein the L-nucleic acid molecule comprising a sequence ofL-nucleotides and at least one modification has an increased retentiontime in an organism compared to an L-nucleic acid molecule consisting ofthe sequence of L-nucleotides.
 108. The L-nucleic acid moleculeaccording to claim 104, wherein the L-nucleic acid molecule comprises atleast one modification.
 109. The L-nucleic acid molecule according toclaim 108, wherein excretion rate of the L-nucleic acid moleculecomprising a sequence of L-nucleotides and at least one modificationgroup from an organism is decreased compared to an L-nucleic acidmolecule consisting of the sequence of L-nucleotides.
 110. The L-nucleicacid molecule according to 108, wherein the L-nucleic acid moleculecomprising a sequence of L-nucleotides and at least one modification hasan increased retention time in an organism compared to an L-nucleic acidmolecule consisting of the sequence of L-nucleotides.
 111. The L-nucleicacid molecule according to claim 104, wherein the nucleic acid moleculecomprises a method for the treatment and/or prevention of a disease.112. The nucleic acid molecule according to of claim 104, wherein thenucleic acid molecule comprises a method for the diagnosis of a disease.113. A pharmaceutical composition comprising the L-nucleic acid moleculeaccording to claim 104 and a pharmaceutically acceptable carrier.
 114. Amethod comprising administering to a subject in need of treatment theL-nucleic acid molecule according to claim 104 and a pharmaceuticallyacceptable carrier.
 115. A method comprising exposing a sample of asubject suspected of comprising a condition to the L-nucleic acidmolecule according to claim 104 and determining whether a complex isformed with said L-nucleic acid molecule.